株探米国株
英語
エドガーで原本を確認する
0001307579 LIQTECH INTERNATIONAL INC false --12-31 FY 2024 true true true true true false 0.001 0.001 2,500,000 2,500,000 0 0 0 0 0.001 0.001 50,000,000 50,000,000 9,475,443 9,475,443 5,727,310 5,727,310 3 10 0 1 10 5 0 3 10 3 10 3 10 3 5 3 5 3 5 5 10 2 http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet 6.7 5 5 0 5 0 1 3 4 2041 9,475,443 5,727,310 0 0 0 1 1 1 1 1 5 false false false false Includes write-offs, the impact of foreign currency exchange rates. 00013075792024-01-012024-12-31 iso4217:USD 00013075792024-06-30 xbrli:shares 00013075792025-03-28 thunderdome:item 00013075792024-12-31 00013075792023-12-31 iso4217:USDxbrli:shares 00013075792023-01-012023-12-31 0001307579us-gaap:CommonStockMember2023-12-31 0001307579us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001307579us-gaap:RetainedEarningsMember2023-12-31 0001307579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001307579us-gaap:CommonStockMember2024-01-012024-12-31 0001307579us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-31 0001307579us-gaap:RetainedEarningsMember2024-01-012024-12-31 0001307579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-31 0001307579us-gaap:CommonStockMember2024-12-31 0001307579us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001307579us-gaap:RetainedEarningsMember2024-12-31 0001307579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31 0001307579us-gaap:CommonStockMember2022-12-31 0001307579us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001307579us-gaap:RetainedEarningsMember2022-12-31 0001307579us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 00013075792022-12-31 0001307579us-gaap:CommonStockMember2023-01-012023-12-31 0001307579us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-31 0001307579us-gaap:RetainedEarningsMember2023-01-012023-12-31 0001307579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-31 xbrli:pure 0001307579liqt:LiqTechUSAMember2024-12-31 0001307579liqt:LiqTechInternationalDKMemberliqt:LiqTechUSAMember2024-12-31 0001307579liqt:LiqTechNAMemberliqt:LiqTechUSAMember2024-12-31 0001307579liqt:LiqtechJitriMember2024-12-06 utr:Y 0001307579srt:MinimumMember2024-12-31 0001307579srt:MaximumMember2024-12-31 0001307579us-gaap:CustomerRelationshipsMember2024-12-31 0001307579srt:ReportableGeographicalComponentsMembersrt:AmericasMember2024-01-012024-12-31 0001307579srt:ReportableGeographicalComponentsMembersrt:AmericasMember2023-01-012023-12-31 0001307579srt:ReportableGeographicalComponentsMembersrt:AsiaPacificMember2024-01-012024-12-31 0001307579srt:ReportableGeographicalComponentsMembersrt:AsiaPacificMember2023-01-012023-12-31 0001307579srt:ReportableGeographicalComponentsMembersrt:EuropeMember2024-01-012024-12-31 0001307579srt:ReportableGeographicalComponentsMembersrt:EuropeMember2023-01-012023-12-31 0001307579srt:ReportableGeographicalComponentsMemberliqt:MiddleEastAndAfricaMember2024-01-012024-12-31 0001307579srt:ReportableGeographicalComponentsMemberliqt:MiddleEastAndAfricaMember2023-01-012023-12-31 0001307579liqt:WaterSegmentMember2024-01-012024-12-31 0001307579liqt:WaterSegmentMember2023-01-012023-12-31 0001307579liqt:CeramicsSegmentMember2024-01-012024-12-31 0001307579liqt:CeramicsSegmentMember2023-01-012023-12-31 0001307579liqt:PlasticsSegmentMember2024-01-012024-12-31 0001307579liqt:PlasticsSegmentMember2023-01-012023-12-31 0001307579us-gaap:CorporateMember2024-01-012024-12-31 0001307579us-gaap:CorporateMember2023-01-012023-12-31 0001307579liqt:ProductionEquipmentMembersrt:MinimumMember2024-12-31 0001307579liqt:ProductionEquipmentMembersrt:MaximumMember2024-12-31 0001307579liqt:ProductionEquipmentMember2024-12-31 0001307579liqt:ProductionEquipmentMember2023-12-31 0001307579liqt:ProductionEquipmentUnderFinanceLeaseMembersrt:MinimumMember2024-12-31 0001307579liqt:ProductionEquipmentUnderFinanceLeaseMembersrt:MaximumMember2024-12-31 0001307579liqt:ProductionEquipmentUnderFinanceLeaseMember2024-12-31 0001307579liqt:ProductionEquipmentUnderFinanceLeaseMember2023-12-31 0001307579liqt:LabEquipmentMembersrt:MinimumMember2024-12-31 0001307579liqt:LabEquipmentMembersrt:MaximumMember2024-12-31 0001307579liqt:LabEquipmentMember2024-12-31 0001307579liqt:LabEquipmentMember2023-12-31 0001307579us-gaap:ComputerEquipmentMembersrt:MinimumMember2024-12-31 0001307579us-gaap:ComputerEquipmentMembersrt:MaximumMember2024-12-31 0001307579us-gaap:ComputerEquipmentMember2024-12-31 0001307579us-gaap:ComputerEquipmentMember2023-12-31 0001307579liqt:ComputerEquipmentUnderFinanceLeaseMembersrt:MinimumMember2024-12-31 0001307579liqt:ComputerEquipmentUnderFinanceLeaseMembersrt:MaximumMember2024-12-31 0001307579liqt:ComputerEquipmentUnderFinanceLeaseMember2024-12-31 0001307579liqt:ComputerEquipmentUnderFinanceLeaseMember2023-12-31 0001307579us-gaap:VehiclesMembersrt:MinimumMember2024-12-31 0001307579us-gaap:VehiclesMembersrt:MaximumMember2024-12-31 0001307579us-gaap:VehiclesMember2024-12-31 0001307579us-gaap:VehiclesMember2023-12-31 0001307579us-gaap:FurnitureAndFixturesMember2024-12-31 0001307579us-gaap:FurnitureAndFixturesMember2023-12-31 0001307579liqt:FurnitureAndFixturesUnderFinanceLeaseMember2024-12-31 0001307579liqt:FurnitureAndFixturesUnderFinanceLeaseMember2023-12-31 0001307579us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2024-12-31 0001307579us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2024-12-31 0001307579us-gaap:LeaseholdImprovementsMember2024-12-31 0001307579us-gaap:LeaseholdImprovementsMember2023-12-31 0001307579liqt:PropertyPlantAndEquipmentNotUnderFinanceLeaseMember2024-12-31 0001307579liqt:PropertyPlantAndEquipmentNotUnderFinanceLeaseMember2023-12-31 0001307579liqt:PropertyPlantAndEquipmentUnderFinanceLeaseMember2024-12-31 0001307579liqt:PropertyPlantAndEquipmentUnderFinanceLeaseMember2023-12-31 0001307579us-gaap:CostOfSalesMember2024-01-012024-12-31 0001307579us-gaap:OperatingExpenseMember2023-01-012023-12-31 0001307579us-gaap:CustomerRelationshipsMember2023-12-31 0001307579us-gaap:PatentsMember2024-12-31 0001307579us-gaap:PatentsMember2023-12-31 0001307579liqt:SeniorPromissoryNotesMember2022-06-22 utr:M 0001307579liqt:SeniorPromissoryNotesMember2022-06-222022-06-22 0001307579liqt:SeniorPromissoryNotesMembersrt:MaximumMember2022-06-22 0001307579liqt:SeniorPromissoryNotesPlacementAgentWarrantsMember2022-06-22 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputExpectedTermMember2022-06-22 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputSharePriceMember2022-06-22 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputExercisePriceMember2022-06-22 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputPriceVolatilityMember2022-06-22 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-06-22 0001307579liqt:SeniorPromissoryNotesMemberliqt:MeasurementInputForfeitureRateMember2022-06-22 0001307579liqt:The2023WarrantsMember2023-09-30 0001307579liqt:SeniorPromissoryNotesMember2023-10-13 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputExpectedTermMember2023-10-13 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputSharePriceMember2023-10-13 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputExercisePriceMember2023-10-13 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputPriceVolatilityMember2023-10-13 0001307579liqt:SeniorPromissoryNotesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-10-13 0001307579liqt:SeniorPromissoryNotesMemberliqt:MeasurementInputForfeitureRateMember2023-10-13 0001307579liqt:SeniorPromissoryNotesMember2024-12-31 0001307579liqt:SeniorPromissoryNotesMember2023-12-31 0001307579liqt:SeniorPromissoryNotesMember2024-01-012024-12-31 0001307579liqt:SeniorPromissoryNotesMember2023-01-012023-12-31 0001307579srt:MaximumMember2024-01-012024-12-31 0001307579us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2024-12-31 0001307579us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberus-gaap:LatestTaxYearMember2024-01-012024-12-31 0001307579us-gaap:ForeignCountryMemberliqt:DanishMinistryOfTaxationMember2024-12-31 0001307579liqt:LiqTechInternationalAndLiqTechNAMember2024-12-31 0001307579liqt:LiqTechInternationalAndLiqTechNAMember2023-12-31 0001307579liqt:LiqTechInternationalASAndLiqTechSystemsASMember2024-12-31 0001307579liqt:LiqTechInternationalASAndLiqTechSystemsASMember2023-12-31 0001307579liqt:LiqtechChinaMember2024-12-31 0001307579liqt:LiqtechChinaMember2023-12-31 0001307579us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2024-01-012024-12-31 0001307579us-gaap:DomesticCountryMemberliqt:DanishMinistryOfTaxationMember2024-01-012024-12-31 0001307579us-gaap:DomesticCountryMemberliqt:ChineseMinistryOfTaxationMember2024-01-012024-12-31 0001307579us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2023-01-012023-12-31 0001307579us-gaap:DomesticCountryMemberliqt:DanishMinistryOfTaxationMember2023-01-012023-12-31 0001307579us-gaap:DomesticCountryMemberliqt:ChineseMinistryOfTaxationMember2023-01-012023-12-31 0001307579liqt:DanishMinistryOfTaxationMember2024-01-012024-12-31 0001307579liqt:DanishMinistryOfTaxationMember2023-01-012023-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-31 0001307579liqt:PrefundedWarrantsMember2024-01-012024-12-31 0001307579us-gaap:WarrantMember2024-01-012024-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-31 0001307579liqt:PrefundedWarrantsMember2023-01-012023-12-31 0001307579us-gaap:WarrantMember2023-01-012023-12-31 0001307579us-gaap:ConvertiblePreferredStockMember2023-12-31 0001307579us-gaap:ConvertiblePreferredStockMember2024-12-31 0001307579srt:DirectorMember2023-06-262023-06-26 0001307579srt:ManagementMember2024-01-032024-01-03 0001307579srt:ManagementMember2024-06-242024-06-24 0001307579srt:ManagementMember2024-09-122024-09-12 0001307579liqt:SecuritiesPurchaseAgreementMember2024-09-272024-09-27 0001307579liqt:PrefundedWarrantsMemberliqt:SecuritiesPurchaseAgreementMember2024-09-27 0001307579us-gaap:WarrantMemberliqt:SecuritiesPurchaseAgreementMember2024-09-27 0001307579srt:MaximumMemberliqt:SecuritiesPurchaseAgreementMember2024-09-272024-09-27 0001307579us-gaap:WarrantMemberliqt:SecuritiesPurchaseAgreementMember2024-09-272024-09-27 0001307579liqt:SecuritiesPurchaseAgreementMember2024-09-27 0001307579liqt:PrefundedWarrantsMemberliqt:SecuritiesPurchaseAgreementMember2024-09-272024-09-27 0001307579srt:MinimumMemberliqt:SecuritiesPurchaseAgreementMember2024-09-27 0001307579liqt:SecuritiesPurchaseAgreementTrancheOneMember2024-09-272024-09-27 0001307579liqt:PrefundedWarrantsMemberliqt:SecuritiesPurchaseAgreementTrancheOneMember2024-09-27 0001307579us-gaap:WarrantMemberliqt:SecuritiesPurchaseAgreementTrancheOneMember2024-09-27 0001307579liqt:SecuritiesPurchaseAgreementTrancheTwoMember2024-09-272024-09-27 0001307579liqt:PrefundedWarrantsMemberliqt:SecuritiesPurchaseAgreementTrancheTwoMember2024-09-27 0001307579us-gaap:WarrantMemberliqt:SecuritiesPurchaseAgreementTrancheTwoMember2024-09-27 0001307579liqt:SecuritiesPurchaseAgreementTrancheTwoMember2024-11-122024-11-12 0001307579liqt:WarrantPurchaseAgreementMember2022-05-17 0001307579liqt:PublicOfferingMember2022-05-17 0001307579liqt:WarrantPurchaseAgreementMember2022-05-172022-05-17 0001307579us-gaap:PrivatePlacementMember2022-06-232022-06-23 0001307579liqt:PrivatePlacementWarrantsMember2022-06-23 0001307579liqt:PrivatePlacementWarrantsMember2022-06-232022-06-23 0001307579us-gaap:WarrantMember2024-09-27 0001307579liqt:PrefundedWarrantsMember2024-09-27 0001307579liqt:WarrantsInSecurityPurchaseAgreementTrancheTwoMember2024-11-12 0001307579liqt:WarrantsInSecurityPurchaseAgreementTrancheTwoMember2024-11-12 0001307579liqt:PrefundedWarrantsInSecurityPurchaseAgreementTrancheTwoMember2024-11-12 0001307579us-gaap:RestrictedStockUnitsRSUMembersrt:DirectorMember2024-01-012024-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMembersrt:DirectorMember2013-01-012013-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMembersrt:BoardOfDirectorsChairmanMember2013-01-012013-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMemberliqt:The2022IncentivePlanMember2024-01-012024-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMember2024-12-31 0001307579us-gaap:RestrictedStockUnitsRSUMember2023-12-31 0001307579us-gaap:OperatingSegmentsMemberliqt:WaterSegmentMember2024-01-012024-12-31 0001307579us-gaap:OperatingSegmentsMemberliqt:WaterSegmentMember2023-01-012023-12-31 0001307579us-gaap:OperatingSegmentsMemberliqt:CeramicsSegmentMember2024-01-012024-12-31 0001307579us-gaap:OperatingSegmentsMemberliqt:CeramicsSegmentMember2023-01-012023-12-31 0001307579us-gaap:OperatingSegmentsMemberliqt:PlasticsSegmentMember2024-01-012024-12-31 0001307579us-gaap:OperatingSegmentsMemberliqt:PlasticsSegmentMember2023-01-012023-12-31 0001307579us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2024-01-012024-12-31 0001307579us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2023-01-012023-12-31 0001307579liqt:PlasticProductsMember2024-01-012024-12-31 0001307579liqt:PlasticProductsMember2023-01-012023-12-31 0001307579us-gaap:AllOtherSegmentsMember2024-01-012024-12-31 0001307579us-gaap:AllOtherSegmentsMember2023-01-012023-12-31 0001307579liqt:WaterSegmentMember2024-12-31 0001307579liqt:WaterSegmentMember2023-12-31 0001307579liqt:CeramicsSegmentMember2024-12-31 0001307579liqt:CeramicsSegmentMember2023-12-31 0001307579liqt:PlasticProductsMember2024-12-31 0001307579liqt:PlasticProductsMember2023-12-31 0001307579us-gaap:AllOtherSegmentsMember2024-12-31 0001307579us-gaap:AllOtherSegmentsMember2023-12-31 0001307579us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberliqt:CustomerAMember2024-01-012024-12-31 0001307579us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberliqt:CustomerAMember2023-01-012023-12-31 0001307579us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberliqt:CustomerBMember2023-01-012023-12-31 0001307579us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:DK2024-01-012024-12-31 0001307579us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:US2024-01-012024-12-31 0001307579us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:CN2024-01-012024-12-31 0001307579us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:DK2023-01-012023-12-31 0001307579us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:US2023-01-012023-12-31 0001307579us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:CN2023-01-012023-12-31 0001307579us-gaap:SubsequentEventMemberliqt:SeniorLeadershipTeamAndKeyEmployeesMember2025-01-012025-01-01 0001307579us-gaap:SubsequentEventMemberliqt:BoardOfDirectorsMember2025-01-032025-01-03 0001307579us-gaap:SubsequentEventMembersrt:ManagementMember2025-01-032025-01-03 0001307579liqt:SecondAmendmentToTheNoteMembersrt:ScenarioForecastMember2026-01-01 0001307579liqt:SecondAmendmentToTheNoteMemberus-gaap:SubsequentEventMemberliqt:EventOfDefaultMember2025-03-26 0001307579liqt:SecondAmendmentToTheNoteMemberus-gaap:SubsequentEventMemberliqt:EventOfDefaultMember2025-03-262025-03-26 0001307579liqt:SecondAmendmentToTheNoteMembersrt:MaximumMemberus-gaap:SubsequentEventMemberliqt:EventOfDefaultMember2025-03-26 0001307579liqt:SeniorPromissoryNotesWarrantMember2022-06-22 0001307579liqt:SeniorPromissoryNotesWarrantMemberus-gaap:SubsequentEventMember2025-03-26 0001307579us-gaap:InventoryValuationReserveMember2024-01-012024-12-31 0001307579us-gaap:InventoryValuationReserveMember2023-01-012023-12-31 0001307579us-gaap:InventoryValuationReserveMember2023-12-31 0001307579us-gaap:InventoryValuationReserveMember2024-12-31 0001307579us-gaap:AllowanceForCreditLossMember2023-12-31 0001307579us-gaap:AllowanceForCreditLossMember2024-01-012024-12-31 0001307579us-gaap:AllowanceForCreditLossMember2024-12-31 0001307579us-gaap:InventoryValuationReserveMember2022-12-31 0001307579us-gaap:AllowanceForCreditLossMember2022-12-31 0001307579us-gaap:AllowanceForCreditLossMember2023-01-012023-12-31
 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2024

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-36210

 

LiqTech International, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

20-1431677

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

     

Industriparken 22C, DK 2750 Ballerup, Denmark

   

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: +4531315941

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol(s)

 

Name of each exchange on which

registered

Common Stock, $0.001 par value

 

LIQT

 

The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ☐   No   ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes ☐   No   ☒

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ☒     No   ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes   ☒     No   ☐

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer 

Smaller reporting company

Emerging growth company

   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

  

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.   ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).   ☐

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes ☐   No   ☒

 

On June 30, 2024, the aggregate market value of the common stock outstanding and held by non-affiliates (as defined in Rule 405 under the Securities Act of 1933) of the registrant based on the closing price of the registrant’s common stock of $2.36 per share on June 30, 2024, was $12,282,163. As of March 28, 2025, there were 9,606,024 shares of common stock, $0.001 par value per share, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s Definitive Proxy Statement for the registrant’s 2025 Annual Meeting of Shareholders are incorporated by reference in Part III of this report. The Definitive Proxy Statement or an amendment to this Form 10-K will be filed with the Securities and Exchange Commission within 120 days after the registrant’s fiscal year ended December 31, 2024. 

 

  

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

 

TABLE OF CONTENTS

 

     

Page

PART I

   
 

Item 1

Business

1

 

Item 1A

Risk Factors

10

 

Item 1B

Unresolved Staff Comments

21

  Item 1C Cybersecurity 21
 

Item 2

Properties

22

 

Item 3

Legal Proceedings

22

 

Item 4

Mine Safety Disclosures

22

PART II

   
 

Item 5

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

22

 

Item 6

[Reserved]

23

 

Item 7

Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

 

Item 7A

Quantitative and Qualitative Disclosures About Market Risk

31

 

Item 8

Financial Statements and Supplementary Data

32

 

Item 9

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

63

 

Item 9A

Controls and Procedures

63

 

Item 9B

Other Information

65

 

Item 9C

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

66

PART III

   
 

Item 10

Directors, Executive Officers and Corporate Governance

67

 

Item 11

Executive Compensation

67

 

Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

67

 

Item 13

Certain Relationships and Related Transactions, and Director Independence

67

 

Item 14

Principal Accountant Fees and Services

67

PART IV

   
 

Item 15

Exhibits and Financial Statement Schedules

68

 

Item 16

Form 10-K Summary

72

 

Signatures

73

 

  

 

Cautionary Language Regarding Forward-Looking Statements and Industry Data

 

This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. In some cases, you can identify forward-looking statements by the following words: “may,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential” or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking.

 

The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future political, legislative, economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. This is especially underlined by the anticipated impacts from the prevailing macro-economic uncertainty on the Company, including the related effects to our business operations, results of operations, cash flows, and financial position. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this Annual Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

 

Forward-looking statements include, but are not limited to, statements concerning:

 

 

The potential adverse effects on our operations and financial performance from armed conflicts or geopolitical tensions;
     
  The potential adverse impact of global trade restrictions and geopolitical tensions on our business and supply chain;
     
 

The potential negative impact of prolonged energy market volatility and supply disruptions on our business;

     
 

The potential adverse impact of health crises, pandemics, and public health emergencies on our business, financial condition, and operations;

     
 

Our dependence on a few major customers and the ability to maintain future relationships with one or more of these major customers;

     
 

Our ability to operate with financial stability and secure access to external financing and adequate liquidity;

     
 

Our ability to secure and source supplies of raw materials and key components in due time and at competitive prices;

     
 

Our ability to achieve revenue growth and penetrate new markets;

     
 

Our dependence on the expertise and experience of our management team and the retention of key employees;

     
 

Our reliance and access to qualified personnel to expand our business;

   

 

 

Our ability to adapt to potentially adverse changes in legislative, regulatory and political frameworks;

     
  Changes in interest rates of tightening of debt capital markets
     
 

Changes in emissions and environmental regulations, and potential further tightening of emission standards;

 

 

 

 

The exposure to potentially adverse tax consequences;

   

 

  Our ability to compete under changing governmental standards by which our products are evaluated;
     
 

The financial impact from the fluctuation and volatility of foreign currencies;

   

 

 

The potential monetary costs of defending our intellectual property rights;

   

 

 

Our ability to successfully protect our intellectual property rights and manufacturing know-how;
   

 

 

The possibility of a dispute over intellectual property developed in conjunction with third parties with whom we have contractual relationships;

   

 

 

The possibility that we could become subject to litigation that could be costly, limit, or cancel our intellectual property rights or divert time and efforts away from our business operations;

   

 

 

The potential negative impact to the sale of our products caused by technological advances of our competitors;

   

 

 

The potential liability for environmental harm or damages resulting from technical faults or failures of our products;

   

 

 

The possibility that an investor located within the United States may not be able to, or find it difficult to, enforce any judgments obtained in United States courts because a significant portion of our assets and some of our officers and directors may be located outside of the United States;

   

 

 

The possibility that we may not be able to develop and maintain an effective system of internal controls over financial reporting, leading to inaccurate reports of our financial results;

   

 

 

The possibility of breaches in the security of our information technology systems;

   

 

 

The liability risk of our compliance to environmental laws and regulations;

   

 

 

The potential negative impact of more stringent environmental laws and regulations as governmental agencies seek to improve minimum standards; and

 

 

 

 

PART I

 

Item 1.

Business

 

Overview

 

LiqTech International, Inc. is a clean technology company that manufactures and markets highly specialized filtration products and systems. For more than two decades, we have developed and manufactured products of re-crystallized silicon carbide. We specialize in three business areas: ceramic membranes for liquid filtration systems, ceramic diesel particulate filters (DPFs) to control soot exhaust particles and black carbon emission from diesel engines, and plastic components for usage across various industries. Using nanotechnology, we develop proprietary products using patented silicon carbide technology. Our products are based on unique silicon carbide membranes that facilitate new applications and improve existing technologies. We market our products from our offices in Denmark and through local representatives and distributors. The products are shipped directly to customers from our production facilities in Denmark.

 

The terms “LiqTech”, “we”, “our”, “us”, the “Company” or any derivative thereof, as used herein, refer to LiqTech International, Inc., a Nevada corporation, together with its direct and indirect wholly owned subsidiaries, which we collectively refer to herein as our “Subsidiaries”.  

 

At present, we conduct our operations in the Kingdom of Denmark. Our Danish operations are located in the Copenhagen area and Hobro.

 

Our Products

 

We manufacture and sell a broad range of systems and products based on the application of our ceramic filters and membranes for the filtration of liquids and gases within a range of uses, such as industrial wastewater, oil & gas, commercial pool, road & non-road machinery, marine, chemicals/petrochemicals and other industrial applications. We also provide engineered plastic parts and products for various internal and external industrial applications in the food & beverage and pharmaceutical industries. 

 

1

 

Silicon Carbide Ceramic Membranes for Liquid Filtration

 

For more than two decades, LiqTech has developed, manufactured, and sold innovative silicon carbide ceramic membranes for liquids purification.  Based on our continuous R&D efforts, patented technologies, and advanced production methods, we produce state-of-the-art silicon carbide products for various applications with the current membrane portfolio consisting of:

 

 

Silicon Carbide (SiC) ceramic membranes, a unique patented technology designed as a tubular membrane. It utilizes a crossflow structure to handle high concentrations of suspended solids found in produced water from the oil & gas and chemical industries, wastewater from industrial processes, and other applications. It offers consistent removal of oil and suspended solids at high throughput rates regardless of feed conditions. We offer onshore and offshore solutions and have experience within petrochemicals, chemicals and produced water streams. We believe our SiC filters are the best alternative to microfiltration and walnut shell filters due to the operational efficiencies of our SiC filters including operating cost savings, reduced installation cost, and product resilience. Our chemically inert, plug-and-play membranes are extremely hard, chemically resistant, and consist of durable ceramics with high flux (flow). SiC membranes are stronger, harder, longer-lasting, more temperature-resistant, and perform more efficiently than conventional ceramic or polymeric membranes; and

 

 

Hybrid Technology Membranes (HTM), a patented asymmetric membrane that combines the desired properties from silicon carbide (SiC) and zirconia (ZrO₂) ceramics. With a pore size of 60 nanometers (nm), it is suitable for ultrafiltration applications. This state-of-the-art membrane technology facilitates new separation processes and new filtration applications; and

 

 

Aqua Solution®, which integrates an enclosed structural design with cutting-edge membrane technology in a solution specifically designed for applications including pre-treatment, wastewater treatment, and swimming pool and spa water filtration. Our Aqua Solution® offers the same water purification as conventional sand filters, which typically require up to 400 times more space and have pore sizes at least three times larger than our Aqua Solution® SiC membrane. The Aqua Solution® also reduces the number of membrane elements, pressure vessels, and both water and energy consumption as well as CO2 footprint by offering high-flow capabilities at very low pressure with improved filtration characteristics.

 

2

 

Diesel Particulate Filters (DPFs) for Gas Purification

 

We offer diesel particulate filters for exhaust emission control solutions to the verified retrofit and original equipment manufacturer (OEM) markets through our direct sales force and distributors specializing in sales to end users. We use a proprietary “nano wash coat” to provide a catalytic coating for anything from diesel particulate filters to catalytic converters. Our DPF products are sold worldwide under the LiqTech brand.

 

We have developed a robust silicon carbide diesel particulate filter that is especially effective for vehicles, generators, marine, and non-road applications that produce a high soot load. If properly maintained, a LiqTech DPF can last as long as the application machinery or engine. Our DPFs are ideal for both on- and off-road vehicles and machinery because of their strength, chemical non-reactive nature, temperature resilience, and thermal conductivity.

 

Our DPF filters can handle higher soot loads than filters that do not use a silicon carbide membrane, making them ideal for situations in which engines infrequently reach high enough temperatures to burn off the soot. Examples include: 

 

 

Garbage trucks and port vehicles;

 

Diesel pickup trucks not carrying a full load;

 

Intra-city vehicles that do not reach highway speeds;

 

Off-road construction vehicles that idle for long periods of time;

 

Marine “black carbon” exhaust applications; and

 

Back-up generators and general “gen-set” applications.

 

Liquids Filtration Systems & Solutions

 

LiqTech develops, manufactures, and sells liquid filtration systems using our patented silicon carbide technology (sometimes also referred to herein as our “Aqua Solution®, SiC, and HTM membranes”). Our current focus is to strengthen our position within certain industrial applications such as difficult industrial water streams and hydrocarbon production-derived contaminated water, which we refer to herein as “produced water”. Furthermore, we remain focused on segments within marine scrubber wastewater, pool, metal & mining, microplastics removal, and other applications.

 

Our filtration systems have been used in the following applications by our clients:

 

 

Pool and Spa Water: We have supplied turnkey water filtration systems for medium to very large public swimming pool installations in Europe and Asia Pacific. Our Aqua Solution® ceramic membranes provide unique advantages for the commercial pool filtration industry in terms of reduced energy consumption, lower CO2 emissions, smaller footprint, reduced water and chemical consumption, and consistent, high-quality water filtration.

 

 

Produced Water: Our systems can be used for the filtration of produced water, which is a byproduct of oil & gas production. The amount of produced water varies from 0.1 to 10 times the amount of oil or gas produced. We have today three installations with international oil & gas companies both in the US and Middle East, all of which are operating with stable performance. 

 

Oil & Gas companies require water treatment units with high capacity and efficiency. In 2024, we developed the PureFlow™ container solution, designed to operate cost-effectively at capacities starting from 10,000 barrels per day.

 

 

Marine Scrubber Wastewater: Sustainability is getting more and more attention in the shipping industry. Most commercial new vessels are built with dual-fuel engines. This type of engine requires efficient and reliable water treatment systems for exhaust gas recirculation, for which it is necessary for engine combustion efficiency. Based on our many commercially operated water treatment systems, we have developed a special water treatment solution for this new application. We are actively repositioning our WTU to match the emerging new opportunity for exhaust gas recirculation in dual-fuel engines. This new market development supports the energy transition for the marine industry and will be a major trend in the coming years.

 

Today, more than 80% of commercial ships are manufactured in China. To accelerate our entry into the emerging dual-fuel engine market, we established a joint venture in Nantong, China, in December 2024.

 

3

 

 

Industrial Applications: We have delivered complete liquid filtration systems for aggressive fluid applications such as heavy metal removal for energy providers and water treatment systems for mining wastewater. Furthermore, our systems have been deployed successfully to reduce OPEX and enhance product quality in chemicals/petrochemicals applications. In 2024, we piloted a new application area for microplastics removal for a chemical/petrochemical company.

 

Highly Flexible & Innovative Plastic Manufacturing

 

LiqTech provides highly flexible and innovative plastics manufacturing, focusing on machining, welding, bending, and solvent cementing. With an intense focus on customer demand, LiqTech serves market leaders in the clean technology, pharmaceuticals, foods, healthcare, and graphics industries. Furthermore, LiqTech delivers benefits through vertical integration by manufacturing some key components for the fabrication and assembly of liquid filtration systems for pool and marine scrubber applications.

 

 

Our Competitive Strengths

 

Our products and systems compete with other filtration technologies made from ceramic, aluminum oxide, and polymeric materials. While most of our competitors are large industrial companies, we hold a unique position by combining proprietary membrane technology with extensive system and application expertise. We believe our patented technology as well as our in-depth application knowledge allow us to offer reliable products that provide an advantage over many of our direct and, in many cases, larger competitors. We intend to continue investing in R&D with the aim of developing new technologies and improving our existing products to strengthen our competitive advantages, retain our existing customers, and acquire new customers.

 

We believe the following strengths underpin our ability to increase revenue and profitability:

 

 

Advantages of Silicon Carbide Membranes and Filters: Our liquid filtration and diesel exhaust products utilize silicon carbide substrate and membrane technology, which have unique qualities that we believe make our products more effective than those of our competitors. Unlike filtration products made of aluminum oxide, silicon carbide membranes are chemically inert and temperature-resistant. Furthermore, silicon carbide membranes exhibit a high degree of hydrophilicity (the tendency of a surface to become wet or absorb water), which results in uniquely high flux (and correspondingly low energy consumption). Silicon carbide is also very durable, and its hardness is only surpassed by select unique material compositions such as diamonds, making it a highly desirable material for various abrasive fluids in industrial applications. As a result, we believe that such superior physical properties make our products desirable in both liquid filtration products and exhaust emission control products. 

   

 

 

Complete In-house Systems Fabrication: LiqTech provides full fabrication and integration of our membranes into complete filtration systems made from corrosion-resistant materials and components. We possess in-house engineering capabilities for process design, 3D modeling, automation, and control. Our professional staff of dedicated engineers and craftsmen assume responsibility for the specification, engineering, fabrication, and commissioning process. We believe that supplying our customers with a modular-based solution built upon our silicon carbide membranes is unique in the market, considering our vertical integration with in-house manufacturing of silicon carbide products and engineered plastic components, coupled with the design, engineering, and assembly of the integrated systems. 

   

 

 

Broad Application of LiqTech Membranes: Our membranes can be applied in a variety of applications, including the filtration of industrial wastewater, separation of metals from liquids in industrial processes, marine scrubber wastewater, chemicals and produced water within oil & gas, oil emulsion separation, bacteria removal, commercial swimming pool water treatment, food and beverage production, chemicals/petrochemicals processing, and other applications.

 

4

 

 

Marketing and Manufacturing in Key Markets and Expanding to Other Markets: While production is centered in Denmark, we have distribution and sales activities across multiple jurisdictions. We also sell our products through distributors and agents in many other countries and regions such as China, Korea, Spain, UK, France, Greece, Middle East, Singapore, Australia, and the U.S. Moreover, we have established customer relationships in more than 25 countries. 

   

 

 

Strong and Experienced Management Team: Our management team has deep experience in the clean technology and filtration industries and drives growth through developing new applications and technologies and cultivating relationships with customers. 

 

Our Strategy 

 

Our strategy is to leverage our core competencies in material science, advanced filtration, systems integration, and application knowledge, creating differentiated products with compelling value propositions to penetrate attractive end markets with regulatory tailwinds. Essential imperatives associated with our strategy include the following:

 

 

Develop and reinforce new products and applications to provide clean water and reduce pollution. We currently provide water filtration systems for commercial pool owners, scrubber technology providers, shipowners, and ship operators as well as tailored filtration systems for oil & gas operators, energy companies, and services companies. We are expanding our range of products to better leverage existing customer relationships and develop new relationships within the oil & gas, marine, chemical, and other industries.

   

 

 

Better penetration of existing end markets where our value proposition is strong. We have successfully sold products and installed systems into several end market segments--including automotive/transportation, clean water and pool filtration, marine, industrial wastewater, chemical/petrochemical, energy, and oil & gas applications. We are focused on targeting and developing new customers in these end markets while working with distributors, agents, and partners to access other important geographic markets.

   

 

 

Develop new end markets for our core products and applications. Our existing products and systems are relevant for and valuable to other end markets, and we regularly evaluate opportunities to develop strategic partners to perfect new applications and validate associated value propositions.

 

Our Industry 

 

Overview

 

We serve primarily two industries: the liquid filtration market and the silicon carbide ceramic membrane & diesel particulate filter (DPF) market. Our goal is to leverage our products and core technologies to take advantage of favorable market trends.

 

Liquid Filtration Systems and Aftermarket

 

Water is essential to life on earth and clean water shortages are affecting billions of people. Today, 2.2 billion people lack safe drinking water, and 3 billion people worldwide lack basic handwashing facilities at home. In addition, more than 700 million people could be displaced due to water scarcity (according to the UN). According to the World Health Organization, approximately 395,000 children die every year due to unsafe water and lack of basic sanitation. In this context, the Company seeks to deploy our unique filtration systems across industries to help unlock a more sustainable future with lower resource consumption and more efficient and responsible operations, with the objective of creating both economic value and environmental benefits.

 

According to relevant industry research published in 2022, the global ceramic membrane market is expected to grow at a compound annual growth rate (CAGR) of 11.4%, from $5.4 billion in 2021 to $14.3 billion in 2030. LiqTech is differentiated by what we believe is our superior SiC membrane technology and our ability to provide a complete water treatment system for select industries and applications.

 

5

 

Our applications within industrial wastewater and more specific applications such as chemical/petrochemical purification represent a core part of our strategic plan. We seek to leverage our innovative and patented SiC ceramic membrane technology by designing and deploying our filtration systems into complex and demanding industrial applications where our clients can benefit from cost savings and value creation. Recent deployments have showcased attractive returns on investment, as our solutions yield improved product characteristics, lower operational costs, and higher output. We are currently focused on evaluating future market potential to more accurately assess the commercial potential within each industrial end-market segment. Based on industry research, the total addressable market within the global industrial water & wastewater treatment market is projected to reach $7.7 billion by 2030.

 

In the oil & gas market, we see growing global demand for high-quality re-injection water. In addition, we see tightening water discharge legislation, increasing public awareness of water scarcity, and heightening adoption of reuse as key growth drivers in this end market. In the past two years, we have worked closely with industry partners to validate and accelerate our ultra-filtration technology applications within the global oil & gas industry, in both onshore and offshore environments, evidenced by a commercial installation in the Middle East for produced water and in the Mediterranean Sea for monoethylene glycol (MEG) recovery. In 2024, we have succeeded in two commercial installations in the U.S. onshore market. The projected global market for produced water treatment has large potential for the Company. According to Zion Market Research, the market will grow with a CAGR of 8% and reach a market size of $16 billion in 2032 from $8 billion in 2023

 

The market for marine water filtration systems is dependent on the development of new regulations for sulfur and ballast water emissions. In 2020, IMO (International Maritime Organization) issued Marpol VI with clear regulation of SOx emissions for marine ships. The regulation can be reached in one of two ways: 1) use of fuel with low SOx content for a cost that is 150-200 $/MT higher than normal bunker fuel; 2) installation of open-loop, hybrid, or closed-loop scrubbers.  Only hybrid and closed-loop systems can be used in “ECA” zones (Emission Control Areas).  For hybrid and closed-loop systems, there is a need to install a water treatment system. Up to now, approximately 6,000 vessels have installed a scrubber, of which 1,200 include hybrid or closed-loop systems. Since 2018, LiqTech has sold and installed more than 170 water treatment units (WTU) for marine scrubbers, with an estimated market share of 14%. Sustainability is gaining increasing attention in the shipping industry. Most commercial new vessels are built with dual-fuel engines. This type of engines requires an efficient and reliable water treatment system for exhaust gas recirculation, for which it is necessary for engine combustion efficiency. Based on our many commercially operated water treatment systems, we have developed a unique for this new application. We are actively repositioning our WTU to match the emerging new opportunity for exhaust gas recirculation in dual-fuel engines. This new market development supports the energy transition for the marine industry and will be a major trend in the coming years. According to Clarkson shipping intelligence and other public sources, there are greater than 400 new dual-engine vessels on order for 2024 to 2027.

 

In addition to our industrial, oil & gas, and marine applications, our Company offers industry-leading commercial pool filtration systems globally through distributors and local partners. Based on more than 20 years of experience in the filtration industry, we have developed a superior and cost-effective industrial pool filter system with a smaller footprint, lower chlorine consumption, and higher quality of water filtration. Conventional technologies use large amounts of chemicals for disinfection, whereas our superior commercial pool system reduces chemical consumption. We believe our offering is uniquely positioned to unlock future growth in the context of the global focus on ESG, since our commercial pool application delivers safe, clean, and clear water to our clients with lower energy consumption and reduced lifecycle costs. According to Frost & Sullivan's report European Swimming Pool Water Treatment Growth Opportunities (June 2022), the European commercial pool market is projected to grow at a CAGR of 6.1% from 2024 to 2028, reaching a total addressable market of $687 million. We remain committed to expand our geographical reach outside of Europe through new partnerships and distribution agreements.

 

Furthermore, we have recently intensified our focus on aftermarket sales through service & maintenance agreements and the sale of spare parts to our clients and partners. We intend to leverage the installed base of our filtration systems delivered and commissioned over the last decade by engaging with both new and existing clients to develop a closer and more comprehensive partnership structure and ultimately bundle our filtration systems and aftermarket offering. We believe the aftermarket segment benefits from robust growth fundamentals as clients and technology providers are increasingly focused on unlocking value through close collaboration, for which service and maintenance will yield improved customer satisfaction and growth.

 

6

 

Silicon Carbide Ceramic Membrane & Diesel Particulate Filter (DPF) Market

 

Our legacy business related to the provision of DPF filters is expected to continue growing across Europe and North America as regulators require diesel engines to comply with new and more stringent environmental rules and regulations. In Europe, for example, cities in Germany and the Benelux countries are enforcing increasingly stringent requirements for diesel engines to include DPF filters, with the same trend also taking place in select Asian countries.

 

Furthermore, our proprietary DPF technology has paved the way for new market opportunities such as black carbon emission reduction in the marine industry, where our solutions allow both ocean-going and inland marine vessels to comply with current and future regulatory thresholds as defined by both IMO and regional regulators.

 

According to industry research, the global market for new DPF filters manufactured by OEMs is expected to grow at approximately 13% per year. Diesel emissions consist of several toxic gases and particles, including particulate matter (soot), carbon monoxide, and hydrocarbons. Soot has been linked to a variety of human health problems. Reducing diesel emissions will have both health and social benefits along with reduced costs.

 

In response to health impacts, governments have been implementing legislation to regulate emissions from diesel engines. California implemented the Diesel Risk Reduction Plan, and New York City implemented binding directives for the retrofitting of buses, garbage trucks, and construction machines. In the European Union, Directive EC 715/2007 of June 20, 2007, defines particle count limits for certain cars and light utility vehicles. Also, low emission zones have been implemented locally in various places in Europe, creating a patchwork of regulation.

 

Historically, our business has predominantly sold our integrated filtration systems with embedded SiC, HTM, and Aqua Solution® membranes to our partners, distributors, and end users. Recently, we have intensified our focus on the direct sale of SiC and HTM membrane products to clients and integrators across jurisdictions to directly access the global market for ceramics membrane solutions in the context of the growing need for clean water and responsible handling of industrial wastewater, while also placing value-enhancing applications across core industrial processes such as chemical/petrochemical, enhanced oil recovery, and other applications.

 

7

 

Research and Development

 

We have eight (8) full-time employees who are primarily engaged in R&D activities pertaining to the development of technology and intellectual property rights related to silicon carbide product formulas, applications, and manufacturing processes.

 

Manufacturing

 

We currently manufacture our ceramic membrane and DPF products in Ballerup, Denmark (Copenhagen area). We assemble our liquid filtration systems and manufacture plastic products at our facilities located in Hobro, Denmark. We plan to consolidate, optimize, and expand our production capacity within the existing facilities with further support from partnerships across the U.S. and Asia.

 

Raw Materials and Components

 

The main raw materials used in our manufacturing processes are silicon carbide, steel, pumps, electrical components, plastic, platinum, and palladium. We purchase these commodities from various sources generally based upon availability, lead time, quality, and price.

 

Sales, Marketing and Business Intelligence

 

Our products and services are sold both directly and indirectly to end users across multiple jurisdictions and end-markets through direct sales, systems integrators, distributors, agents, and partners.

 

Our Company initially focused on selling DPF filters to the automotive industry to reduce exhaust gas emissions in diesel engines. In 2014, we acquired Provital Solutions, a Danish filtration system manufacturing company that enabled our Company to broaden our offering of products and systems for ceramic filters, SiC membranes, and modular liquid filtration systems. The liquid filtration systems business has become a highly complementary offering to our SiC membrane and DPF business.

 

We plan to actively market our existing products to new customers as we penetrate new end markets and optimize our manufacturing capacity. As of December 2024, we employed ten (10) full-time sales, marketing and strategy personnel in addition to partnership and distribution agents. We promote our products through direct sales to potential customers and marketing activities such as participation in tradeshows and exhibitions, with a new focus on digital marketing.

 

In certain instances, our products are delivered to the end customer through system integrators. These system integrators use our filtration products and membranes in larger filtration systems, which eventually are installed in systems used by the end customers. Due to legislative regulation, system integrators are often required by the end customers to receive approval for their systems, including the components used in such systems, which requires significant time and expense. As a result, we believe that certain system integrators using our products will not replace our filters with competitive products unless there are compelling reasons to do so. 

 

Intellectual Property

 

We have two issued patents in Denmark, one issued European patent, and one pending European and US patent application that we co-own with a third party. Scope and duration of each of our foreign patents vary in keeping with local laws. On July 7, 2014, we obtained a new Danish patent application related to our silicon carbide membrane technology. In 2023, we have submitted 3 patent applications to further strengthen our intellectual property for SiC membranes.

 

8

 

We also rely on trade secret protection for our confidential and proprietary information. Trade secrets, however, can be difficult to protect. We may not be able to maintain our technology or know-how as trade secrets, and competitors may develop or acquire equally valuable or more valuable technology or know-how related to the manufacture of comparable silicon carbide products. We also seek to protect our confidential and proprietary information, in part, by requiring all employees, consultants, and business partners to execute confidentiality and/or nondisclosure agreements upon the commencement of any employment, consulting arrangement, or engagement with us. These agreements generally require that all confidential and proprietary information developed by the employee, consultant, or business partner, or made known to the employee, consultant, or business partner by us, during the course of the relationship with us and thereafter, be kept confidential and not disclosed to third parties.

 

We also believe that having distinctive names is an important factor in marketing our products and therefore use trademarks to brand some of our products. As of March 2025, we had three trademark registrations in China and four trademark registrations in Denmark (AQUA SOLUTION, CoMem, CDPX, and FUTURE FILTRATION). We are also in the process of proactively renewing and developing new trademarks in select geographic areas.

 

Government Regulation

 

We do not believe that we are subject to any special governmental regulations affecting our products in the countries in which we operate, although we are subject to numerous health and safety laws and regulations. We actively seek to maintain a safe, healthy, and environmentally friendly workplace for all of our employees and other stakeholders.

 

Environmental Matters

 

We are subject to a broad range of environmental laws and regulations that govern, among other things, air emissions, wastewater discharges, and the handling, storage, disposal, and release of waste and hazardous substances. It is our policy to comply with all applicable environmental requirements at each of our facilities.

 

Competition 

 

Our products compete with other filters that are made using polymer, silicon carbide ceramic, and aluminum oxide membranes. Most of our competitors are large industrial companies; however, we believe our patented technology, manufacturing know-how, and trade secrets allow us to produce high-quality products that provide an advantage over most of our competitors, many of which have greater financial, technological, manufacturing and personnel resources. We intend to continue to devote resources to the development of new technologies and the improvement of our products to retain existing customers and acquire new customers.

 

Employees

 

At December 31, 2024 we had 105 employees, including 66 in production; 20 in administration; 8 in research and development; 10 in sales, marketing and strategy; and 1 in executive management.

 

Certain employees in Denmark are represented by workers’ councils that have collective bargaining agreements. With the exception of such Danish employees, no other employees are members of a labor union or are represented by workers’ councils that have collective bargaining agreements. We believe that we have good relations with our employees.

 

Corporate Information

 

We filed our Articles of Incorporation on July 1, 2004, and are incorporated under the laws of the State of Nevada. Our principal executive office is located at Industriparken 22C, 2750 Ballerup, Denmark, and our telephone number is +45 3131 5941. We maintain an Internet website at www.liqtech.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available free of charge through our website as soon as reasonably practicable after we electronically file with or furnish them to the SEC and are available in print to any stockholder who requests a copy.  The information contained in, or accessible from, our website is not a part of this Annual Report. 

 

Additionally, the SEC maintains a website that contains reports, proxy statements, information statements, and other information regarding issuers, including us, that file electronically with the SEC at www.sec.gov.

 

9

 

Item 1A.   Risk Factors

 

RISKS RELATED TO OUR BUSINESS AND OPERATIONS 

 

The adverse effect to our business operations from armed conflicts (such as Ukraine/Russia and Hamas/Israel) or similar political, social, regulatory, or economic tension may challenge our operational flexibility and financial performance.

 

The continuation of the war between Ukraine and Russia as well as the war/armed conflict related to Hamas/Israel and the situation in the Red Sea fuels uncertainty and risk to our business as we rely on the ability to manufacture, ship, service, and operate across multiple jurisdictions. The wars may result in sanctions and increased uncertainties, thus restricting our ability to service our clients and execute orders globally due to supply chain risk, import/export restrictions, and increased demand uncertainty. Additionally, if customers are not successful in generating sufficient revenue or are precluded from securing financing due to the ongoing wars, they may not be able to pay, or may delay payment of, owed amounts to the Company for the provision of products and services. Any inability of current or new potential customers to purchase or pay for our products may adversely affect our sales, earnings, and cash flow.

 

Sales and earnings could also be affected by our ability to manage the risks and uncertainties associated with changes in local legal requirements or the enforceability of laws and contractual obligations, trade protection measures, changes in tax laws, regional political instability, war, terrorist activities, severe or prolonged adverse weather conditions, natural disasters, and health epidemics or pandemics.

 

Global trade restrictions and geopolitical tensions could adversely impact our business and supply chain

 

Our business operates in a global market and is subject to risks arising from increasing trade restrictions, geopolitical tensions, and shifting regulatory frameworks. In recent years, governments have imposed new tariffs, sanctions, and export controls, particularly in relation to advanced technologies, critical raw materials, and industrial goods. Trade conflicts between major economies, such as the United States and China, as well as evolving sanctions on Russia, have created uncertainty in supply chains and increased the complexity of cross-border trade. More recently, the change in administration in the U.S. elevates the potential for trade conflict and tariffs on imports, which could potentially impact our business. 

 

New or expanded trade restrictions, including export controls on key materials or technologies used in our products, could disrupt our supply chain, limit our ability to source critical components, and increase costs. Additionally, changes in import/export regulations or retaliatory trade policies from foreign governments could affect our ability to serve certain markets or delay customer orders.

 

Our ability to mitigate these risks depends on the stability of global trade relations, our ability to identify alternative suppliers, and potential shifts in regulatory frameworks that could impact our industry. There can be no assurance that future trade restrictions or geopolitical conflicts will not have a material adverse effect on our business, financial condition, and results of operations.

 

Prolonged period of energy market volatility and supply disruptions could negatively impact our business

 

The European energy crisis, which escalated in 2022 amid the Russia-Ukraine war, has largely stabilized; however, our business remains exposed to fluctuations in energy prices and potential supply disruptions caused by geopolitical instability, regulatory changes, or natural disasters. While natural gas and electricity prices in Europe have moderated compared to prior peaks, continued uncertainty regarding global energy markets, including potential disruptions from conflicts in the Middle East and instability affecting key shipping routes, could result in renewed price volatility and supply constraints.

 

Our business is heavily exposed to both gas and electricity prices used to power operating equipment and high-temperature kilns, as well as to heat office and manufacturing facilities. Any significant increase in energy costs or supply shortages, whether due to geopolitical conflicts, new regulatory restrictions, or logistical challenges in securing energy inputs, could negatively impact profitability and reduce our competitive position compared to competitors operating in regions with lower energy costs.

 

Additionally, evolving energy policies, such as carbon taxes, emissions trading schemes, and government-mandated energy transition initiatives, may increase operating costs and impact the cost structure of our production processes. While management continues to evaluate energy efficiency measures and alternative supply arrangements, there can be no assurance that future energy market volatility or supply disruptions will not have a material adverse effect on our business, financial condition, and results of operations.

 

10

 

Our business has been right-sized to help protect our profitability and cash flow; however, we remain exposed to near-term market fundamentals as we rely on short lead-time products and orders that may be cancelled if customers are facing weakened end-market demand or increased uncertainty.

 

Health crises, pandemics, and other public health emergencies could adversely affect our business, financial condition, and results of operations.

 

Our business could be adversely affected by the emergence or resurgence of health crises, pandemics, or other public health emergencies. While the global impact of COVID-19 has diminished, recent years have demonstrated the significant disruptions that pandemics or widespread health emergencies can cause to supply chains, labor markets, and overall economic activity.

 

Authorities worldwide continue to implement measures to mitigate potential future outbreaks, including vaccination campaigns, travel restrictions, and quarantine protocols, however, new infectious diseases or resurgences of existing ones could lead to disruptions in our supply chain, temporary facility closures, labor shortages, and delays in customer orders. Additionally, prolonged health crises could negatively impact the financial position of our customers or suppliers, increasing the risk of delayed payments, order cancellations, or defaults on contractual obligations.

 

Our ability to navigate future public health emergencies will depend on the severity and duration of such events, as well as the effectiveness of mitigation strategies implemented by governments, businesses, and healthcare systems. There can be no assurance that future health crises will not have a material adverse effect on our business, financial condition, and results of operations.

 

Historically, we have been dependent on a few major customers for a significant portion of the Company’s revenue. Our revenue could decline if we are unable to maintain or develop relationships with additional customers and our results of operations could be adversely affected if any one of these customers is unable to meet their financial obligations to us.

 

For the year ended December 31, 2024, our four largest customers accounted for approximately 7%, 7%, 5%, and 5% of our net sales (approximately 24% in total). For the year ended December 31, 2023, our four largest customers accounted for approximately 7%, 5%, 4%, and 4% of our net sales (approximately 20% in total). If we are unable to diversify our customer base, our future results will be heavily dependent on these customers. Our dependence on a limited number of customers means that the loss of a major customer or any reduction in orders by a major customer would materially reduce our net sales and adversely affect our results of operations. We expect that sales to relatively few customers will continue to account for a significant percentage of our net sales for the foreseeable future; however, these customers or our other customers may not use our products at current levels in the future, if at all. We have no firm, long-term volume commitments from any of our major customers, and we generally enter into individual purchase orders with our customers, in certain cases under master agreements that govern the terms and conditions of the relationship. We have experienced delays or cancellations of orders and fluctuations in order levels from period to period and expect that we will continue to experience such delays, cancellations, and fluctuations in the future. Customer purchase orders may be delayed or cancelled, and order volume levels can be changed with limited or no penalties. We may not be able to replace cancelled, delayed, or reduced purchase orders with new orders. If any one of these customers reduces its demand for our products, it will likely have a material adverse effect on our financial results.

 

Furthermore, a significant portion of our accounts receivable is concentrated with a few major customers who may not be able to meet their financial obligations to us. The failure of any such customer to pay amounts owed to us in a timely fashion or at all could have an adverse effect on our results of operations. The Company is also exposed to credit risk on its accounts receivable, and this risk is heightened during periods when economic conditions worsen. The Company’s outstanding receivables are not covered by collateral or credit insurance. The Company's exposure to credit and collection risk on its receivables may also be higher in certain international markets, and its ability to mitigate such risks may be limited. While the Company has procedures to monitor and limit exposure to credit risk on its receivables, there can be no assurance such procedures will effectively limit our credit risk and avoid losses.

 

11

 

If we fail to restore financial stability through improved profitability and access to adequate liquidity, our business options and financial condition would be impacted.

 

Our business has undergone significant changes in the past few years to help restore financial flexibility to the Company through an enhanced capital structure, improved profitability, reduced investments, and changes to the organization. Our ability to achieve financial beak-even is heavily dependent on external macroeconomic and competitive industry dynamics that are outside of our control; therefore, our business may not achieve its financial objectives in a period with increased competition or weakening market fundamentals.

 

Furthermore, future growth and operations may require public or private equity offerings or debt financings. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be required to delay or reduce the scope of our plans to grow our revenues, to pass on one or more opportunities, or to scale back our business plans. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. In addition, debt financing, if available, may involve restrictive covenants. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. Our access to the financial markets and the pricing and terms we receive in the financial markets could be adversely impacted by various factors, including changes in financial markets and interest rates.

 

The potential interruption or failure to obtain raw materials and components at affordable prices caused by continued global and regional supply chain constraints could negatively affect our ability to supply products to our customers and negatively affect our profit and delay revenue.

 

We use silicon carbide, steel, plastic, platinum, and palladium in the manufacturing process. As other industries develop products utilizing silicon carbide, we may not be able to obtain adequate supplies of silicon carbide required for the manufacture of our existing and future products that would prevent us from supplying products to our customers and materially affect our business. Furthermore, any increased demand for, the raising of tariff rates on, or an increase of non-tariff trade barriers that apply to silicon carbide, steel, plastic, platinum, or palladium could increase the price we must pay to obtain it and could adversely affect our profitability, which would have an adverse effect on our financial results. Additionally, fluctuation in demand for ceramics or global bottlenecks in shipping may result in supply chain constraints and longer lead times on key components which may result in delayed order shipments or risk of cancellation from clients demanding short lead times.

 

If we are unable to manage our expected growth, our business may be materially and adversely affected.

 

We expect to expand our operations by increasing our production capacity and penetrating new markets. The growth of our business could place significant strain on our management, operational, and financial resources. To manage our future growth, we could be required to improve existing or implement new operational or financial systems, procedures, and controls as well as to expand, train, and manage a growing employee base. Our failure to accomplish any of these tasks could materially and adversely affect our business. We also may not recognize the anticipated benefits of completed dispositions or other divestitures we may pursue in the future.

 

Our success will depend, to a large degree, on the expertise and experience of the members of our management team, the loss of whom could have a material adverse effect on our business.

 

Our success is, to a large degree, dependent upon the expertise and experience of the management team and its ability to attract and retain qualified personnel who are technically proficient. The loss of the services of one or more of such personnel could have a material adverse effect on our business. Our business may also be adversely affected if we are unable to continue to attract and retain such personnel.

 

12

 

Adverse conditions, regulatory challenges, or lack of funding for emission control programs, may delay or negatively affect our future growth and market potential within the transportation and marine industries.

 

Global health crises such as the COVID-19 pandemic or significant macroeconomic uncertainty exacerbated by current or future geopolitical conflicts and high inflationary pressure can significantly impact our Company, customers, and suppliers. For example, the global shipping industry has been negatively impacted by the coronavirus outbreak and may be further adversely affected by an extended shutdown of various businesses or delayed implementation of regulatory frameworks and environmental policies. This, in turn, could adversely affect the demand for our marine scrubbers as shipowners delay or even cancel their orders for new closed-loop scrubber systems.

 

Future growth of our business depends in part on the availability of funding for emissions control programs, which can be affected by economic as well as political reasons that are beyond our control. If such funding is not available, or delayed, it can negatively affect our future growth prospects. In addition to funding, we also expect that our future business growth will be driven, in part, by the enforcement of existing emissions-related environmental regulations and tightening of emissions standards worldwide, where regulations and standards are frequently contested in litigation. For example, our ability to expand our business in the marine industry is dependent on the effective implementation of IMO 2020, which requires the burning of low-sulfur oil for marine vessels or the inclusion of marine scrubber technology. If existing regulations and emissions standards do not continue to become stricter, are loosened, or are not enforced by governmental authorities due to commercial and business pressures, economic conditions, or otherwise, it could have a material adverse effect on our business, operating results, financial condition, and long-term prospects.

 

We face changes in governmental standards by which our products are evaluated, and if we cannot meet any such changes, some of our products could become obsolete, which could have a material adverse effect on our business.

 

We believe that, due to the intensifying focus on the environment and clean air and water standards throughout the world, new requirements to adhere to more stringent regulations are possible in the future as governmental agencies seek to promote clean air and water along with new product certifications. In the event that our products fail to meet these evolving standards, some or all of our products may become obsolete, which could have an adverse effect on our business, operating results, financial condition, and long-term prospects.

 

Our international operations are exposed to potential adverse tax consequence.

 

Our international operations create a risk of potentially adverse tax consequences. Taxes on income in future internationally based operations are dependent upon acceptance of our operational practices and intercompany transfer pricing by local tax authorities as being on an arm's length basis. Due to inconsistencies among taxing authorities in application of the arm's length standard, transfer pricing challenges by tax authorities could, if successful, materially increase our consolidated income tax expense. We may be subject to tax audits, and an audit could result in the assessment of additional income tax against us. This could have a material adverse effect on our operating results or cash flows in the period or periods for which that determination is made and could result in increases to our overall tax expense in subsequent periods. 

 

Our business could face adverse impacts due to increased interest rates, tightening debt capital markets, and market volatility.

 

Our business and capital structure are dependent upon our ability to raise financing and optimize our cash management activities through timely access to credit and loan markets at attractive terms. The prevailing uncertainty and increased interest rates represent a significant risk to our business as we are relying upon our ability to refinance our capital structure and maintain access to relevant financing. Furthermore, elevated interest rates may cause increased uncertainty and cash flow constraints, including the inability of the Company to meet existing debt service commitments. Increased market and interest rate uncertainty may also elevate execution risk and ultimately restrict our ability to refinance our debt obligations.

 

13

 

Foreign currency fluctuations could adversely impact financial performance.

 

Our reporting currency is the United States Dollar ($). Because of our activities in Denmark, the European Continent, Middle East, U.S., and other countries, we are exposed to fluctuations in foreign currency rates. Most income and expense-related transactions are denominated in currencies other than the reporting currency, and a certain portion of the excess cash balances may be held in other currencies or in bank accounts outside of the United States, causing risks of currency fluctuations when translating balances to the reporting currency at the end of the reporting period. We may manage the risk to such exposure through active cash flow management, and in some cases, by entering into foreign currency futures and option contracts; however, we can make no assurance that such actions will be sufficient to offset a material adverse effect on our operations in the future. As of December 31, 2024, we have not entered into any derivative contracts to hedge our currency exposure.

 

Our inability to protect our intellectual property rights could negatively affect our business and results of operations.

 

Our ability to compete effectively depends in part upon developing, maintaining, and/or protecting intellectual property rights relevant to our re-crystallized silicon carbide product forms, applications, and manufacturing processes. We rely principally on a combination of patent protection, trade secrets, confidentiality and non-disclosure agreements, and trusted business relationships to establish, maintain, and protect the intellectual property rights relevant to our business. These measures, however, may not be adequate in every given case to permit us to gain or retain any competitive advantage, particularly in those countries where the laws do not protect our proprietary rights as fully as those in the United States. In particular, because silicon carbide is a well-known material (developed over 100 years ago), and there has been extensive research, development, and publication related to this material and its wide range of applications, obtaining intellectual property rights to key elements of silicon carbide technology can be challenging. Accordingly, at least some of the technology employed in our manufacture of re-crystallized silicon carbide products is not protected by patents.

 

Where we consider it appropriate, we seek patent protection in the United States and other countries for technologies used in, or relating to, our re-crystallized silicon carbide product forms, applications, and manufacturing processes. The issuance of a patent is not conclusive as to its scope, validity, and enforceability. Thus, any patent or patent application which may issue into a patent held by us could be challenged, invalidated, or held unenforceable in litigation or proceedings before the U.S. Patent and Trademark Office and/or other patent tribunals, or they may be circumvented by others. No consistent policy regarding the breadth of patent claims has emerged to date in the United States, and the landscape could become more uncertain in view of future rule changes by the United States Patent and Trademark Office, the introduction of patent reform legislation, and decisions in patent law cases by United States federal courts. The patent landscape outside of the United States is even less predictable. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, we may fail to apply for patents on important technologies or product candidates in a timely fashion, if at all, and our existing and future patents may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products or technologies, especially given the long history of silicon carbide development. 

 

Our patent strategy involves complex legal and factual questions. Our ability to maintain and solidify our proprietary technology may depend in part upon our success in obtaining patent rights and enforcing those rights once granted or licensed. We do not know whether any of our pending patent applications will result in the issuance of any patents. Our issued patents and those that may be issued in the future may be challenged, invalidated, rendered unenforceable, or circumvented, which could limit our ability to prevent competitors from marketing similar or related products or shorten the term of patent protection that we may have for our products, processes, and enabling technologies. In addition, the rights granted under any issued patents may not provide us with competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies, duplicate technology developed by us, or otherwise possess intellectual property rights that could limit our ability to manufacture our products and operate our business. 

 

14

 

We also rely on trade secret protection for our confidential and proprietary information. Trade secrets, however, can be difficult to protect. We may not be able to maintain our technology or know-how as trade secrets, and competitors may develop or acquire equally valuable or more valuable technology or know-how related to the manufacture of comparable silicon carbide products. We also seek to protect our confidential and proprietary information, in part, by requiring all employees, consultants, and business partners to execute confidentiality and/or nondisclosure agreements upon the commencement of any employment, consulting arrangement, or engagement with us. These agreements generally require that all confidential and proprietary information developed by the employee, consultant, or business partner, or made known to the employee, consultant, or business partner by us, during the relationship with us, be kept confidential and not disclosed to third parties. These agreements may be breached and may not provide adequate remedies in the event of breach. To the extent that our employees, consultants, or business partners use intellectual property owned by others in their work for and/or with us, disputes could arise as to the rights in related or resulting technologies, know-how, or inventions. Moreover, while we also require customers and vendors to execute agreements containing confidentiality and/or nondisclosure provisions, we may not have obtained such agreements from all of our customers and vendors. In addition, our trade secrets may otherwise become known or be independently discovered by competitors, customers, or vendors. Such customers or vendors may also be subject to laws and regulations that require them to disclose information that we would otherwise seek to keep confidential.

 

Moreover, others may independently develop and obtain patents covering technologies that are similar or superior to the product forms, applications, or manufacturing processes that we employ. If that happens, we may need to obtain licenses for these technologies and may not be able to obtain licenses on reasonable terms, if at all, which could limit our ability to manufacture our future products and operate our business. In addition, third parties could utilize our intellectual property rights in territories where we do not have intellectual property protection. Such third parties may then try to import products made using our intellectual property rights into the United States or other countries, which could have a material adverse effect on our business.

 

Our contracts with third parties could negatively affect our intellectual property rights.

 

To further strengthen our product development efforts, we continue to work closely with customers and other third parties to research and develop advancements in silicon carbide product forms, applications, manufacturing processes, and related products and technologies. In some instances, the research and development activities that we conduct with customers and other third parties may produce intellectual property to which we may not have ownership or exclusive rights and will be unable to protect or monetize. Furthermore, there could be disputes between us and a private third party as to the ownership rights to any inventions that we develop in collaboration with such third party. Any such dispute may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management from our core business, or harm our reputation. 

 

We could become subject to intellectual property litigation that could be costly, limit or cancel our intellectual property rights, divert time and efforts away from business operations, require us to pay damages, and/or otherwise have an adverse material impact on our business.

 

The success of our business is highly dependent on protecting our intellectual property rights. Unauthorized parties may attempt to copy or otherwise obtain and use our products and/or enabling technologies. Policing the unauthorized use of our intellectual property rights is difficult and expensive, as is enforcing these rights against unauthorized use by others. Identifying unauthorized use of our intellectual property rights is difficult because we may be unable to monitor the processes and/or materials being employed by other parties. The steps we have taken may not prevent unauthorized use of our intellectual property rights, particularly in foreign countries where enforcement of intellectual property rights may be more difficult than in the United States.

 

Our continued commercial success will also depend in part upon not infringing the patents or violating the intellectual property rights of third parties. We are aware of patents and patent applications generally relating to aspects of our technologies filed by, and issued to, third parties. Nevertheless, we cannot determine with certainty whether such patents or patent applications of other parties may materially affect our ability to conduct our business. There may be existing patents of which we are unaware that we may inadvertently infringe, resulting in claims against us or our customers. In the event that the manufacture, use, and/or sale of our products or processes is challenged, or if our product forms or processes conflict with the patent rights of others, third parties could bring legal actions against us or our customers in the United States, Europe, or other countries, claiming damages and seeking to enjoin the manufacturing and/or marketing of our products. Additionally, it is not possible to predict with certainty what patent claims may issue from any relevant third-party pending patent applications. Third parties may be able to obtain patents with claims relating to our product forms, applications, and/or manufacturing processes, which they could attempt to assert against us or our customers.

 

15

 

In any case, litigation may be necessary to enforce, protect, or defend our intellectual property rights or to determine the validity and scope of the intellectual property rights of others. Any litigation could be unsuccessful, cause us to incur substantial costs, divert resources and the efforts of our personnel away from daily operations, harm our reputation, and/or result in the impairment of our intellectual property rights. In some cases, litigation may be threatened or brought by a patent-holding company or other adverse patent owner who has no relevant product revenues and against which our patents may provide little or no deterrence. If we are found to infringe any patents, we could be required to (1) pay substantial monetary damages, including lost profits, reasonable royalties, and/or treble damages if an infringement is found to be willful and/or (2) totally discontinue or substantially modify any products or processes that are found to be in violation of another party’s intellectual property rights. If our competitors are able to use our technology without payment to us, our ability to compete effectively could be harmed.

 

We face competition and technological advances by competitors, which could adversely affect the sales of our products.

 

The growth of our Company depends in part on maintaining and growing the sales of our current products in existing and new markets, but also in developing new products and technologies. There is significant competition among companies that provide solutions for pollutant emissions from diesel engines and liquids purification. Several companies market products that compete directly with our products. Other companies offer products that potential customers may consider to be acceptable or superior alternatives to our products and services, including products that are verified by the Environmental Protection Agency or other environmental authorities. We face direct competition from companies with greater financial, technological, manufacturing, and personnel resources. Newly developed products could be more effective and cost-efficient than our current or future products.

 

Any liability for environmental harm or damages resulting from technical faults or failures of our products could be substantial and could materially adversely affect our business and results of operations.

 

Customers rely upon our products to meet emissions control standards imposed upon them by regulatory bodies. Failure of our products to meet such standards could expose us to claims from customers. Our products are also integrated into goods used by consumers, and therefore a malfunction or the inadequate design of our products could result in product liability claims. Any liability for environmental harm or damages resulting from technical faults or failures could be substantial and could materially and adversely affect our business and results of operations. In addition, a well-publicized actual or perceived problem could adversely affect the market’s perception of our products, which would materially impact our financial condition and operating results.

 

We could become liable for damages resulting from our manufacturing activities, which could have a material adverse effect on our business or cause us to cease operations.

 

The nature of our manufacturing operations exposes us to potential claims and liability for environmental damage, personal injury, loss of life, and damage to, or destruction of, property. Our manufacturing operations are subject to numerous laws and regulations that govern environmental protection and human health and safety. These laws and regulations have changed frequently in the past, and it is reasonable to expect additional and more stringent changes in the future. Our manufacturing operations may not comply with future laws and regulations, and we may be required to make significant unanticipated capital and operating expenditures to bring our operations within compliance with such evolving regulations. If we fail to comply with applicable environmental laws and regulations, manufacturing guidelines, and workplace safety requirements, governmental authorities may seek to impose fines and penalties on us or to revoke or deny the issuance or renewal of operating permits, and private parties may seek damages from us. Under such circumstances, we could be required to curtail or cease operations, conduct site remediation or other corrective action, or pay substantial damage claims for which we may not have sufficient or any insurance coverage for claims.

 

Our actual or perceived failure to adequately protect personal data could adversely affect our business, financial condition, and results of operations.

 

A wide variety of provincial, state, national, foreign, and international laws and regulations apply to the collection, use, retention, protection, disclosure, transfer, and other processing of personal data. These privacy and data protection-related laws and regulations are evolving, with new or modified laws and regulations proposed and implemented frequently and existing laws and regulations subject to new or different interpretations. Further, our legal and regulatory obligations in foreign jurisdictions are subject to unexpected changes, including the potential for regulatory or other governmental entities to enact new or additional laws or regulations, to issue rulings that invalidate prior laws or regulations, or to increase penalties significantly. Compliance with these laws and regulations can be costly and can delay or impede the development and offering of new products and services. 

 

16

 

For example, the General Data Protection Regulation, which became effective in May 2018, imposes more stringent data protection requirements and provides for significantly greater penalties for noncompliance than the European Union laws that previously applied. Additionally, California enacted legislation, the California Consumer Privacy Act, which became effective on January 1, 2020. We may also be subject to additional obligations relating to personal data by contract that industry standards apply to our practices. Our actual or perceived failure to comply with applicable laws and regulations or other obligations to which we may be subject relating to personal data, or to protect personal data from unauthorized access, use, or other processing, could result in enforcement actions and regulatory investigations against us, claims for damages by customers and other affected individuals, fines, damage to our reputation, and loss of goodwill, any of which could have a material adverse effect on our operations, financial performance, and business. Further, evolving and changing definitions of personal data and personal information, including the classification of IP addresses, machine identification information, location data, and other information, may limit or inhibit our ability to operate or expand our business, including limiting business relationships and partnerships that may involve the sharing or uses of data and may require significant costs, resources, and efforts to comply.

 

Some of our officers and directors are located outside of the United States; therefore, it may be difficult for an investor to enforce within the United States any judgments obtained against us or such officers and directors.

 

The majority of our officers and some of our directors are nationals and/or residents of countries other than the United States, and all or a substantial portion of such persons’ assets may be located outside of the United States. As a result, it may be difficult for an investor to affect service of process or enforce within the United States any judgments obtained against us or such officers or directors, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state thereof. In addition, there is uncertainty as to whether the courts of other jurisdictions would recognize or enforce judgments of United States courts obtained against us or our directors and officers predicated upon the civil liability provisions of the securities laws of the United States or any state thereof or be competent to hear original actions brought in other jurisdictions against us or such officers and directors predicated upon the securities laws of the United States or any state thereof. 

 

We have signed partnership, distribution, and joint venture agreements and may engage in additional collaborations, joint ventures, or strategic alliances in the future, and we may not realize the benefits of such arrangements.

 

From time to time, we may enter into partnership, exclusivity, distribution, or joint venture agreements. Establishment of these agreements involves significant risks and uncertainties, including (i) our inability to cooperate with our local partner, (ii) our local partner having economic, business, or legal interests or goals that are inconsistent with ours, and (iii) the potential that our local partner may be unable to meet its economic or other obligations, which may require us to fulfill those obligations alone. In any joint venture in which we engage, we will rely on our local partner for the implementation of much of any such joint venture operation, and the success of any such operation is thus not entirely within our control. Any failure or perceived failure of a joint venture may have a material impact on our operations and financial condition.

 

If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results, and current and potential stockholders may lose confidence in our financial reporting.

 

Section 404 of the Sarbanes-Oxley Act of 2002 requires our management to assess the effectiveness of our internal control over financial reporting and to disclose in our filing if such controls were unable to provide assurance that a material error would be prevented or detected in a timely manner. We have an ongoing program to review the design of our internal controls framework in keeping with changes in business needs, implement necessary changes to our controls design, and test the system and process controls necessary to comply with these requirements. If our internal controls over financial reporting is determined to be ineffective, resulting in material weaknesses and/or significant deficiencies, investor perceptions regarding the reliability of our financial statements may be adversely affected, which could cause a decline in the market price of our stock and otherwise negatively affect our liquidity and financial condition.

 

In Item 9A, we disclose that, with respect to the standards of Sarbanes-Oxley Section 404 and the internal controls standard to which we are subjected, we reported material weaknesses in our internal controls over financial reporting. For additional information on this item, please see Item 9A, Controls and Procedures.

 

Although we believe our historical efforts have strengthened our internal control over financial reporting (and we concluded that our financial statements were reliable, notwithstanding the material weakness we reported), we cannot be certain that our revised internal control practices will ensure that we will have or maintain adequate internal control over financial reporting in future periods. Any failure to have or maintain such internal controls could adversely impact our ability to report our financial results accurately and on a timely basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations.

 

17

 

We may have risks associated with security of our information technology systems.

 

We make significant efforts to maintain the security and integrity of our information technology systems and data. Despite significant efforts to create security barriers to such systems, it is virtually impossible for us to entirely mitigate this risk. There is a risk of industrial espionage, cyber-attacks, misuse or theft of information or assets, or damage to assets by people who may gain unauthorized access to our facilities, systems, or information. Such cybersecurity breaches, misuse, or other disruptions could lead to the disclosure of confidential information; improper usage and distribution of our intellectual property; theft, manipulation, and destruction of private and proprietary data; and production downtimes. Although we actively employ measures to prevent unauthorized access to our information systems, preventing unauthorized use is inherently difficult. These events could adversely affect our financial results, and any legal action in connection with any such cybersecurity breach could be costly and time-consuming, may divert management’s attention and adversely affect the market’s perception of us and our products. In addition, we must frequently expand our internal information system to meet increasing demand in storage, computing, and communication, which may result in increased costs. Our internal information system is expensive to expand and must be highly secure due to the sensitive nature of our customers’ information that we transmit. Building and managing the support necessary for our growth places significant demands on our management and resources. These demands may divert such resources from the continued growth of our business and implementation of our business strategy.

 

RISKS RELATED TO OUR COMMON STOCK

 

Future equity financings or convertible debt issuances would dilute your ownership and could adversely affect your common stock ownership rights in comparison with those of other security holders.

 

Our Board of Directors has the power to issue additional shares of common or preferred stock without stockholder approval. In general, stockholders do not have preemptive rights to any common stock issued by us in the future; therefore, stockholders may experience additional dilution of their equity investment if we issue additional shares of common stock in the future, including shares issuable under equity incentive plans, or if we issue securities that are convertible into shares of our common stock. 

 

If additional funds are raised through the issuance of equity or convertible debt securities, the percentage of ownership of our existing stockholders will be reduced, and such newly issued securities may have rights, preferences, or privileges senior to those of existing stockholders. If we issue additional common stock or securities convertible into common stock, such issuance will reduce the proportionate ownership and voting power of each other stockholder. In addition, such stock issuances might result in a reduction of the market value of our common stock, which could make our stock unattractive to existing stockholders.

 

We will not receive a significant amount, or potentially any, additional funds upon the exercise of our pre-funded warrants; however, any exercise would increase the number of shares eligible for future resale in the public market and result in substantial dilution to our stockholders.

 

As of December 31, 2024, we have issued pre-funded warrants to purchase a total of 5,299,879 shares of our common stock, consisting of 3,930,008 pre-funded warrants issued prior to 2024 and an additional 1,369,871 pre-funded warrants issued in 2024. Of these, none have been exercised. Each of the pre-2024 pre-funded warrants is exercisable for $0.008 per share of common stock underlying such pre-funded warrant, while the pre-funded warrants issued in 2024 are exercisable for $0.001 per share of common stock underlying such pre-funded warrant. These warrants may be exercised through a cashless exercise mechanism, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant.

 

Accordingly, we will not receive a significant amount, or potentially any, additional funds upon the exercise of the pre-funded warrants. To the extent such pre-funded warrants are exercised, additional shares of common stock will be issued for nominal or no additional consideration, which will result in substantial dilution to the then-existing holders of our common stock and will increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect the market price of our common stock, causing our stock price to decline.

 

 

18

 

Provisions in our articles of incorporation and bylaws could discourage a change in control or an acquisition of us by a third party, even if the acquisition would be favorable to you, thereby adversely affecting existing stockholders.

 

Our articles of incorporation and bylaws contain provisions that may have the effect of making it more difficult or delaying attempts by others to obtain control of our Company, even when these attempts may be in the best interests of stockholders. For example, our articles of incorporation authorize our Board of Directors, without stockholder approval, to issue one or more series of preferred stock, which could have voting and conversion rights that adversely affect or dilute the voting power of the holders of common stock. These provisions and others that could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in our control or management, including transactions in which stockholders might otherwise receive a premium for their shares over then-current market prices. These provisions may also limit the ability of stockholders to approve transactions that they may deem to be in their best interests.

 

There is limited trading volume of our common stock, which could make it difficult for you to liquidate an investment in our common stock in a timely manner.

 

Since April 16, 2019, our common stock has been traded on Nasdaq Capital Market under the ticker LIQT. Because there is limited volume in our common stock, investors may not be able to liquidate their investments when they desire to do so.

 

In addition, if we fail to meet the criteria set forth in SEC and Nasdaq Capital Market rules and regulations, various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from recommending or selling our common stock, which may further affect its liquidity.

 

The market price of our common stock has been and may continue to be volatile.

 

The market price of our common stock has been volatile and fluctuates widely in response to various factors that are beyond our control. The price of our common stock is not necessarily indicative of our operating performance or long-term business prospects. In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock. Factors such as the following could cause the market price of our common stock to fluctuate substantially:

 

 

the underlying price of the commodities that affect our key markets of industrial water filtration, marine, and oil & gas;

 

announcements of capital budget changes by major customers;

 

the introduction of new products by our competitors;

 

announcements of technology advances by us or our competitors;

 

current events affecting the political and economic environment in the United States, Europe, or Asia;

 

conditions or industry trends, including demand for our products, services, and technological advances;

 

changes to financial estimates by us or by any securities analysts who might cover our stock;

 

additions or departures of our key personnel;

 

government regulation of our industry;

 

seasonal, economic, or financial conditions;

 

our quarterly operating and financial results;

 

litigation or public concern about the safety of our products; or

 

the effect of macroeconomic uncertainty, global supply chain disruptions, or public health crises.

 

The realization of any of these risks and other factors beyond our control could cause the market price of our common stock to decline significantly. In particular, the market price of our common stock may be influenced by changes in governmental regulations regarding diesel particle emissions and marine wastewater because demand for our products and services is closely related to those regulations. The stock market in general experiences, from time to time, extreme price and volume fluctuations. Periodic and/or continuous market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility may be worse if the trading volume of our common stock is low.

 

 

19

 

If securities analysts do not publish research or reports about our business or if they downgrade us or our sector, the price of our common stock could decline.

 

The trading market for our common stock will depend in part on research and reports that industry or financial analysts publish about us or our business. Furthermore, if one or more of the analysts who cover us downgrades us, the industry in which we operate, or the stock of any of our competitors, the price of our common stock may decline. If one or more of these analysts ceases coverage altogether, we could lose visibility, which could also lead to a decline in the price of our common stock. 

 

Future sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline.

 

If any significant number of our outstanding shares are sold, such sales could have a depressive effect on the market price of our stock. We are unable to predict the effect, if any, that the sale of shares, or the availability of shares for future sale, will have on the market price of the shares prevailing from time to time. Sales of substantial amounts of shares in the public market, or the perception that such sales could occur, could depress prevailing market prices for the shares. Such sales may also make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that we deem appropriate.

 

The Company is considered a “smaller reporting company” and is exempt from certain disclosure requirements, which could make our common stock less attractive to potential investors.

 

As a “smaller reporting company” (as defined in Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”)), we are not required and may not include a Compensation Discussion and Analysis section in our proxy statements,  provide only three years of business information, provide fewer years of selected financial data and have other “scaled” disclosure requirements that are less comprehensive than issuers that are not “smaller reporting companies,” which could make our stock less attractive to potential investors and could make it more difficult for stockholders to sell their shares.

 

We have no current plan to pay dividends on our common stock, and investors may lose the entire amount of their investment.

 

We have no current plans to pay dividends on our common stock; therefore, investors will not receive any funds absent a sale of their shares. We cannot assure investors of a positive return on their investment when they sell their shares, nor can we assure investors will not lose the entire amount of their investment.

 

PUBLIC COMPANY RISK FACTORS

 

We will continue to incur significant costs from operating as a public company, and our management may be required to devote substantial time to compliance initiatives that ultimately could have a material adverse effect on our financial condition and results of operations.   

 

As a public company, we expect to continue to incur significant legal, accounting, and other expenses. In addition, the Sarbanes-Oxley Act, along with rules subsequently implemented by the SEC, have imposed various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls as well as mandating certain corporate governance practices. Our management and other personnel will continue to devote a substantial amount of time and financial resources to these compliance initiatives.

 

20

 

If we fail to staff our accounting and finance function adequately or maintain internal control systems sufficient to meet the demands that are placed upon us as a public company, we may be unable to report our financial results accurately or in a timely manner and our business and stock price may suffer. The costs of being a public company, as well as the diversion of management’s time and attention, may have a material adverse effect on our future business, financial condition, and results of operations.

 

Changes in U.S. Generally Accepted Accounting Principles (“GAAP”) could adversely affect our financial results and may require significant changes to our internal accounting systems and processes.

 

We prepare our consolidated financial statements in conformity with GAAP. These principles are subject to interpretation by the Financial Accounting Standards Board (“FASB”), the SEC, and various bodies formed to interpret and create appropriate accounting principles and guidance. The FASB periodically issues new accounting standards on a variety of topics. For information regarding new accounting standards, please refer to Note 1, “Description of Business and Significant Accounting Policies – Recent Accounting Pronouncements,” of the Notes to Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data,” of this Annual Report on Form 10-K. These and other such standards generally result in different accounting principles, which may significantly impact our reported results or could result in variability of our financial results.

 

In preparing our financial statements, we make certain assumptions, judgments and estimates that affect amounts reported in our consolidated financial statements, which, if not accurate, may significantly impact our financial results.

 

We make assumptions, judgments, and estimates for a number of items, including the fair value of financial instruments, goodwill, long-lived assets, and other intangible assets; the realizability of deferred tax assets; the recognition of revenue; the fair value of stock awards; and others. We also make assumptions, judgments, and estimates in determining the accruals for employee-related liabilities, including commissions and variable compensation, and in determining the allowance or provisions for uncertain tax positions, doubtful accounts, excess or obsolete inventory, and legal contingencies. These assumptions, judgments, and estimates are drawn from historical experience and various other factors that we believe are reasonable under the circumstances as of the date of the consolidated financial statements. Actual results could differ materially from our estimates, and such differences could significantly impact our financial results.

 

Item 1B.

Unresolved Staff Comments

 

None.

 

Item 1C.

Cybersecurity

 

 

We maintain a cyber risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. This program is integrated within the Company’s enterprise risk management system and addresses both the corporate information technology environment and customer-facing products.

 

The underlying controls and processes of our cyber risk management program are consistent with recognized practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework and the International Organization Standardization 27001 Information Security Management System Requirements.

 

Cyber partners are also a key part of our cybersecurity infrastructure. We utilize third-party software to provide continuous monitoring of our infrastructure and to coordinate the investigation and remediation of alerts. A program for staging incident response drills is intended to prepare support teams in the event of a significant incident.

 

The Chief Financial Officer, who is responsible for assessing and managing our cyber-risk management program, informs senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents and supervises such efforts. The Chief Financial Officer has experience selecting, deploying, and operating cybersecurity technologies, initiatives, and processes, and relies on threat intelligence as well as other information obtained from governmental, public, or private sources, including external consultants.

 

21

 

The Audit Committee of the Board of Directors is responsible for overseeing cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. Management briefs the Audit Committee on the effectiveness of our cyber risk management program. In addition, cybersecurity risks are reviewed by the Board of Directors, at least annually.

 

We face risks from cybersecurity threats that could have a material adverse effect on our business, financial condition, results of operations, cash flows, or reputation. We have experienced, and will continue to experience, cyber incidents in the normal course of our business, however, prior cybersecurity incidents have not had a material adverse effect on our business, financial condition, results of operations, or cash flows. See “Risk Factors – Risks Relating to Our Business – We may have risks associated with security of our information technology systems”.
 

 

Item 2.

Properties

 

Our corporate headquarters are located at Industriparken 22C, 2750 Ballerup, Denmark. We lease approximately 67,000 square feet at our Ballerup location, of which approximately 10,000 square feet is used for office space and 57,000 square feet is used for production. The lease will expire on August 31, 2028. We also conduct operations at Benshøj Industrivej 24, 9500 Hobro, Denmark, where we lease approximately 45,750 square feet, of which approximately 10,750 square feet is used for office space and 35,000 square feet is used for production. The lease will expire on November 30, 2034. In addition, in 2024, we entered into a new lease agreement for additional production and office space at Benshøj Industrivej 1, 9500 Hobro, Denmark. This facility consists of approximately 18,800 square feet, including 13,500 square feet of production space and 5,300 square feet of office space. The lease will expire on April 30, 2034.

 

Item 3.

Legal Proceedings

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. Please reference Note 8 - Agreements, Commitments and Contingencies for details on such litigation.

 

Item 4.

Mine Safety Disclosures.

 

Not applicable. 

 

 

PART II

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Our common stock is quoted on the Nasdaq Capital Market under the symbol LIQT.

 

As of December 31, 2024, there were approximately 42 stockholders of record of our common stock as reported by our transfer agent, one of which is Cede & Co., a nominee for Depository Trust Company (“DTC”). All of the shares of common stock held by brokerage firms, banks, and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede & Co. as one stockholder.

 

We have not paid any cash dividends on our common stock and have no intention of paying any dividends on the shares of our common stock in the future. Subject to Nevada law, our Board of Directors will determine the payment of future dividends on our common stock, if any, and the amount of any dividends subject to:

 

 

any contractual restrictions limiting our ability to pay dividends that may be applicable at such time;

 

our earnings and cash flow;

 

our capital requirements;

 

our financial condition; and

 

other factors that our Board of Directors deems relevant.

 

Since the beginning of our fiscal year ended December 31, 2024, we have not sold any equity securities that were not registered under the Securities Act of 1933 and that were not previously reported in a quarterly report on Form 10-Q or in a current report on Form 8-K.

 

Since the beginning of our fiscal year ended December 31, 2024, we have not repurchased any of our equity securities.

 

22

 

Item 6.

[Reserved]

 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

We are a Nevada corporation, formerly named Blue Moose Media, Inc. In October 2011, we changed our name to LiqTech International, Inc. For more than two decades, we have developed and provided state-of-the-art technologies for gas and liquid purification using silicon carbide ceramic filters, particularly highly specialized filters for the control of soot exhaust particles from diesel engines and for liquid filtration. Using nanotechnology, LiqTech develops products using proprietary silicon carbide technology. LiqTech's products are based on unique silicon carbide membranes that facilitate new applications and improve existing technologies. In particular, the Company has developed a new standard of water filtration technology to meet the ever-increasing demand for higher water quality. By incorporating LiqTech's SiC liquid membrane technology with its long-standing systems design experience and capabilities, the Company offers solutions to the most difficult water pollution problems.

 

2024 Developments

 

On January 10, 2024, Simon Stadil tendered his resignation as Chief Financial Officer of the Company, effective as of April 10, 2024.

 

On February 14, 2024, the Company entered into a distribution agreement with Razorback Direct for produced water treatment solutions in the U.S.

 

On March 19, 2024, the Board of Directors of the Company appointed Phillip Massie Price as Interim Chief Financial Officer of the Company, effective April 1, 2024.

 

On May 7, 2024, the Company entered into a distribution agreement with Dan Marine Group for marine water treatment solutions for the Chinese market.

 

On May 14, 2024, the Company entered into a distribution agreement with Franman for marine water treatment solutions for the Greek Market.

 

On July 25, 2024, the Company entered into a distribution agreement with Danbee Marine Co. for marine water treatment solutions for the South Korean market.

 

On September 27, 2024, the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company agreed to issue and sell an aggregate of 3,630,129 shares of Common Stock, 1,369,871 pre-funded warrants to purchase shares of Common Stock, and warrants to purchase up to an aggregate of 5,000,000 shares of Common Stock for gross proceeds of approximately $10 million. The combined purchase price of one share of Common Stock and one accompanying warrant to purchase one share of Common Stock is $2.00. The combined purchase price of one pre-funded warrant and one accompanying warrant to purchase one share of Common Stock under the Purchase Agreement is $1.999.

 

The Company agreed to issue the Common Stock, warrants, and pre-funded warrants in two tranches: (i) a first tranche comprised of 29,227 shares of Common Stock, 555,302 pre-funded warrants, and warrants to purchase an aggregate of 584,529 shares of Common Stock, which closed on September 27, 2024; and (ii) a second tranche comprised of 3,600,902 shares of Common Stock, 814,569 pre-funded warrants, and warrants to purchase an aggregate of 4,415,471 shares of Common Stock, which closed on November 12, 2024.

 

On November 7, 2024, the Company announced the establishment of a joint venture in China for the marine water treatment market.

 

 

23

 

Results of Operations

 

Results of Operations for the Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023 

 

The following table sets forth our revenues, expenses, and net income for the years ended December 31, 2024, and 2023 in U.S. dollars, except for percentages.  

 

   

Year Ended December 31,

 
                                   

Period to Period Change

 
           

As a %

           

As a %

           

Percent

 
   

2024

   

of Sales

   

2023

   

of Sales

   

Variance

      %

Revenue

  $ 14,604,618       100.0 %   $ 18,001,652       100.0 %   $ (3,397,034 )     (18.9 )%

Cost of goods sold

    14,353,713       98.3     $ 15,226,176       84.6       (872,463 )     (5.7 )

Gross Profit

    250,905       1.7       2,775,476       15.4       (2,524,571 )     (91.0 )
                                                 

Operating Expenses

                                               

Selling expenses

    2,725,239       18.7       4,298,905       23.9       (1,573,666 )     (36.6 )

General and administrative expenses

    5,661,455       38.8       4,856,779       27.0       804,676       16.6  

Research and development expenses

    1,352,060       9.3       1,418,842       7.9       (66,782 )     (4.7 )

Total Operating Expenses

    9,738,754       66.7       10,574,526       58.7       (835,772 )     (7.9 )
                                                 

Loss from Operation

    (9,487,849 )     (65.0 )     (7,799,050 )     (43.3 )     (1,688,799 )     21.7  
                                                 

Other Income (Expense)

                                               

Interest and other income

    178,834       1.2       366,365       2.0       (187,531 )     (51.2 )

Interest expense

    (167,556 )     (1.1 )     (151,670 )     (0.8 )     (15,886 )     10.5  

Amortization of debt discount

    (615,552 )     (4.2 )     (400,903 )     (2.2 )     (214,649 )     53.5  

Gain (loss) on foreign currency transactions

    164,310       1.1       (359,960 )     (2.0 )     524,270       (145.6 )

Gain (loss) on disposal of property and equipment

    (456,282 )     (3.1 )     7,254       0.0       (463,536 )     (6,390.1 )

Loss on assets held for sale

    -       -       (439,388 )     (2.4 )     439,388       (100.0 )

Total Other Expense

    (896,246 )     (6.1 )     (978,302 )     (5.4 )     82,056       (8.4 )
                                                 

Loss Before Income Taxes

    (10,384,095 )     (71.1 )     (8,777,352 )     (48.8 )     (1,606,743 )     18.3  

Income Tax Benefit

    (38,837 )     (0.3 )     (206,207 )     (1.1 )     167,370       (81.2 )
                                                 

Net Loss

  $ (10,345,258 )     (70.8 )%   $ (8,571,145 )     (47.6 )%   $ (1,774,113 )     20.7 %

 

Revenues

 

Revenue for the year ended December 31, 2024, was $14,604,618 compared to $18,001,652 for the same period in 2023, representing a decrease of $3,397,034, or 18.9%. The decline was mainly due to reduced deliveries of liquid filtration systems, plastics products, ceramic membranes, and aftermarket sales, partly offset by increased sales of DPFs.

 

The decrease in deliveries of liquid filtration systems was mainly driven by reduced deliveries of pool filtration systems and marine scrubber systems. The decline in aftermarket sales was primarily due to remediation work carried out in the same period of 2023, which did not recur in 2024. The reduction in sales of plastic products was largely due to a significant one-time sale recorded in 2023 that did not recur in the current period. The increase in sales of DPFs was primarily driven by the effective execution of strategies designed to capitalize on the increased demand for DPFs.

 

 

 

24

 

Gross Profit

 

Gross profit for the year ended December 31, 2024, was $250,905 (or a gross profit margin of 1.7%), compared to $2,775,476 (or a gross profit margin of 15.4%) for the same period in 2023, representing a decrease of $2,524,571, or approximately 91.0%. This decline in gross profit can be attributed to the decrease in revenue, resulting in lower overall activity levels and underutilization of our manufacturing capacity, as well as an unfavorable sales mix, which resulted in a lower proportion of high-margin products such as liquid filtration systems and ceramic membranes. Specifically, the deliveries of containerized oil and gas pilot systems to the Middle East and the U.S. contributed to lower-than-usual margins, reflecting a strategic decision aimed at demonstrating and validating the value proposition associated with our technology and seeding the market for future growth. This approach has proven successful, securing an order for a full-scale system scheduled for delivery in 2025. Additionally, a thorough inventory review led to necessary adjustments for obsolescence and slow-moving items. The decline in gross profit was partly offset by decreased depreciation as well as continued initiatives aimed at optimizing manufacturing processes, which have improved profitability within DPF and ceramic membrane production. Included in the gross profit was depreciation of $1,830,553 and $2,598,095 for the years ended December 31, 2024, and 2023, respectively.

 

Operating Expenses

 

Total operating expenses for the year ended December 31, 2024, were $9,738,754, representing a decrease of $835,772, or 7.9%, compared to $10,574,526 for the same period in 2023.

 

Selling expenses for the year ended December 31, 2024, were $2,725,239, compared to $4,298,905 for the same period in 2023, representing a decrease of $1,573,666, or 36.6%. This decline was primarily driven by a reduction in executive officers, along with reductions in bonus payouts, travel costs, marketing expenses, and expenditures related to external sales consultancy services. The decrease was partially offset by increased bad debt expenses.

 

General and administrative expenses for the year ended December 31, 2024, were $5,661,455 compared to $4,856,779 for the same period in 2023, representing an increase of $804,676, or 16.6%. The increase was primarily due to newly created positions in supply chain and project management, as well as higher legal expenses, insurance costs, and recruitment costs associated with the resignations of our CFO and VP of Sales. Additionally, one-time expenses were incurred for the relocation of our plastics production facility. The increase was also partially attributable to the release of bonus provisions in the comparable period of 2023. Included in general and administrative expenses was non-cash compensation of $664,434 and $627,904 for the years ended December 31, 2024, and 2023, respectively.

 

The following is a summary of our non-cash compensation:

 

   

2024

   

2023

 

Compensation for vesting of restricted stock awards issued to the Board of Directors

  $ 202,125     $ 203,708  

Compensation for vesting of restricted stock awards issued to management

    462,309       424,196  

Total Non-Cash Compensation

  $ 664,434     $ 627,904  

 

Research and development expense for the year ended December 31, 2024, was $1,352,060 compared to $1,418,842 for the same period in 2023, representing a decrease of $66,782, or 4.7%. The decrease was primarily due to a more focused R&D strategy with fewer ongoing projects and a reduced average number of employees engaged in external research and development activities, as the Company streamlined and centralized its R&D function. This was partially offset by one-time exit costs associated with a loss-making external development project.

 

Other income (expense)

 

Total Other expense for the year ended December 31, 2024, was $896,246 compared to $978,302 for the comparable period in 2023, representing decreased expense of $82,056, or 8.4%. The decrease was primarily attributable to a gain on currency transactions resulting from the EUR/DKK decline against the USD during the period and a loss on assets held for sale in the comparable period in 2023. This decrease in other expenses was partially offset by a non-cash loss related to the disposal of property and equipment, decreased interest income, and higher debt discount amortization costs due to the extension of the maturity date for the senior promissory notes, with additional warrants issued as consideration for the extension.

 

25

 

Income taxes provision

 

The income tax benefit for the year ended December 31, 2024, was $38,837 compared to a benefit of $206,207 for the comparable period in 2023, representing a decrease of $167,370, or 81.2%, mainly driven by a decrease in tax credits associated with research and development activities in Denmark.

 

Net Loss

 

As a result of the cumulative effect of the factors described above, we had a net loss for the year ended December 31, 2024, of $10,345,258 compared to $8,571,145 for the comparable period in 2023, representing an increase in net loss of $1,774,113, or 20.7%.

 

Cash Flows

 

Year Ended December 31, 2024, Compared to Year Ended December 31, 2023

 

Cash used by operating activities is net loss adjusted for certain non-cash items and changes in assets and liabilities. Cash used by operating activities for the year ended December 31, 2024, was $7,534,072 compared to cash used by operating activities of $4,183,918 for the year ended December 31, 2023, representing an increase of $3,350,154. The cash used by operating activities for the year ended December 31, 2024, consists mainly of the net loss for the year of $(10,345,258) adjusted by depreciation and other non-cash items of $4,432,671. Further, changes in assets and liabilities included a decrease in accounts payable of $1,050,406, a decrease in accrued expenses of $908,607, and an increase in inventories of $587,806, partly offset by a decrease in contract assets of $1,102,791 and a decrease in accounts receivable of $620,116.

 

Net cash used in investing activities was $424,036 for the year ended December 31, 2024, as compared to $2,886,036 for the year ended December 31, 2023, representing a decrease of $2,462,000. The investing activities include general purchases of production equipment to continue optimizing production throughput and the internal production of rental assets, partly offset by proceeds from the disposition of production equipment in our Ballerup facility.

 

Cash provided by financing activities was $8,493,300 for the year ended December 31, 2024, as compared to $580,645 for the year ended December 31, 2023, representing an increase of $7,912,655. The increase was mainly driven by the equity raise, generating net proceeds of $9,922,063 from the issuance of common stock and prefunded warrants, partly offset by the repayment of lease agreements in connection with the sales of production equipment in Ballerup as mentioned above.

 

   

2024

   

2023

 

Net Cash Used in Operating Activities

  $ (7,534,072 )   $ (4,183,918 )

Net Cash Used in Investing Activities

    (424,036 )     (2,886,036 )

Net Cash Provided by Financing Activities

    8,493,300       580,645  

Net Change in Cash and Cash Equivalents

    446,547       (6,175,190 )

Cash and Cash Equivalents at End of Period

  $ 10,868,728     $ 10,422,181  

 

Off-Balance Sheet Arrangements

 

As of December 31, 2024, we had no off-balance sheet arrangements. We are not aware of any material transactions that are not disclosed in our consolidated financial statements.

 

Critical Accounting Policies

 

The methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. Our most critical accounting estimates include:

 

26

 

 

The assessment of revenue recognition, which impacts revenue and cost of sales;

 

The assessment of allowance for product warranties, which impacts cost of sales;

 

The assessment of collectability of accounts receivable, which impacts operating expenses when and if we record bad debt or adjust the allowance for doubtful accounts;

 

The assessment of recoverability of long-lived assets, which impacts gross margin or operating expenses when and if we record asset impairments or accelerate their depreciation;

 

The recognition and measurement of current and deferred income taxes (including the measurement of uncertain tax positions), which impact our provision for taxes;

 

The valuation of inventory, which impacts cost of sales; and

 

The recognition and measurement of loss contingencies, which impact cost of sales or operating expenses when we recognize a loss contingency, revise the estimate for a loss contingency, or record an asset impairment.

 

We discuss these policies further below as well as the estimates and judgments involved. 

 

Accounts Receivable and Allowance for Current Expected Credit Losses

 

Accounts receivable consist of trade receivables arising from credit sales to customers in the normal course of business. These receivables are recorded at the time of sale, net of an allowance for current expected credit losses. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 326, “Financial Instruments – Credit Losses,” the Company estimates expected credit losses based on historical bad debt experience, the aging of accounts receivable, the current creditworthiness of customers, prevailing economic conditions, and reasonable and supportable forward-looking information. Accounts receivable balances are written off when they are determined to be uncollectible.

 

The roll-forward of the allowance for current expected credit losses for the year ended December 31, 2024, and December 31, 2023 were as follows:

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Allowance for current expected credit losses at the beginning of the period

  $ 134,912     $ 59,559  

Bad debt expense

    578,423       82,066  

Receivables written off during the periods

    (49,577 )     (10,298 )

Effect of exchange rate changes

    (26,202 )     3,585  

Allowance for current expected credit losses at the end of the period

  $ 637,556     $ 134,912  

 

Inventories

 

Inventories directly purchased are carried at the lower of cost or net realizable value, as determined on the first-in, first-out (“FIFO”) method. For inventories produced, standard costs that approximate actual cost on the FIFO method are used to value inventories. Standard costs are reviewed at least annually by management or more often if circumstances indicate a change in cost has occurred. Work in process and finished goods include material, labor, and production overhead costs.

 

The Company adjusts the value of its inventories to the extent management determines that the cost cannot be recovered due to obsolescence or other factors. Inventory valuation adjustments for excess and obsolete inventories are calculated based on current inventories levels, movement, expected useful lives, and estimated future demand for our products.

 

Goodwill and Intangible assets

 

The purchase price of an acquired company is allocated between intangible assets and the net tangible assets of the acquired business, with the residual purchase price recorded as goodwill. The determination of the value of the intangible assets acquired involves certain judgments and estimates. These judgments can include, but are not limited to, the cash flows that an asset is expected to generate in the future and the appropriate weighted average cost of capital.

 

Acquired intangible assets with determinable useful lives are amortized on a straight-line or accelerated basis over the estimated periods benefited, ranging from one to ten years. Customer relationships and other non-contractual intangible assets with determinable lives are amortized over periods of five years.

 

27

 

The Company evaluates the recoverability of long-lived assets by comparing the carrying amount of an asset to estimated future net undiscounted cash flows generated by the asset. If such assets are considered to be impaired, the impairment recognized is measured as the amount by which the carrying value of the assets exceeds the fair value of the assets. The evaluation of recoverability involves estimates of future operating cash flows based upon certain forecasted assumptions, including, but not limited to, revenue growth rates, gross profit margins, and operating expenses over the expected remaining useful life of the related asset. A shortfall in these estimated operating cash flows could result in an impairment charge in the future.

 

Goodwill is not amortized but is evaluated annually for impairment at the reporting unit level or when indicators of a potential impairment are present. The Company estimates the fair value of the reporting unit using the discounted cash flow and market approaches. Forecasts of future cash flows are based on the Company’s best estimate of future net sales and operating expenses, using primarily expected category expansion, pricing, market segment fundamentals, and general economic conditions. During the years ended December 31, 2024, and 2023, no impairment charge for goodwill was recorded.

 

Long-Lived Assets

 

The Company assesses the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in its use of the assets. The Company measures the recoverability of assets that will continue to be used in its operations by comparing the carrying value of the asset grouping to its estimate of the related total future undiscounted net cash flows. If an asset grouping’s carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The impairment is measured by comparing the difference between the asset grouping’s carrying value and its fair value.

 

Impairments of long-lived assets are determined for groups of assets related to the lowest level of identifiable independent cash flows. Due to the Company’s asset usage model and the interchangeable nature of its ceramic filter manufacturing capacity, the Company must make subjective judgments in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company makes manufacturing process changes and other factory planning decisions, it must make subjective judgments regarding the remaining useful lives of assets, primarily process-specific filter manufacturing tools and building improvements. If the Company determines that the useful lives of assets are shorter than it had originally estimated, the Company accelerates the rate of depreciation over the assets’ new, shorter useful lives.

 

Management has analyzed the impact of the current economic climate on its financial statements as of December 31, 2024, and has determined that the changes to its significant judgements and estimates did not have a material impact with respect to goodwill, intangible assets, or long-lived assets. During the years ended December 31, 2024, and 2023, no impairment charge of long-lived assets has been recorded.

 

Revenue Recognition

 

The Company records revenue in accordance with FASB ASC Topic 606, “Revenue from Contracts with Customers.” Revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, the Company applies the following five-step approach: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as a performance obligation is satisfied. 

 

The Company sells products throughout the world. Sales by geographical region for the years ended December 31, 2024, and 2023 were as follows:

 

   

% Distribution

   

For the Year Ended December 31

 
   

2024

   

2023

   

2024

   

2023

 

Americas

    18 %     12 %   $ 2,693,002     $ 2,125,460  

Asia-Pacific

    5 %     14 %     645,044       2,506,215  

Europe

    71 %     65 %     10,440,040       11,820,674  

Middle East & Africa

    6 %     9 %     826,532       1,549,303  

Totals

    100 %     100 %   $ 14,604,618     $ 18,001,652  

 

28

 

The Company’s sales by product line for the years ended December 31, 2024, and 2023 were as follows:

 

   

% Distribution

   

For the Year Ended December 31

 
   

2024

   

2023

   

2024

   

2023

 

Water

    38 %     42 %   $ 5,538,741     $ 7,705,080  

Ceramics

    39 %     35 %     5,634,973       6,232,628  

Plastics

    23 %     21 %     3,381,408       3,736,529  

Corporate

    0 %     2 %     49,496       327,415  

Totals

    100 %     100 %   $ 14,604,618     $ 18,001,652  

 

For Water (systems and aftermarket), Ceramics (diesel particulate filters and membranes), and Plastics (components), revenue is recognized when performance obligations specified within the terms of a contract with the customer are satisfied, which occurs when control of the product transfers to the customer or when services are rendered by the Company. The majority of the Company's sales contracts contain performance obligations satisfied at a point in time when title along with risks and rewards of ownership have transferred to the customer. This generally occurs when the product is shipped or accepted by the customer. Revenue for service contracts is recognized as the services are provided. Revenue is measured as the amount of consideration expected to be received in exchange for transferring the goods or providing services. The satisfaction of performance obligations under the terms of a revenue contract generally gives rise to the right to receive payment from the customer. The Company's standard payment terms vary by the type and location of the customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. Pre-payments received prior to satisfaction of performance obligations are recorded as a contract liability. Considering the relatively short time between revenue recognition and receipt of payment, financing components do not exist between the Company and its customers.

 

For contracts with customers that include multiple performance obligations, judgment is required to determine whether performance obligations specified in these contracts are distinct and should be accounted for as separate revenue transactions for recognition purposes. For such arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are generally determined based on the prices charged to customers or using expected cost-plus margin.

 

System sales are recognized when the Company transfers control to the customer based upon sales and delivery conditions specified in the sales contract. This typically occurs upon shipment of the system from the production facility but can also occur upon other agreed delivery terms. In connection with the completion of the system, it is normal procedure to issue a FAT (Factory Acceptance Test) asserting that the customer has accepted the performance of the system as it is being shipped from our production facility in Hobro. As part of the performance obligation, the customer is normally offered commissioning services (final assembly and configuration at a place designated by the customer), and this commissioning is therefore considered a second performance obligation and is valued at cost, with the addition of a standard gross profit. This second performance obligation is recognized as revenue at the time of the commissioning services being rendered together with the cost incurred. Part of the invoicing to the customer is also attributed to the commissioning, and at transfer of the control of the system (i.e., the first performance obligation), this portion is recognized as contract liabilities. 

 

29

 

Aftermarket sales represent parts, extended warranties, and maintenance services. For the sale of aftermarket parts, the Company transfers control and recognizes revenue when parts are shipped to the customer. When customers are given the right to return eligible parts and accessories, the Company estimates the expected returns based on an analysis of historical experience. The Company adjusts estimated revenues at the earlier of when the most likely amount of consideration expected to be received changes or when the consideration becomes fixed. The Company recognizes revenue for extended warranty and maintenance agreements based on the standalone selling price over the life of the contract.

 

The Company has received long-term contracts for grants from government entities for the development and use of silicon carbide membranes in various water filtration and treatment applications and historically in the installation of various water filtrations systems. We measure transfer of control of the performance obligation on long-term contracts utilizing the cost-to-cost measure of progress, with cost of revenue including direct costs such as labor and materials. Under the cost-to-cost approach, the use of estimated costs to complete each performance obligation is a significant variable in the process of determining recognized revenue and a significant factor in the accounting for such performance obligations. The timing of when we bill our customers is generally dependent upon advance billings terms, milestone billings based on completion of certain phases of the work or when services are provided, or when products are shipped. Projects with performance obligations recognized over time that have costs and estimated earnings recognized to date in excess of cumulative billings are reported on our balance sheet as Contract assets. Projects with performance obligations recognized over time that have cumulative billings in excess of costs and estimated earnings recognized to date are reported on our balance sheet as contract liabilities.

 

Contracts Assets and Liabilities

 

Contract assets are the Company’s rights to consideration in exchange for goods or services and are recognized when a performance obligation has been satisfied but has not yet been billed. When the Company issues invoices to the customer, and the billing is higher than the capitalized Contract assets, the net amount is transferred to Contract liabilities. Contract assets/liabilities are transferred to revenue and cost of revenues when the right to consideration is unconditional and billed per the terms of the contractual agreement.

 

Contract assets also include unbilled receivables, which usually comprise the last invoice remaining after the delivery of the water treatment unit, where revenue is recognized at the transfer of control based upon signed acceptance of the unit by the customer. Most commonly, this invoice is sent to the customer at commissioning of the product or no later than 12 months after delivery. Further included in Contract Assets are short-term receivables such as VAT and other receivables.

 

The roll-forward of contract assets and contract liabilities for the years ended December 31, 2024, and 2023 were as follows: 

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Cost incurred

  $ 2,512,901     $ 3,225,728  

Unbilled project deliveries

    51,442       582,557  

VAT

    93,961       329,980  

Other receivables

    20,972       92,619  

Prepayments

    (1,121,897 )     (1,688,427 )

Deferred Revenue

    -       (33,360 )
    $ 1,557,379     $ 2,509,097  
                 

Distributed as follows:

               

Contract assets

  $ 1,666,698     $ 2,891,744  

Contract liabilities

    (109,319 )     (382,647 )
    $ 1,557,379     $ 2,509,097  

 

 

30

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method in accordance with ASC 740, “Income Taxes.” Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and establishes a valuation allowance if, based on the weight of available evidence, it believes it is more likely than not that all or a portion of the deferred tax assets will not be realized.

 

The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not the position will be sustainable upon examination by the taxing authority, including resolution of any related appeals or litigation processes. This evaluation is based on all available evidence and assumes that the tax authorities have full knowledge of all relevant information concerning the tax position. The tax benefit recognized is measured as the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in income tax expense.

 

Stock-Based Compensation  

 

Stock-based awards granted to qualified employees, non-employee directors, and consultants are measured at fair value and recognized as an expense in accordance with ASC Topic 718, “Share-Based Payments.” For service-based awards, stock-based compensation is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using a Black-Scholes option valuation model. Restricted stock awards are valued based on the closing stock price on the date of grant. The Company has elected to recognize forfeitures as they occur.

 

Warrant Liabilities

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants in accordance with ASC 480, “Distinguishing Liabilities from Equity,” and ASC 815-40, “Contracts in Entity’s Own Equity.” This assessment, which requires the use of professional judgment, considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own shares and whether the events where holders of the warrants could potentially require net cash settlement are within the Company’s control, among other conditions for equity classification. Warrant liabilities are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period.

 

Loss Contingencies

 

We are subject to various legal and administrative proceedings along with asserted and potential claims, accruals related to product warranties, and potential asset impairments (loss contingencies) that arise in the ordinary course of business. An estimated loss from such contingencies is recognized as a charge to income if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Disclosure of a loss contingency is required if there is at least a reasonable possibility that a loss has been incurred. The outcomes of legal and administrative proceedings and claims, and the estimation of product warranties and asset impairments, are subject to significant uncertainty. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. To estimate the losses associated with repairing and replacing parts in connection with product warranties, we make judgments with respect to customer claim rates. At least quarterly, we review the status of each significant matter, and we may revise our estimates. These revisions could have a material impact on our results of operations and financial position. 

 

 

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk.

 

We are not required to provide quantitative and qualitative disclosures about market risk because we are a smaller reporting company.

 

31

 

Item 8.

Financial Statements and Supplementary Data.

 

 

Index to Consolidated Financial Statements

 

 

Page

Report of Independent Registered Public Accounting Firm (PCAOB ID NO: 3627)

33

   

Consolidated Balance Sheets at December 31, 2024 and 2023

35

   

Consolidated Statements of Operations for the years ended December 31, 2024 and 2023

37

   

Consolidated Statement of Comprehensive Loss for the years ended December 31, 2024 and 2023

38

   

Consolidated Statement of Stockholders’ Equity for the years ended December 31, 2024 and 2023

39

   

Consolidated Statement of Cash Flows for the years ended December 31, 2024 and 2023

41

   

Notes to the Consolidated Financial Statements

43

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

To the Board of Directors and Shareholders of LiqTech International, Inc.:

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of LiqTech International, Inc. (“the Company”) as of December 31, 2024, and 2023, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2024 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) related to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Inventory Costing

 

Critical Audit Matter Description

 

As described in Notes 1 and 2 to the consolidated financial statements, the Company uses a standard costing method to value inventory produced. Management reviews and assesses the standard costing estimates annually or more frequently in the event circumstances indicate a change in cost structure or material variance from actual has occurred. In addition to raw materials, labor and energy usage charges, the Company applies production overhead allocations to each item.

 

 

We identified the auditing of inventory costing as a critical audit matter because of the significant estimates and assumptions management used in the determination of the standard costing allocation and related overhead allocations. Performing audit procedures to evaluate the reasonableness of these estimates and assumptions required a high degree of auditor judgment and an increased extent of effort.

 

How the Critical Audit Matter was Addressed in the Audit

 

Our audit procedures consisted of the following:

 

 

Obtaining an understanding and testing management’s process for developing the standard costing model and overhead allocations.

 

Assessing the accuracy, completeness, and reasonableness of the costs included in the standard costing model, including overhead allocations to ensure all costs capitalized were appropriate, complete and proper.

 

Evaluating the appropriateness and reasonableness of the assumptions used by management to allocate costs to specific inventory products, including assessing the reasonableness of production times, labor requirement and energy usage utilized.

 

Performing cost testing on raw material inputs purchased by tracing the recorded costs to supporting third party invoices.

 

Revenue Recognition – Contracts with Multiple Performance Obligations

 

Critical Audit Matter Description

 

As described in Note 1 to the consolidated financial statements, the Company has some contracts with customers that contain multiple performance obligations. For these contracts, management accounts for individual performance obligations separately if they are distinct. As described by management, management exercises judgment and uses estimates in order to (1) determine whether performance obligations are distinct and should be accounted for separately; (2) determine the standalone selling price of each performance obligation; (3) allocate the transaction price among the various performance obligations on a relative standalone selling price basis; and (4) determine whether revenue for each performance obligation should be recognized at a point in time or over time. Revenue recognized in 2024 related to contracts with multiple performance obligations was approximately $3.6 million.

 

We identified the auditing of revenue from contracts with multiple performance obligations as a critical audit matter because there was significant judgments by management in identifying, evaluating and accounting for performance obligations in contracts with multiple performance obligations, which led to significant auditor judgment and effort in performing procedures to evaluate whether contracts with multiple performance obligations were appropriately identified, evaluated and accounted for by management.

 

How the Critical Audit Matter was Addressed in the Audit

 

Our audit procedures consisted of the following:

 

 

Obtaining an understanding and testing management’s process for identifying, evaluating, and accounting for contracts with multiple performance obligations.

 

Examining revenue arrangements on a test basis, including assessing the key terms and conditions of the arrangements and testing the identification, evaluation, and accounting of the performance obligation for conformity with relevant authoritative guidance.

 

Performing procedures to test the completeness and accuracy of the data used to determine estimated stand-alone selling price.

 

Evaluating the reasonableness of the approaches used to determine estimated stand-alone selling price.

 

/s/ Sadler, Gibb & Associates, LLC

We have served as the Company’s auditor since 2018.

 

Draper, UT

March 28, 2025

 

  

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

 

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 
                 

Assets

               
                 

Current Assets:

               

Cash and restricted cash

  $ 10,868,728     $ 10,422,181  

Accounts receivable, net

    2,396,056       3,171,047  

Inventories, net

    5,541,192       5,267,816  

Contract assets

    1,666,698       2,891,744  

Prepaid expenses and other current assets

    168,443       337,391  
                 

Total Current Assets

    20,641,117       22,090,179  
                 

Non-Current Assets:

               

Property and equipment, net

    6,618,822       9,007,166  

Operating lease right-of-use assets

    4,450,822       4,055,837  

Deposits and other assets

    456,658       470,349  

Intangible assets, net

    39,367       114,593  

Goodwill

    220,693       233,723  
                 

Total Non-Current Assets

    11,786,362       13,881,668  
                 

Total Assets

  $ 32,427,479     $ 35,971,847  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

35

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

 

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 
                 

Liabilities and Stockholders’ Equity

               
                 

Current Liabilities:

               

Accounts payable

  $ 1,300,966     $ 2,444,653  

Accrued expenses

    2,491,479       3,550,542  

Current portion of finance lease liabilities

    458,347       590,550  

Current portion of operating lease liabilities

    544,197       531,355  

Contract liabilities

    109,319       382,647  
                 

Total Current Liabilities

    4,904,308       7,499,747  
                 

Non-Current Liabilities:

               

Deferred tax liability

    57,960       101,059  

Finance lease liabilities, net of current portion

    1,600,931       2,879,932  

Operating lease liabilities, net of current portion

    3,906,625       3,527,082  

Notes payable, net

    5,303,563       4,688,011  
                 

Total Non-Current Liabilities

    10,869,079       11,196,084  
                 

Total Liabilities

    15,773,387       18,695,831  
                 
                 

Stockholders' Equity:

               

Preferred stock; par value $0.001, 2,500,000 shares authorized, 0 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively

    -       -  

Common stock; par value $0.001, 50,000,000 shares authorized and 9,475,443 and 5,727,310 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively

    9,475       5,727  

Additional paid-in capital

    109,274,166       98,796,357  

Accumulated deficit

    (86,267,438 )     (75,922,180 )

Accumulated other comprehensive loss

    (6,362,111 )     (5,603,888 )
                 

Total Stockholders' Equity

    16,654,092       17,276,016  
                 

Total Liabilities and Stockholders' Equity

  $ 32,427,479     $ 35,971,847  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

36

 

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES 

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   

For the Year Ended

 
   

December 31,

 
   

2024

   

2023

 

Revenue

  $ 14,604,618     $ 18,001,652  

Cost of goods sold

    14,353,713       15,226,176  
                 

Gross Profit

    250,905       2,775,476  
                 

Operating Expenses:

               

Selling expenses

    2,725,239       4,298,905  

General and administrative expenses

    5,661,455       4,856,779  

Research and development expenses

    1,352,060       1,418,842  
                 

Total Operating Expenses

    9,738,754       10,574,526  
                 

Loss from Operations

    (9,487,849 )     (7,799,050 )
                 

Other Income (Expense):

               

Interest and other income

    178,834       366,365  

Interest expense

    (167,556 )     (151,670 )

Amortization of debt discount

    (615,552 )     (400,903 )

Gain (loss) on foreign currency transactions

    164,310       (359,960 )

Gain (loss) on disposal of property and equipment

    (456,282 )     7,254  

Loss on assets held for sale

    -       (439,388 )
                 

Total Other Expense

    (896,246 )     (978,302 )
                 

Loss Before Income Taxes

    (10,384,095 )     (8,777,352 )
                 

Income tax benefit

    (38,837 )     (206,207 )
                 

Net Loss

  $ (10,345,258 )   $ (8,571,145 )
                 

Loss Per Common Share – Basic and Diluted

  $ (1.64 )   $ (1.51 )
                 

Weighted-Average Common Shares Outstanding – Basic and Diluted

    6,310,379       5,688,281  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

37

 

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

 

   

For the Year Ended

 
   

December 31,

 
   

2024

   

2023

 
                 

Net Loss

  $ (10,345,258 )   $ (8,571,145 )
                 

Loss on foreign currency translation adjustments

    (758,223 )     716,679  
                 

Other Comprehensive Loss

  $ (11,103,481 )   $ (7,854,466 )

 

The accompanying notes are an integral part of these consolidated financial statements.

 

38

 

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

For the Years Ended December 31, 2024, and 2023

 

                                                 
                                   

Accumulated

         
                                   

Other

         
                   

Additional

           

Compre-

         
   

Common Stock

   

Paid-in

   

Accumulated

   

hensive

         
   

Shares

   

Amount

   

Capital

   

Deficit

   

Loss

   

TOTAL

 
                                                 

Balance, December 31, 2023

    5,727,310     $ 5,727     $ 98,796,357     $ (75,922,180 )   $ (5,603,888 )   $ 17,276,016  
                                                 

Common stock issued in settlement of RSUs

    148,002       148       (148 )     -       -       -  
                                                 

Tax withholdings paid related to stock-based compensation

    (29,998 )     (30 )     (104,910 )     -       -       (104,940 )
                                                 

Issuance of common shares, warrants and prefunded warrants in connection with a private offering

    3,630,129       3,630       9,918,433       -       -       9,922,063  
                                                 

Stock-based compensation

    -       -       664,434       -       -       664,434  
                                                 

Currency translation, net

    -       -       -       -       (758,223 )     (758,223 )
                                                 

Net Loss for the year ended December 31, 2024

    -       -       -       (10,345,258 )     -       (10,345,258 )
                                                 

Balance, December 31, 2024

    9,475,443     $ 9,475     $ 109,274,166     $ (86,267,438 )   $ (6,362,111 )   $ 16,654,092  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

39

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

For the Years Ended December 31, 2024, and 2023

 

                                                 
                                   

Accumulated

         
                                   

Other

         
                   

Additional

           

Compre-

         
   

Common Stock

   

Paid-in

   

Accumulated

   

hensive

         
   

Shares

   

Amount

   

Capital

   

Deficit

   

Loss

   

TOTAL

 
                                                 

Balance, December 31, 2022

    5,498,260     $ 5,498     $ 96,975,476     $ (67,351,035 )   $ (6,320,567 )   $ 23,309,372  
                                                 

Common stock issued in settlement of RSUs

    212,254       212       (212 )     -       -       -  
                                                 

Fractional shares from individual shareholder round-up following reverse split

    16,796       17       (17 )     -       -       -  
                                                 

Warrants issued in connection with Senior Promissory Notes

    -       -       1,193,206       -       -       1,193,206  
                                                 

Stock-based compensation

    -       -       627,904       -       -       627,904  
                                                 

Foreign currency translation adjustments

    -       -       -       -       716,679       716,679  
                                                 

Net loss for the year ended December 31, 2023

    -       -       -       (8,571,145 )     -       (8,571,145 )
                                                 

Balance, December 31, 2023

    5,727,310     $ 5,727     $ 98,796,357     $ (75,922,180 )   $ (5,603,888 )   $ 17,276,016  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

40

 

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   

For the Year Ended

 
   

December 31,

 
   

2024

   

2023

 

Cash Flows from Operating Activities:

               

Net loss

  $ (10,345,258 )   $ (8,571,145 )
                 

Adjustments to reconcile net loss to net cash used in operations:

               

Depreciation and amortization

    2,160,837       2,575,286  

Amortization of debt discount

    615,552       400,903  

Stock-based compensation

    664,434       627,904  

Amortization of right-of-use assets

    574,403       565,493  

Deferred taxes

    (38,837 )     (57,539 )

Loss on disposal of assets held for sale

    -       439,388  

(Gain) loss on disposal of property and equipment

    456,282       (7,254 )
                 

Changes in assets and liabilities:

               

Accounts receivable

    620,116       (765,956 )

Inventories

    (587,806 )     (1,045,838 )

Contract assets

    1,102,791       (825,974 )

Prepaid expenses and other current assets

    40,598       1,403,707  

Accounts payable

    (1,050,406 )     990,538  

Accrued expenses

    (908,607 )     639,309  

Operating lease liabilities

    (576,948 )     (562,948 )

Contract liabilities

    (261,223 )     (282,614 )

Assets held for sale

    -       292,822  
                 

Net Cash used in Operating Activities

    (7,534,072 )     (4,183,918 )
                 

Cash Flows from Investing Activities:

               

Purchase of property and equipment

    (1,367,729 )     (2,893,290 )

Proceeds from the disposal of property and equipment

    943,693       7,254  
                 

Net Cash used in Investing Activities

    (424,036 )     (2,886,036 )
                 

Cash Flows from Financing Activities:

               

Repayments of finance lease liabilities

    (1,428,763 )     (435,343 )

Proceeds from sale and leaseback agreement

    -       1,015,988  

Proceeds from issuance of common stock and prefunded warrants

    9,922,063       -  
                 

Net Cash provided by Financing Activities

    8,493,300       580,645  
                 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

    (88,645 )     314,119  
                 

Net Change in Cash, Cash Equivalents, and Restricted Cash

    446,547       (6,175,190 )
                 

Cash, Cash Equivalents, and Restricted Cash at Beginning of Period

    10,422,181       16,597,371  
                 

Cash, Cash Equivalents, and Restricted Cash at End of Period

  $ 10,868,728     $ 10,422,181  

 

The accompanying notes are an integral part of these consolidated financial statements. 

 

41

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

   

For the Year Ended

 
   

December 31,

 
   

2024

   

2023

 

Supplemental Disclosures of Cash Flow Information:

               

Cash paid for interest

  $ 160,926     $ 178,872  

Cash paid for income taxes

    -       -  
                 

Non-Cash Financing Activities

               

Financed purchases of property and equipment

  $ 166,443     $ 1,196,206  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

42

 

LIQTECH INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Business Organization

 

The consolidated financial statements include the accounts of LiqTech International, Inc. and its subsidiaries (the “Company”). The terms "Company", “us", "we" and "our" as used in this report refer to the Company and its subsidiaries, which are set forth below. The Company engages in the development, design, production, marketing, and sale of automated filtering systems, ceramic silicon carbide liquid applications, and diesel particulate air filters in the Americas, Asia-Pacific, Europe, and Middle East & Africa. Set forth below is a description of the Company and each of its subsidiaries:

 

LiqTech International, Inc., a Nevada corporation organized in July 2004, formerly known as Blue Moose Media, Inc.

 

LiqTech USA Inc., a Delaware corporation and a 100% owned subsidiary of the Company formed in May 2011.

 

LiqTech Holding A/S (formerly known as LiqTech International A/S), a Danish corporation, incorporated on January 15, 2000 (“LiqTech Holding”), a 100% owned subsidiary of LiqTech USA Inc., handling all joint group activities such as management, marketing, finance, IT, and others.

 

LiqTech NA, Inc. (“LiqTech NA”), incorporated in Delaware on July 1, 2005, a 100% owned subsidiary of LiqTech USA Inc., engaged in the production, marketing, and sale of ceramic diesel particulate and liquid filters in the United States and Canada. LiqTech NA closed operations in January 2021, and all activity in this company has ceased.

 

LiqTech Water A/S (formerly known as LiqTech Systems A/S), a Danish corporation (“LiqTech Water”), incorporated on September 1, 2009, engaged in the manufacture of fully automated filtering systems for use within marine applications, municipal pool and spa applications, and other industrial applications within Denmark and international markets.

 

LiqTech Plastics A/S (formerly known as BS Plastic A/S), a Danish corporation (“LiqTech Plastics”), acquired on September 1, 2019, engaged in the manufacture of specialized machined and welded plastic parts within Denmark and international markets.

 

LiqTech Ceramics A/S, a Danish corporation (“LiqTech Ceramics”), incorporated on December 20, 2019, engaged in the development, design, application, marketing, and sales of membranes, ceramic diesel particulate and liquid filters, and catalytic converters in Europe, Asia, and South America.

 

LiqTech Water Projects A/S, a Danish corporation (“LiqTech Water Projects”), incorporated on July 28, 2020, that is a dormant company without activity. 

 

LiqTech Emission Control A/S, a Danish corporation (“LiqTech Emission Control”), incorporated on March 1, 2021, that is a dormant company without activity. 

 

Nantong JiTRI LiqTech Green Energy Technology Co., Ltd., a Chinese corporation (“LiqTech JiTRI”), incorporated on December 6, 2024, as a joint venture in which the Company holds a 90% ownership stake. The company is focused on developing and commercializing systems for marine water treatment market in China.

 

Basis of Presentation 

 

The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) as codified in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and its majority-owned subsidiary. All material intercompany transactions and accounts have been eliminated in the consolidation.

 

43

 

Use of Estimates 

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and judgments include revenue recognition, allowance for estimated credit losses, reserves for excess and obsolete inventories, impairment evaluations of long-lived assets and goodwill, fair value measurements of warrants and stock-based compensation, and assessments of contingent liabilities.

 

Foreign Currency

 

The functional currency of LiqTech International, Inc. and LiqTech USA, Inc. is the U.S. Dollar. The functional currency of LiqTech Holding, LiqTech Water, LiqTech Plastics, LiqTech Ceramics, LiqTech Water Projects, and LiqTech Emission Control is the Danish Krone (“DKK”); and the functional currency of LiqTech JiTRI is the Renminbi (“RMB”). The Company’s reporting currency is the U.S. Dollar for the purpose of these consolidated financial statements. The balance sheet accounts of the foreign subsidiaries are translated into U.S. Dollars at the period-end exchange rates, equity is translated at historical cost, and all revenue and expenses are translated into U.S. Dollars at the average exchange rates prevailing during the twelve months ended December 31, 2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income (loss) in stockholders’ equity. Transaction gains and losses that arose from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred. 

 

Cash, Cash Equivalents, and Restricted Cash

 

The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. As of December 31, 2024, and 2023, the Company held $0 and $941,361, respectively, of restricted cash. The restricted cash is held as security by a local financial institution for ensuring a leasing facility and for payment guarantees issued for the benefit of customers in connection with prepayments of sales orders and for warranties after the delivery of sales orders.

 

Accounts held in each U.S. institution are insured by the Federal Deposit Insurance Company (“FDIC”) up to $250,000. At December 31, 2024, and December 31, 2023, the Company had $4,414,510 and $0 in excess of the FDIC insured limit, respectively.

 

Accounts Receivable and Current Expected Credit Losses

 

Accounts receivable consist of trade receivables arising from credit sales to customers in the normal course of business. These receivables are recorded at the time of sale, net of an allowance for current expected credit losses. In accordance with FASB ASC Topic 326, “Financial Instruments – Credit Losses,” the Company estimates expected credit losses based on historical bad debt experience, the aging of accounts receivable, the current creditworthiness of customers, prevailing economic conditions, and reasonable and supportable forward-looking information. Accounts receivable balances are written off when they are determined to be uncollectible.

 

The roll-forward of the allowance for current expected credit losses as of  December 31, 2024, and 2023 were as follows: 

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Allowance for current expected credit losses at the beginning of the period

  $ 134,912     $ 59,559  

Bad debt expense

    578,423       82,066  

Receivables written off during the periods

    (49,577 )     (10,298 )

Effect of exchange rate changes

    (26,202 )     3,585  

Allowance for current expected credit losses at the end of the period

  $ 637,556     $ 134,912  

 

44

 

Inventories

 

Inventories directly purchased is carried at the lower of cost or net realizable value, as determined on the first-in, first-out (“FIFO”) method. For inventories produced, standard costs that approximate actual cost on the FIFO method are used to value inventories. Standard costs are reviewed at least annually by management or more often if circumstances indicate a change in cost has occurred. Work in process and finished goods include material, labor, and production overhead costs.

 

The Company adjusts the value of its inventories to the extent management determines that the cost cannot be recovered due to obsolescence or other factors. Inventory valuation adjustments for excess and obsolete inventories are calculated based on current inventories levels, movement, expected useful lives, and estimated future demand for our products.

 

Leases

 

The Company has elected to not recognize lease assets and liabilities with an initial term of 12 months or less and to not separate lease and non-lease components. The Company’s accounting for finance leases remains substantially unchanged. Operating lease right-of-use (“ROU”) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value. The Company uses the implicit rate when determinable. The operating lease ROU asset also included prepaid lease payments, reduced by accrued lease payments. The Company’s lease terms may include options to extend or terminate the lease, recognized when it is reasonably certain that those options will be exercised. Operating lease cost for lease payments will be recognized on a straight-line basis over the lease term.

 

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets, which range from three to ten years.

 

Long-Lived Assets

 

The Company assesses the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in its use of the assets. The Company measures the recoverability of assets that will continue to be used in its operations by comparing the carrying value of the asset grouping to its estimate of the related total future undiscounted net cash flows. If an asset grouping’s carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The impairment is measured by comparing the difference between the asset grouping’s carrying value and its fair value.

 

Impairments of long-lived assets are determined for groups of assets related to the lowest level of identifiable independent cash flows. Due to the Company’s asset usage model and the interchangeable nature of its ceramic filter manufacturing capacity, the Company must make subjective judgments in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company makes manufacturing process changes and other factory planning decisions, it must make subjective judgments regarding the remaining useful lives of assets, primarily process-specific filter manufacturing tools and building improvements. If the Company determines that the useful lives of assets are shorter than it had originally estimated, the Company accelerates the rate of depreciation over the assets’ new, shorter useful lives.

 

Management has analyzed the impact of the current economic climate on its financial statements as of December 31, 2024, and has determined that the changes to its significant judgements and estimates did not have a material impact with respect to goodwill, intangible assets, or long-lived assets. During the years ended December 31, 2024, and 2023, no impairment charges for long-lived assets were recorded.

 

45

 

Goodwill and Intangible Assets

 

The purchase price of an acquired company is allocated between intangible assets and the net tangible assets of the acquired business, with the residual purchase price recorded as goodwill. The determination of the value of the intangible assets acquired involves certain judgments and estimates. These judgments can include, but are not limited to, the cash flows that an asset is expected to generate in the future and the appropriate weighted average cost of capital.

 

Acquired intangible assets with determinable useful lives are amortized on a straight-line or accelerated basis over the estimated periods benefited, ranging from one to ten years. Customer relationships and other non-contractual intangible assets with determinable lives are amortized over periods of five years.

 

The Company evaluates the recoverability of long-lived assets by comparing the carrying amount of an asset to estimated future net undiscounted cash flows generated by the asset. If such assets are considered to be impaired, the impairment recognized is measured as the amount by which the carrying value of the assets exceeds the fair value of the assets. The evaluation of recoverability involves estimates of future operating cash flows based upon certain forecasted assumptions, including, but not limited to, revenue growth rates, gross profit margins, and operating expenses over the expected remaining useful life of the related asset. A shortfall in these estimated operating cash flows could result in an impairment charge in the future.

 

Goodwill is not amortized but is evaluated annually for impairment at the reporting unit level as of December 31 or when indicators of a potential impairment are present. The Company estimates the fair value of the reporting unit using the discounted cash flow and market approaches. Forecasts of future cash flows are based on the Company’s best estimate of future net sales and operating expenses, using primarily expected category expansion, pricing, market segment fundamentals, and general economic conditions. During the years ended December 31, 2024, and 2023, no impairment charge for goodwill was recorded.

 

Revenue Recognition

 

The Company records revenue in accordance with FASB ASC Topic 606, “Revenue from Contracts with Customers.” Revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, the Company applies the following five-step approach: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as a performance obligation is satisfied.

 

The Company sells products throughout the world. Sales by geographical region for the year ended December 31, 2024, and 2023 were as follows:

 

   

% Distribution

   

For the Year Ended December 31

 
   

2024

   

2023

   

2024

   

2023

 

Americas

    18 %     12 %   $ 2,693,002     $ 2,125,460  

Asia-Pacific

    5 %     14 %     645,044       2,506,215  

Europe

    71 %     65 %     10,440,040       11,820,674  

Middle East & Africa

    6 %     9 %     826,532       1,549,303  

Totals

    100 %     100 %   $ 14,604,618     $ 18,001,652  

 

The Company’s sales by product line for the years ended December 31, 2024, and 2023 were as follows:

 

   

% Distribution

   

For the Year Ended December 31

 
   

2024

   

2023

   

2024

   

2023

 

Water

    38 %     42 %   $ 5,538,741     $ 7,705,080  

Ceramics

    39 %     35 %     5,634,973       6,232,628  

Plastics

    23 %     21 %     3,381,408       3,736,529  

Corporate

    0 %     2 %     49,496       327,415  

Totals

    100 %     100 %   $ 14,604,618     $ 18,001,652  

 

46

 

For Water (systems and aftermarket), Ceramics (diesel particulate filters and membranes), and Plastics (components), revenue is recognized when performance obligations specified within the terms of a contract with the customer are satisfied, which occurs when control of the product transfers to the customer or when services are rendered by the Company. The majority of the Company's sales contracts contain performance obligations satisfied at a point in time when title along with risks and rewards of ownership have transferred to the customer. This generally occurs when the product is shipped or accepted by the customer.  Revenue for service contracts is recognized as the services are provided. Revenue is measured as the amount of consideration expected to be received in exchange for transferring the goods or providing services. The satisfaction of performance obligations under the terms of a revenue contract generally gives rise to the right to receive payment from the customer. The Company's standard payment terms vary by the type and location of the customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. Pre-payments received prior to satisfaction of performance obligations are recorded as a Contract liability. Considering the relatively short time between revenue recognition and receipt of payment, significant financing components do not exist between the Company and its customers.

 

For contracts with customers that include multiple performance obligations, judgment is required to determine whether performance obligations specified in these contracts are distinct and should be accounted for as separate revenue transactions for recognition purposes. For such arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are generally determined based on the prices charged to customers or using an expected cost-plus margin.

 

System sales are recognized when the Company transfers control to the customer based upon sales and delivery conditions specified in the sales contract. This typically occurs upon shipment of the system from the production facility but can also occur upon other agreed delivery terms. In connection with the completion of the system, it is normal procedure to issue a Factory Acceptance Test (“FAT”) asserting that the customer has accepted the performance of the system as it is being shipped from our production facility in Hobro. As part of the performance obligation, the customer is normally offered commissioning services (final assembly and configuration at a place designated by the customer), and this commissioning is therefore considered a second performance obligation and is valued at cost, with the addition of a standard gross margin. This second performance obligation is recognized as revenue at the time of the commissioning services being rendered together with the cost incurred. Part of the invoicing to the customer is also attributed to the commissioning, and at transfer of the control of the system (i.e., the first performance obligation), this portion is recognized as Contract liabilities.

 

Aftermarket sales represent parts, extended warranties, and maintenance services. For the sale of aftermarket parts, the Company transfers control and recognizes revenue when parts are shipped to the customer. When customers are given the right to return eligible parts and accessories, the Company estimates the expected returns based on an analysis of historical experience. The Company adjusts estimated revenues at the earlier of when the most likely amount of consideration expected to be received changes or when the consideration becomes fixed. The Company recognizes revenue for extended warranty and maintenance agreements based on the standalone selling price over the life of the contract.

 

The Company has received long-term contracts for grants from government entities for the development and use of silicon carbide membranes in various water filtration and treatment applications and historically in the installation of various water filtration systems. We measure the transfer of control of the performance obligation on long-term contracts utilizing the cost-to-cost measure of progress, with cost of revenue including direct costs such as labor and materials. Under the cost-to-cost approach, the use of estimated costs to complete each performance obligation is a significant variable in the process of determining recognized revenue and a significant factor in the accounting for such performance obligations. The timing of when we bill our customers is generally dependent upon advance billings terms, milestone billings based on completion of certain phases of the work, or when services are provided or products are shipped. Projects with performance obligations recognized over time that have costs and estimated earnings recognized to date in excess of cumulative billings are reported on our balance sheet as Contract assets. Projects with performance obligations recognized over time that have cumulative billings in excess of costs and estimated earnings recognized to date are reported on our balance sheet as contract liabilities.

 

47

 

Contracts Assets and Contract Liabilities

 

Contract assets are the Company’s rights to consideration in exchange for goods or services and are recognized when a performance obligation has been satisfied but has not yet been billed. When the Company issues invoices to the customer, and the billing is higher than the capitalized Contract assets, the net amount is transferred to Contract liabilities. Contract assets/liabilities are transferred to revenue and cost of goods sold when the right to consideration is unconditional and billed per the terms of the contractual agreement.

 

Contract assets also include unbilled receivables, which usually comprise the last invoice remaining after the delivery of the water treatment unit, where revenue is recognized at the transfer of control based upon signed acceptance of the unit by the customer. Most commonly, this invoice is sent to the customer at commissioning of the product or no later than 12 months after delivery. Further included in Contract Assets are short-term receivables such as VAT and other receivables.

 

The roll-forward of contract assets and liabilities for the year ended December 31, 2024, and 2023 were as follows: 

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Cost incurred

  $ 2,512,901     $ 3,225,728  

Unbilled project deliveries

    51,442       582,557  

VAT

    93,961       329,980  

Other receivables

    20,972       92,619  

Prepayments

    (1,121,897 )     (1,688,427 )

Deferred Revenue

    -       (33,360 )
    $ 1,557,379     $ 2,509,097  
                 

Distributed as follows:

               

Contract assets

  $ 1,666,698     $ 2,891,744  

Contract liabilities

    (109,319 )     (382,647 )
    $ 1,557,379     $ 2,509,097  

 

Cost of Sales

 

The Company includes product costs (i.e., material, direct labor and overhead costs), shipping and handling expense, production-related depreciation expense, and product license agreement expense in cost of sales.

 

Advertising Costs

 

Costs incurred in connection with advertising of the Company’s products are expensed as incurred. Advertising costs are included in selling expenses, and total advertising costs amounted to $56,037 and $70,580 for the years ended December 31, 2024, and 2023, respectively.

 

Research and Development Cost

 

The Company expenses research and development costs for the development of new products as incurred. Included in operating expense for the years ended December 31, 2024, and 2023 were $1,352,060 and $1,418,842, respectively, of research and development costs.

 

48

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method in accordance with ASC 740, “Income Taxes.” Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and establish a valuation allowance if, based on the weight of available evidence, it believes it is more likely than not that all or a portion of the deferred tax assets will not be realized.

 

The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not the position will be sustainable upon examination by the taxing authority, including resolution of any related appeals or litigation processes. This evaluation is based on all available evidence and assumes that the tax authorities have full knowledge of all relevant information concerning the tax position. The tax benefit recognized is measured as the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in income tax expense.

 

Loss Contingencies

 

The Company is subject to various legal and administrative proceedings along with asserted and potential claims, accruals related to product warranties, and potential asset impairments (loss contingencies) that arise in the ordinary course of business. An estimated loss from such contingencies is recognized as a charge to income if it is probable that a liability has been incurred, and the amount of the loss can be reasonably estimated. Disclosure of a loss contingency is required if there is at least a reasonable possibility that a loss has been incurred. The outcomes of legal and administrative proceedings and claims, and the estimation of product warranties and asset impairments, are subject to significant uncertainty. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. To estimate the losses associated with repairing and replacing parts in connection with product warranties, the Company makes judgments with respect to customer claim rates. At least quarterly, the Company reviews the status of each significant matter, and it may revise its estimates. These revisions could have a material impact on the Company’s results of operations and financial position.

 

Loss Per Share

 

The Company calculates loss per share in accordance with FASB ASC 260, "Earnings Per Share". Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options and warrants that have been granted but have not been exercised.

 

Stock Based Compensation

 

Stock-based awards granted to qualified employees, non-employee directors, and consultants are measured at fair value at the grant date and recognized as an expense in accordance with ASC Topic 718, “Share-Based Payments.” For service-based awards, stock-based compensation is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using a Black-Scholes option valuation model. Restricted stock awards are valued based on the closing stock price on the date of grant. The Company has elected to recognize forfeitures as they occur.

 

Warrant Liabilities

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants in accordance with ASC 480, “Distinguishing Liabilities from Equity,” and ASC 815-40, “Contracts in Entity’s Own Equity.” This assessment, which requires the use of professional judgment, considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own shares and whether the events where holders of the warrants could potentially require net cash settlement are within the Company’s control, among other conditions for equity classification. Warrant liabilities are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period.

 

49

  

Fair Value of Financial Instruments

 

The Company accounts for fair value measurements for financial assets and liabilities in accordance with FASB ASC Topic 820“Fair Value Measurement”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

 

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid expenses, accounts payable, and accrued expenses approximate their recorded values due to their short-term maturities.

 

Recently Adopted Accounting Pronouncements

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company adopted ASU 2023-07 retrospectively on December 31, 2024. See Note 12 for further details.

 

Recently Issued Accounting Pronouncements

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires additional disclosures around specific expense categories in the notes to the financial statements. The additional annual disclosures are effective for our year ending December 31, 2027, and the additional interim disclosures are effective in 2028. These disclosures will be applied prospectively. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

In August 2023, the FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement, which requires a newly-formed joint venture to apply a new basis of accounting to its contributed net assets, resulting in the joint venture initially measuring its contributed net assets at fair value on the formation date. ASU 2023-05 is effective for all joint venture formations with a formation date on or after January 1, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted for joint ventures formed before the effective date. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its financial statements.

 

50

   
 
NOTE 2 - INVENTORIES

 

Inventories consisted of the following on December 31, 2024, and 2023:

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Furnace parts and supplies

  $ -     $ 55,177  

Raw materials

    2,734,781       3,301,526  

Work in process

    2,435,280       1,271,458  

Finished goods and filtration systems

    1,580,255       1,507,113  

Reserve for obsolescence

    (1,209,124 )     (867,458 )

Total inventories, net

  $ 5,541,192     $ 5,267,816  

 

Inventory valuation adjustments for excess and obsolete inventories are calculated based on current inventory levels, movements, expected useful lives, and estimated future demand for the products.

  

 

NOTE 3 - PROPERTY AND EQUIPMENT

 

Property and equipment consisted of the following on December 31, 2024, and 2023:

 

    Useful life     December 31,     December 31,  
   

(Years)

   

2024

   

2023

 

Production equipment

  3 - 10     $ 9,553,545     $ 9,433,581  

Production equipment - finance lease

  3 - 10       3,675,935       5,182,375  

Lab equipment

  3 - 10       123,611       130,909  

Computer equipment

  3 - 5       1,103,623       1,141,790  

Computer equipment - finance lease

  3 - 5       80,518       -  

Vehicles

  3 - 5       21,067       26,897  

Furniture and fixture

  5       1,378,252       1,474,032  

Furniture and fixture - finance lease

  5       326,411       260,911  

Leasehold improvements

  5 - 10       3,007,321       3,184,871  
            19,270,283       20,835,366  

Less accumulated depreciation

          (11,494,435 )     (10,950,622 )

Less accumulated depreciation - finance lease

          (1,157,026 )     (877,578 )

Net Property and Equipment

        $ 6,618,822     $ 9,007,166  

 

Depreciation expense amounted to $2,089,478 and $2,472,031 for the year ended December 31, 2024, and 2023, respectively. Of the $2,089,478 for the year ended December 31, 2024, $1,830,553 is allocated to cost of goods sold and $258,925 is allocated to operating expenses. 

   

 

NOTE 4 - LEASES

 

The Company leases certain vehicles, real property, production equipment, and office equipment under lease agreements. The Company evaluates each lease to determine its appropriate classification as an operating lease or finance lease for financial reporting purposes. The majority of our operating leases are non-cancelable operating leases for production and office space in Hobro (two facilities) and Copenhagen, Denmark. The lease agreements expire on April 30, 2034,  November 30, 2034, and August 31, 2028, respectively (for the two facilities in Hobro and the office space in Copenhagen, in that order)

.

During the year ended December 31, 2024, cash paid for amounts included for the measurement of operating lease liabilities was $853,566, and the Company recorded operating lease expenses of $851,110 in operating expenses.

 

During the year ended December 31, 2024, cash paid for amounts included for the measurement of finance lease liabilities was $1,378,297, and the Company recorded finance lease expenses of $154,598 in other expenses.

 

51

 

Supplemental balance sheet information related to leases as of December 31, 2024, and 2023 were as follows:

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Operating leases:

               

Operating lease right-of-use assets

  $ 4,450,822     $ 4,055,837  
                 

Operating lease liabilities – current

  $ 544,197     $ 531,355  

Operating lease liabilities – long-term

    3,906,625       3,527,082  

Total operating lease liabilities

  $ 4,450,822     $ 4,058,437  
                 

Finance leases:

               

Property and equipment, at cost

  $ 4,082,864     $ 5,443,287  

Accumulated depreciation

    (1,157,025 )     (877,578 )

Property and equipment, net

  $ 2,925,839     $ 4,565,709  
                 

Finance lease liabilities – current

  $ 458,347     $ 590,550  

Finance lease liabilities – long-term

    1,600,931       2,879,932  

Total finance lease liabilities

  $ 2,059,278     $ 3,470,482  
                 

Weighted average remaining lease term:

               

Operating leases

    8.1       8.3  

Finance leases

    3.1       4.3  
                 

Weighted average discount rate:

               

Operating leases

    6.8 %     6.7 %

Finance leases

    5.5 %     6.0 %

 

Maturities of lease liabilities at December 31, 2024 were as follows:

 

   

Operating

   

Finance

 
   

Leases

   

Leases

 

2025

  $ 828,986     $ 562,072  

2026

    818,823       544,452  

2027

    818,823       506,462  

2028

    700,078       613,474  

2029

    462,587       76,893  

Thereafter

    2,128,429       57,288  

Total payment under lease agreements

    5,757,726       2,360,641  

Less imputed interest

    (1,306,904 )     (301,363 )

Total lease liabilities

  $ 4,450,822     $ 2,059,278  

 

52

   
 

NOTE 5 - INTANGIBLE ASSETS

 

On  December 31, 2024, and 2023, other intangible assets, net of accumulated amortization, consisted of customer relationships acquired in connection with the purchase of BS Plastic A/S and the cost of patent applications for the Company’s products.

 

Intangible assets consisted of the following at December 31, 2024, and 2023:

 

   

2024

   

2023

 

Customer relationships

  $ 461,997     $ 489,273  

Patent cost

    173,624       183,874  
      635,621       673,147  

Less accumulated amortization

    (596,254 )     (558,554 )

Intangible assets, net

  $ 39,367     $ 114,593  

 

Amortization expense amounted to $71,359 and $105,522 for the years ended December 31, 2024, and 2023, respectively.

 

Expected future amortization expense for the next five years consists of the following as of  December 31, 2024:

 

   

Amortization

 

Year ending December 31,

 

Expenses

 

2025

    7,238  

2026

    7,238  

2027

    7,238  

2028

    7,238  

2029

    7,238  

Thereafter

    3,177  
    $ 39,367  

  

  

 

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses consisted of the following at December 31, 2024, and 2023:

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Accounts payable

  $ 1,300,966     $ 2,444,653  

Accrued payroll liabilities

    746,938       1,223,712  

Product warranty accrual

    621,031       629,100  

Other accrued expenses

    1,123,510       1,697,730  

Total accounts payable and accrued expenses

  $ 3,792,445     $ 5,995,195  

 

 

 

 

53

  
 

NOTE 7 - LONG-TERM DEBT

 

Senior Promissory Notes

 

On June 22, 2022, the Company issued and sold Senior Promissory Notes in an aggregate principal amount of $6.0 million (the “Notes”) and issued warrants to purchase 531,250 shares of Common Stock to affiliates of Bleichroeder L.P., 21 April Fund, L.P., and 21 April Fund, Ltd. (together, the “Purchasers”), pursuant to a note and warrant purchase agreement entered into with the Purchasers (the “Note and Warrant Purchase Agreement”). The warrants issued in this transaction have an exercise price of $5.20 per share, a term of five years and are exercisable for cash at any time.

 

The Notes originally had a term of 24 months and did not bear interest during this period. If the Notes are not repaid on or before the second anniversary of issuance, however, the Notes will thereafter bear interest of 10% per annum, which would increase by 1% each month the Notes remain unpaid, up to a maximum of 16% per annum, payable monthly.

 

Additionally, as part of the transaction, the Company issued 28,846 warrants to the placement agent. The warrants issued in this transaction have an exercise price of $5.20 per share, a term of five years, and are exercisable for cash at any time.

 

As a result, the Company recorded an initial debt discount of $695,749 based on the relative fair value of the warrants and Notes issued. The Company determined the fair value of the warrants by using the Black-Scholes Option Pricing Model, with the following assumptions: expected term of 2.5 years, stock price of $3.44, exercise price of $5.20, volatility of 80.8%, risk-free rate of 3.13%, and no forfeiture rate. The debt discount will be accreted according to the effective interest method over the contractual term of the Notes. The warrants qualified for equity classification and were reported within Additional Paid-In Capital.

 

On October 13, 2023, the Company and the Purchasers entered into an amendment to the Note and Warrant Purchase Agreement (the “Amendment”) and Allonge No. 1 to each of the Notes (collectively, the “Allonges”) effective as of September 30, 2023, pursuant to which the Company and the Purchasers extended the maturity date of the Notes from June 20, 2024, to January 1, 2026 (the “Extension”). As consideration for the Extension, simultaneously with the entry into the Amendment and Allonges, the Company issued to the Purchasers additional warrants to purchase an aggregate of 531,250 shares of Common Stock at an exercise price of $5.20 per share, subject to adjustment as provided therein (the “2023 Warrants”). The 2023 Warrants are exercisable at any time prior to the five-year anniversary of the initial exercise date of September 30, 2023. The Amendment qualifies as a modification and entitles the Purchasers to registration rights with respect to the shares of Common Stock issuable upon exercise of the 2023 Warrants pursuant to the existing Registration Rights Agreement, dated June 22, 2022, by and between the Company and the Purchasers.

 

54

 

As a result of the Amendment, the Company recorded an initial debt discount of $1,193,206, based on fair value of the warrants issued. The Company determined the fair value of the warrants by using the Black-Scholes Option Pricing Model, with the following assumptions: expected term of 5.0 years, stock price of $3.89, exercise price of $5.20, volatility of 73.66%, risk-free rate of 4.60%, and no forfeiture rate. The debt discount will be accreted according to the effective interest method over the contractual term of the Notes. The warrants qualified for equity classification and were reported within Additional Paid-In Capital.

 

The components of notes payable are as follows:

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Senior promissory notes

  $ 6,000,000     $ 6,000,000  

Less: unamortized debt discount

    (696,437 )     (1,311,989 )

Total senior promissory notes payable, net

  $ 5,303,563     $ 4,688,011  
                 

Current portion of senior promissory notes payable

    -       -  

Senior promissory notes payable, less current portion

    5,303,563       4,688,011  

Total senior promissory notes payable, net

  $ 5,303,563     $ 4,688,011  

 

For the years ended December 31, 2024, and 2023, the Company recognized amortization of debt discount of $615,552 and $400,903, respectively.

    

 

NOTE 8 - AGREEMENTS, COMMITMENTS AND CONTINGENCIES

 

Contingencies - From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business.

 

Product Warranties - The Company provides a standard warranty on its systems, generally for a period of one to three years after customer acceptance. The Company estimates the costs that may be incurred under its standard warranty programs and records a liability for such costs at the time product revenue is recognized.

 

In addition, the Company sells an extended warranty for certain systems, which generally provides a warranty for up to four years from the date of commissioning. The specific terms and conditions of the warranties vary depending upon the product sold and the country in which the Company does business. Revenue received for the sale of extended warranty contracts is deferred and recognized in the same manner as the costs incurred to perform under the warranty contracts.

 

The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Factors that affect the warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and the cost per claim.

 

Changes in the Company's current and long-term warranty obligations included in accrued expenses on the balance sheet for the fiscal years ended December 31, 2024, and 2023 were as follows:

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Balance at January 1

  $ 629,100     $ 898,072  

Warranty costs charged to cost of goods sold

    100,726       115,401  

Utilization charges against reserve

    (72,736 )     (408,234 )

Foreign currency effect

    (36,059 )     23,861  

Balance at the end of the period

  $ 621,031     $ 629,100  

 

55

   
 

NOTE 9 - INCOME TAXES

 

As of December 31, 2024, the Company had net operating loss carry-forwards of approximately $30,953,048 for U.S. federal tax purposes, expiring through 2041, and approximately $28,209,222 for Danish tax purposes, which do not expire.

 

As of December 31, 2024, and December 31, 2023, the Company established a valuation allowance of $7,611,000 and $7,100,000 for the tax components of LiqTech International Inc. and Liqtech NA, respectively; $7,795,000 and $6,303,000 for the tax components of LiqTech Holding, LiqTech Ceramics, LiqTech Water, LiqTech Plastics, LiqTech Emission Control, and LiqTech Water Projects, respectively; and $0 and $479,000 for LiqTech China, respectively, as management could not determine that it was more likely than not that sufficient income could be generated by these components to realize the resulting net operating loss carry-forwards and other deferred tax assets of these components. The change in the valuation allowance for the year ended December 31, 2024, was an increase of $511,000 for the US component, an increase of $1,492,000 for the Danish component, and a decrease of $479,000 for the Chinese component. The change in the valuation allowance for the year ended December 31, 2023, was an increase of $590,000, $1,077,000, and $9,000 for the US, Danish, and Chinese components, respectively.

 

56

 

The temporary differences, tax credits, and carry-forwards gave rise to the following deferred tax assets and liabilities at December 31, 2024, and 2023:

 

   

2024

   

2023

 

Excess of tax over financial accounting

  $ 1,588,748     $ 1,454,389  

Reserve for excess and obsolete inventories

    266,007       190,841  

Discount amortization

    853,619       724,353  

Net operating loss carryover

    12,963,223       11,580,458  

Excess of book over tax depreciation

    (323,115 )     (359,917 )

Excess of book over tax work in progress

    -       190,196  

Valuation allowance

    (15,406,442 )     (13,881,379 )
    $ (57,960 )   $ (101,059 )

Distributed as:

               

Long-term deferred tax asset

    -       -  

Long-term deferred tax liability

    (57,960 )     (101,059 )
    $ (57,960 )   $ (101,059 )

 

A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows for the years ended December 31, 2024, and 2023: 

 

   

2024

   

2023

 

Computed tax at expected statutory rate

  $ (2,177,319 )   $ (1,843,244 )

State and local income taxes, net of federal benefit

    -       (1,177 )

Non-US income taxed at different rates

    (80,280 )     (44,279 )

Non-deductible expenses

    1,259       5,399  

Change in valuation allowance

    1,996,655       1,755,013  

Other

    220,848       (77,919 )

Income tax benefit

  $ (38,837 )   $ (206,207 )

 

The components of income tax benefit from continuing operations for the years ended December 31, 2024, and 2023 consisted of the following:

 

   

2024

   

2023

 

Current income taxes:

               

Danish

  $ -     $ (148,668 )

Federal

    -       -  

State

    -       -  

Current tax (benefit)

  $ -     $ -  
                 

Deferred income taxes:

               

Book in excess of tax depreciation

    (156,342 )     (386,673 )

Work in progress

    -       (442,964 )

Net operating loss carryover

    (2,387,047 )     (402,448 )

Valuation allowance

    2,477,718       1,128,197  

Discount amortization

    129,266       84,190  

Reserve for obsolete inventories

    (102,432 )     (37,841 )

Deferred tax benefit

  $ (38,837 )   $ (57,539 )

Total tax benefit

  $ (38,837 )   $ (206,207 )

 

Deferred income tax benefit results primarily from the reversal of temporary timing differences between tax and financial statement income. 

 

57

 

The Company files Danish, Chinese, U.S. federal, and Minnesota state income tax returns. LiqTech Holding, LiqTech Ceramics, LiqTech Water, LiqTech Plastics, LiqTech Emission Control, and LiqTech Water Projects are generally no longer subject to tax examinations for years prior to 2017 for their Danish tax returns. LiqTech NA is generally no longer subject to tax examinations for years prior to 2017 for U.S. federal and state tax returns. 

  

 

NOTE 10 - LOSS PER SHARE

 

Basic and diluted net loss per common share is determined by dividing net loss by the weighted average common shares outstanding during the year. For the years where there is a net loss, stock options, warrants, and restricted stock units (“RSUs”) have been excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive. Consequently, the weighted-average common shares used to calculate both basic and diluted net loss per common share would be the same.

 

For the year ended December 31, 2024, the Company had outstanding balances of 357,903 RSUs, 5,299,879 prefunded warrants, and 6,091,346 warrants, all exercisable for shares of Common Stock.

 

For the year ended December 31, 2023, the Company had outstanding balances of 314,461 RSUs, 3,930,008 prefunded warrants, and 1,091,346 warrants, all exercisable for shares of Common Stock.

  

 

NOTE 11 - STOCKHOLDERS' EQUITY

 

Common Stock - The Company has 50,000,000 authorized shares of common stock, $0.001 par value. As of December 31, 2024, and 2023, there were 9,475,443 and 5,727,310 common shares issued and outstanding, respectively.      

 

Voting - Holders of common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors. 

 

Dividends - Subject to the rights and preferences of the holders of any series of preferred stock, if any, which may at the time be outstanding, holders of common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.  

 

Liquidation Rights - In the event of any liquidation, dissolution, or winding-up of affairs, after payment of all of our debts and liabilities and subject to the rights and preferences of the holders of any outstanding shares of any series of our preferred stock, the holders of common stock will be entitled to share ratably in the distribution of any of our remaining assets.  

 

Other Matters - Holders of common stock have no conversion, preemptive, or other subscription rights, and there are no redemption rights or sinking fund provisions with respect to our common stock. All of the issued and outstanding shares of common stock on the date of this Annual Report are validly issued, fully paid, and non-assessable.

 

Preferred Stock - Our Board of Directors has the authority to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences, and rights, the qualifications, limitations or restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences, and the number of shares constituting any class or series, without further vote or action by the stockholders. The issuance of preferred stock may have the effect of delaying, deferring, or preventing a change in control without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock.

 

The Company has 2,500,000 authorized shares of preferred stock, $0.001 par value. As of December 31, 2024, and 2023, there were no preferred shares issued and outstanding.

 

Stock Issuances 

 

Since  January 1, 2024, the Company has made the following issuances of Common Stock: 

 

58

 

On January 3, 2024, the Company issued 24,500 shares of Common Stock to settle RSUs. The RSUs were valued at $73,500 for services provided by the Board of Directors in 2023. The Company recognized the stock-based compensation of the award over the requisite service period during the year ended December 31, 2023.

 

On January 3, 2024, the Company issued 85,528 shares of Common Stock to settle RSUs. The RSUs were valued at $289,672 for services provided by management in 2023. The Company recognized the stock-based compensation of the award over the requisite service period during the year ended December 31, 2023. In connection with the issuance, 29,998 shares of Common Stock, with a total value of $104,940, were retired to settle tax withholdings associated with stock-based compensation.

 

On June 24, 2024, the Company issued 11,932 shares of Common Stock to settle RSUs. The RSUs were valued at $36,750 for services provided by the Board of Directors from 2023 to 2024. The Company recognized the stock-based compensation of the award over the requisite service period from 2023 to 2024.

 

On September 12, 2024, the Company issued 26,042 shares of Common Stock to settle RSUs. The RSUs were valued at $116,667 for services provided by management in the last 12 months. The Company recognized the stock-based compensation of the award over the requisite service period during the period ended September 30, 2024.

 

On  September 27, 2024, the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company agreed to issue and sell an aggregate of 3,630,129 shares of Common Stock, 1,369,871 pre-funded warrants to purchase shares of Common Stock, and warrants to purchase up to an aggregate of 5,000,000 shares of Common Stock, for gross proceeds of up to $10 million. The combined purchase price of one share of Common Stock and one accompanying warrant to purchase one share of Common Stock is $2.00. The combined purchase price of one pre-funded warrant and one accompanying warrant to purchase one share of Common Stock under the Purchase Agreement is $1.999.

 

The Company agreed to issue the Common Stock, warrants, and pre-funded warrants in two tranches: (i) a first tranche comprised of 29,227 shares of Common Stock, 555,302 pre-funded warrants, and warrants to purchase an aggregate of 584,529 shares of Common Stock (collectively, the “First Tranche Securities”); and (ii) a second tranche comprised of 3,600,902 shares of Common Stock, 814,569 pre-funded warrants, and warrants to purchase an aggregate of 4,415,471 shares of Common Stock (collectively, the “Second Tranche Securities”).

 

On  September 27, 2024, in connection with the closing of the first tranche, the Company sold and issued the First Tranche Securities for gross proceeds of approximately $1.2 million.

 

On  November 12, 2024, in connection with the closing of the second tranche, the Company sold and issued the Second Tranche Securities for gross proceeds of approximately $8.8 million.

 

Warrants 

 

On May 17, 2022, the Company entered a warrant purchase agreement with existing stockholders to purchase 3,803,133 shares of Common Stock at an offering price of $3.992 per prefunded warrant, which represents the offering price of $4.00 per share of the Company’s Common Stock less the $0.008 per share exercise price for each pre-funded warrant. The warrants represented gross proceeds of approximately $15,182,075 as part of the Company’s public offering of Common Stock and pre-funded warrants totaling $23,000,000 before underwriting discounts, commissions, and offering expenses payable by the Company.

 

On June 22, 2022, the Company completed a private placement of Senior Notes in an aggregate principal amount of $6,000,000 and warrants to purchase 531,250 shares of Common Stock of the Company to affiliates of Bleichroeder L.P., 21 April Fund, L.P., and 21 April Fund, Ltd. (together, the "Purchasers"), pursuant to a note and warrant purchase agreement (the “Note and Warrant Purchase Agreement”). Additionally, as part of the transaction, the Company issued 28,846 warrants to the placement agent. All warrants issued in this transaction have an exercise price of $5.20 per share, a term of five years, and are exercisable for cash at any time. 

 

On October 13, 2023, the Company entered into an amendment to the Note and Warrant Purchase Agreement effective as of September 30, 2023, pursuant to which the Company and the Purchasers extended the maturity date of the Notes from June 20, 2024, to January 1, 2026 (the “Extension”). As consideration for the Extension, the Company issued to the Purchasers additional warrants to purchase an aggregate of 531,250 shares of Common Stock at an exercise price of $5.20 per share. The warrants are exercisable at any time prior to the five-year anniversary of the initial exercise date of September 30, 2023.

 

59

 

On September 27, 2024 (as described under Stock Issuances), the Company closed on a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to issue and sell to such purchasers warrants for the purchase of 584,529 shares of Common Stock at an exercise price of $2.00 per common share and prefunded warrants for the purchase of 555,302 shares of Common Stock at an exercise price of $0.001 per common share.

 

On November 12, 2024 (as described under Stock Issuances), the Company closed on a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to issue and sell to such purchasers warrants for the purchase of 4,415,471 shares of Common Stock at an exercise price of $2.00 per common share and prefunded warrants for the purchase of 814,569 shares of Common Stock at an exercise price of $0.001 per common share.

 

The following is a summary of the periodic changes in warrants outstanding for the years ended December 31, 2024, and 2023:

 

   

2024

   

2023

 

Outstanding, December 31

    5,021,354       4,490,104  

Warrants issued in connection with public offering and private placement

    6,369,871       531,250  

Exercises and conversions

    -       -  

Outstanding, December 31

    11,391,225       5,021,354  

 

Stock-based Compensation 

 

In 2013, the Company’s Board of Directors adopted a Share Incentive Plan (the “Incentive Plan”). Under the terms and conditions of the Incentive Plan, the Board of Directors is empowered to grant RSUs to officers, directors, and consultants of the Company. At December 31, 2024, 26,040 RSUs were granted and outstanding under the Incentive Plan. Directors of the Company receive share compensation consisting of annual grants of $36,750 ($73,500 for the Chairman of the Board) in RSUs per annum with one-year vesting.

 

In 2022, the Company’s Board of Directors adopted an Equity Incentive Plan (the “2022 Incentive Plan”). Under the terms and conditions of the 2022 Incentive Plan, the Board of Directors is empowered to grant RSUs to officers and directors of the Company. At December 31, 2024, 331,863 RSUs were granted and outstanding under the 2022 Incentive Plan.

 

The Company recognizes compensation costs for RSU grants to Directors and management based on the stock price on the date of the grant.

 

The Company recognized stock-based compensation expense related to RSU grants of $664,434 and $627,904 for the years ended December 31, 2024, and 2023, respectively. On December 31, 2024, the Company had $616,234 of unrecognized compensation cost related to non-vested stock grants.

 

A summary of the status of the RSUs as of December 31, 2024, and changes during the period are presented below:

 

   

December 31, 2024

 
           

Weighted

         
           

Average

   

Aggregated

 
   

Number of

   

Grant-Date

   

Intrinsic

 
   

units

   

Fair value

   

Value

 
                         

Outstanding, December 31, 2023

    314,461     $ 3.46     $ -  

Granted

    311,154       3.20       -  

Vested and settled with share issuance

    (148,002 )     (3.49 )     -  

Forfeited

    (119,710 )     (3.38 )     -  

Outstanding, December 31, 2024

    357,903     $ 3.25     $ -  

 

60

   
 

NOTE 12 – SEGMENT REPORTING

 

The Company operates in three segments: Water, Ceramics, and Plastics.

 

The Company’s reportable segment information for the years ended December 31, 2024, and 2023 were as follows:

 

   

For the Year Ended

 
   

December 31,

 

Revenues

 

2024

   

2023

 

Water

  $ 5,538,741     $ 7,705,080  

Ceramics

    5,634,973       6,232,628  

Plastics

    3,381,408       3,736,529  

Corporate

    49,496       327,415  

Total revenues

  $ 14,604,618     $ 18,001,652  

 

   

For the Year Ended

 
   

December 31,

 

Net loss

    2024       2023  

Water

  $ (2,149,224 )   $ (736,148 )

Ceramics

    (3,322,800 )     (2,640,895 )

Plastics

    (1,304,295 )     (660,896 )

Corporate

    (3,568,939 )     (4,533,206 )

Total net loss

    (10,345,258 )     (8,571,145 )

 

   

As of

 
   

December 31,

   

December 31,

 

Total assets

 

2024

   

2023

 

Water

  $ 8,235,726     $ 9,432,991  

Ceramics

    10,679,025       14,550,872  

Plastics

    1,670,644       759,745  

Corporate

    11,842,084       11,228,239  

Total assets

  $ 32,427,479     $ 35,971,847  

 

61

   
 

NOTE 13 - SIGNIFICANT CUSTOMERS / CONCENTRATION

 

The Company did not have any customers accounting for 10% or more of net sales in the reported periods. As a result, there is no significant customer concentration that would materially impact the Company's financial position or results of operations.

 

The following table presents customers accounting for 10% or more of the Company’s accounts receivable:

 

   

December 31,

   

December 31,

 
   

2024

   

2023

 

Customer A

    20 %     22 %

Customer B

    * %     13 %

 

* Zero or less than 10%

 

As of December 31, 2024, approximately 86% of the Company’s assets were located in Denmark, 14% were located in the U.S., and 0% were located in China. As of December 31, 2023, approximately 98% of the Company’s assets were located in Denmark, 0% were located in the U.S., and 2% were located in China.

  

 

NOTE 14 - SUBSEQUENT EVENTS

 

On January 1, 2025, the Company issued 30,704 common shares to settle RSUs. The RSUs were valued at $81,886 for services provided by the senior leadership team and key employees in 2024. The Company is recognizing the stock-based compensation of the award over the requisite service period.

 

On January 3, 2025, the Company issued 52,350 common shares to settle RSUs. The RSUs were valued at $183,750 for services provided by the Board of Directors in 2024. The Company is recognizing the stock-based compensation of the award over the requisite service period.

 

On January 3, 2025, the Company issued 47,527 common shares to settle RSUs. The RSUs were valued at $151,649 for services provided by management in 2024. The Company is recognizing the stock-based compensation of the award over the requisite service period.

 

On January 31, 2025, the Company announced the appointment of David Kowalczyk as its new Chief Financial Officer and Chief Operating Officer ("CFOO"), effective March 1, 2025. In connection with this appointment, Phillip Massie Price, the Company’s Interim Chief Financial Officer, and the Company mutually agreed that Mr. Price will step down as Interim CFO effective March 1, 2025. Mr. Price will continue to serve as the Company’s principal financial officer until April 30, 2025, after which he will depart from the Company. Mr. Kowalczyk is an experienced finance executive with over 20 years of professional experience across multiple industries and ownership structures. He holds a Bachelor of Science in Economics and Business Administration, a Master of Science in Accounting and Auditing, and a Master of Science in Finance and Investments from Copenhagen Business School. He also has extensive experience in technology and R&D-driven companies.

 

On March 26, 2025, the Company entered into a Second Amendment to the Note and Warrant Purchase Agreement originally dated June 22, 2022, with the holders of the Company’s senior promissory notes. In connection with the Second Amendment, the parties executed Allonge No. 2 to each of the existing amended notes, resulting in an extension of the maturity date from January 1, 2026 to May 1, 2027.

 

Additionally, beginning on January 1, 2026, the notes will bear interest at a rate of 10% per annum, payable semi-annually. In the event of a default or if the notes are not repaid on or before the new maturity date, the interest rate increases to 13% per annum, with a monthly 1% step-up up to a cap of 16% per annum, payable monthly. Accrued interest (excluding default interest) may be paid in cash or in shares of common stock, at the Company’s election, subject to certain limitations.

 

As part of the transaction, the Company and the noteholders also agreed to amend and restate the related warrants, reducing the exercise price from $5.20 to $2.00 per share and extending the expiration date to December 31, 2029.

 

The Company evaluated the Second Amendment under ASC 855 and concluded that it represents a non-recognized subsequent event. While it does not impact the financial statements as of December 31, 2024, it is disclosed herein due to its significance.

 

62

  
 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A.

Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the design and effectiveness of our internal controls over financial reporting and disclosure controls and procedures (pursuant to Rule 13a-15(b) and (c) under the Exchange Act) as of the end of the period covered by this Annual Report. A weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a misstatement of the registrant's financial statements will not be prevented or detected on a timely basis.

 

There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

 

Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures as of December 31, 2024, were not effective due to material weaknesses in internal controls over financial reporting, described below.

 

Notwithstanding this finding, we concluded that the consolidated financial statements included in this Report present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States. During the year ended December 31, 2024, the Company was not subject to the requirements of Section 404(b) of the Sarbanes-Oxley Act. As such, our independent registered public accounting firm was not required to, and thus did not, audit our internal control structure.

 

Management's Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting.

 

Internal control over financial reporting is a process designed by, or under the supervision of, the Company's principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles.

 

Internal control over financial reporting is defined in rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the audited consolidated financial statements.

 

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the Company's management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2024, based on the criteria set forth in the Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commissions (2013).

 

Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures as of December 31, 2024, were not effective due to material weaknesses in internal controls over financial reporting.

 

63

 

Material weaknesses as of December 31, 2024

 

A material weakness is a deficiency, or combination thereof, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

 

The material weaknesses we identified related to the following:

 

1)

Ineffective information technology general controls (ITGC’s) in the areas of user access and program change-management over certain IT systems that support the Company’s financial reporting processes Additionally, management has identified a material weakness in its internal control over financial reporting related to ITGCs in the areas of control report reviews for service organization;

2)

The lack of formal documentation of the design, and related execution of, certain transaction level controls related to disbursements, procurement, and inventory management and valuation; and

3)

Ineffective design and operation of process level controls over the existence and accuracy of revenue transactions.

 

Management's Remediation Initiatives

 

In response to the identified material weaknesses, our management, with oversight from the Company’s Audit Committee, has been and will continue to dedicate necessary resources to enhance the Company’s internal control over financial reporting and remediate the identified material weaknesses. As an example of such remediation, the Company in 2024 hired additional employees into the finance department, and we plan to continue to work on remediating the material weaknesses during 2025 by improving competencies and processes. Further, the Company implemented a new ERP system along with other IT programs to help reinforce its controls and processes, and these investments are an important step in the remediation of the material weaknesses. During 2022, the Company introduced an updated Delegation of Authority, with the overall purpose to provide clarity for all employees on the extent to which they can commit the Company and at the same time provide the Company with assurance that decisions about agreements are made by the appropriate functions and employees. Lastly, the Company has started the process of redesigning and ensuring documentation of all processes and procedures related to the financial reporting process to ensure the effective design and operation of process-level controls.

 

While management believes that the steps that we have taken and plan to take will improve the overall system of internal control over financial reporting and will remediate identified material weaknesses, the material weaknesses cannot be considered remediated until the applicable relevant controls operate for a sufficient period of time.

 

Following identification of the material weakness and prior to filing this Annual Report on Form 10-K, we completed substantive procedures for the year ended December 31, 2024. Based on these procedures, management believes that our consolidated financial statements included in this Form 10-K have been prepared in accordance with U.S. GAAP. Our CEO and CFO have certified that, based on their knowledge, the financial statements and other financial information included in this Form 10-K, fairly present in all material respects the financial condition, results of operations, and cash flows of the Company as of, and for, the periods presented in this Form 10-K.

 

Changes in Internal Control

 

During the most recently completed fiscal quarter, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

64

 

Limitations on the Effectiveness of Internal Controls

 

An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

 

While management believes that the steps that we have taken and plan to take will improve the overall system of internal control over financial reporting and will remediate identified material weaknesses, the material weaknesses cannot be considered remediated until the applicable relevant controls operate for a sufficient period of time.

 

 

Item 9B.

Other Information

 

Item 1.01. Entry into a Material Definitive Agreement.

 

As previously disclosed in the Current Report on Form 8-K of LiqTech International, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) on June 27, 2022, on June 22, 2022, the Company issued and sold senior promissory notes in an aggregate principal amount of $6.0 million (the “Original Notes”) and issued warrants to purchase an aggregate of 531,250 shares of common stock, $0.001 par value, of the Company (“Common Stock”) at an exercise price of $5.20 per share (the “Original Warrants”) to 21 April Fund, L.P. and 21 April Fund, Ltd., affiliates of Bleichroeder L.P. (collectively, the “Purchasers”), pursuant to a note and warrant purchase agreement entered into with the Purchasers (the “Note and Warrant Purchase Agreement”). As previously disclosed in the Current Report on Form 8-K of the Company filed with the SEC on October 19, 2023, on October 13, 2023, the Company and the Purchasers entered into an amendment to the Note and Warrant Purchase Agreement (the “First Amendment”) and Allonge No. 1 to each of the Original Notes (the Original Notes, as so amended by the Allonge No. 1, the “First Amended Notes”) effective as of September 30, 2023, to, among other things, extend the maturity date for the Original Notes to January 1, 2026.

 

On March 26, 2025, the Company and the Purchasers entered into a second amendment to the Note and Warrant Purchase Agreement (the “Second Amendment”) and Allonge No. 2 to each of the First Amended Notes (collectively, the “Allonges” and the First Amended Notes, as so amended by the Allonges, the “Second Amended Notes”), pursuant to which the Company and the Purchasers amended the First Amended Notes to extend the maturity date from January 1, 2026 to May 1, 2027 (the “Maturity Date”), and provide that, beginning on January 1, 2026, the Second Amended Notes will bear interest at a rate of 10% per annum payable semi-annually or, if at any time that the Second Amended Notes are outstanding, the Second Amended Notes are not repaid on or before the Maturity Date or an Event of Default (as defined in the Second Amended Notes) occurs, a rate of 13% per annum, which will increase by 1% each month that the Second Amended Notes remain unpaid, up to a maximum of 16% per annum, payable monthly (the “Default Interest”). Pursuant to the Second Amendment, the Company may pay the accrued interest on the Second Amended Notes, other than the Default Interest, in cash or in shares of Common Stock at its election, subject certain limitations set forth in the Second Amended Notes.

 

In addition, pursuant to the Second Amendment, the Company and the Purchasers agreed to amend and restate the Original Warrants (the “Amended and Restated Warrants”) to extend the expiration date to December 31, 2029 and to reset the exercise price to $2.00 per share.

 

The foregoing descriptions of the Second Amendment, the Allonges and the Amended and Restated Warrants are qualified in their entirety by reference to the full text of the Second Amendment, the form of Allonge No. 2 and the form of Amended and Restated Warrant, copies of which are attached hereto as Exhibit 10.19, Exhibit 10.20 and Exhibit 4.9, respectively, and which are incorporated herein by reference.

 

65


Item 3.02 Unregistered Sales of Equity Securities.

 

The information provided in Item 1.01 above with respect to the issuance of the Amended and Restated Warrants and the Second Amended Notes to the Purchasers is incorporated into this Item 3.02 by reference.

 

The Amended and Restated Warrants and the Second Amended Notes were issued to the Purchasers in reliance on the private offering exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder. The Company has relied and will rely on this exemption based in part on representations and warranties made by each of the Purchasers in the Second Amendment as to their qualification as “accredited investors,” as defined pursuant to Rule 501(a) of Regulation D promulgated under the Securities Act.

 

The Amended and Restated Warrants and the Second Amended Notes, and any shares of Common Stock issuable upon exercise or repayment thereof, as applicable, have not been registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration under the Securities Act or an exemption from such registration requirements.

 

Item 408(a) – Insider Trading Arrangements and Policies

 

During the quarter ended   December 31, 2024, no director or Section 16 officer adopted, modified, or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408(a) of Regulation S-K).

 

 

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

66

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance

 

The information required by Item 10 is incorporated herein by reference to our Definitive Proxy Statement relating to our 2025 Annual Meeting of Stockholders. Alternatively, it will be included in an amendment to this Form 10-K, filed under cover of Form 10-K/A, no later than 120 days after the end of the fiscal year covered by this report.

 

Item 11.

Executive Compensation

 

The information required by this Item 11 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The information required by this Item 12 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 

The information required by this Item 13 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.

 

Item 14.

Principal Accountant Fees and Services

 

The information required by this Item 14 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference. 

 

67

 

PART IV

 

Item 15.

Exhibits and Financial Statement Schedules

 

 

(a)

Financial Statements and Schedules

 

The financial statements are set forth under Item 8 of this Annual Report. The following financial statement schedule for the years ended December 31, 2024, and December 31, 2023, is included in this Annual Report on Form 10-K:

 

 

a.

Valuation and Qualifying Accounts for the years ended December 31, 2024, and December 31, 2023.

 

   

2024

   

2023

 

Bad debt expense

    578,423       82,066  

Reserve for obsolete inventory

    404,306       177,953  

 

   

Balance

   

Charges to

           

Balance

 
   

Beginning

   

Costs and

   

Deductions

   

End of

 
   

of Year

   

Expenses

   

(1

)      

Year Ended December 31, 2024

                               

Allowance for inventory obsolescence

  $ 867,458     $ 404,306     $ (62,640 )   $ 1,209,124  

Allowance for current expected credit losses

    134,912       528,846       (26,202 )     637,556  

Totals

  $ 1,002,370     $ 933,152     $ (88,842 )   $ 1,846,680  
                                 

Year Ended December 31, 2023

                               

Allowance for inventory obsolescence

  $ 663,227     $ 177,953     $ 26,278     $ 867,458  

Allowance for current expected credit losses

    59,559       82,066       (6,713 )     134,912  

Totals

  $ 722,786     $ 260,019     $ 19,565     $ 1,002,370  

 

   

2024

   

2023

 

Allowance for current expected credit losses at the beginning of the period

  $ 134,912     $ 59,559  

Bad debt expense

    578,423       82,066  

Receivables written off during the periods

    (49,577 )     (10,298 )

Effect of exchange rate changes

    (26,202 )     3,585  

Allowance for current expected credit losses at the end of the period

  $ 637,556     $ 134,912  

 

(1) Includes write-offs and the impact of foreign currency exchange rates.

 

 

Schedules other than that listed above are omitted because the conditions requiring their filing do not exist or because the required information is provided in the Consolidated Financial Statements, including the Notes thereto. Financial statement schedules have been omitted since they are either not required, not applicable, or the information is otherwise included.

 

68

 
 

 

 

 

(b)

Exhibits

 

Exhibit

No.

 

Description

 

Location

         

3.1

 

Articles of Incorporation, as amended as of November 13, 2023

 

Incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K as filed with the SEC on March 22, 2024

         

3.2

 

Amended and Restated Bylaws

 

Incorporated by reference to Exhibit 3.4 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on May 15, 2012

         

4.1

 

Form of Pre-Funded Warrant

 

Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the SEC on June 2, 2020

         

4.2

 

Form of Amendment to Pre-Funded Warrant

 

Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on November 9, 2020

         

4.3

 

Description of our Common Stock

 

Incorporated by reference to Exhibit 4.3 to the Company’s Annual Report on Form 10-K as filed with the SEC on March 30, 2020

         

4.4

 

Form of Pre-Funded Warrant

 

Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on August 20, 2021

         

4.5

 

Form of Pre-Funded Warrant

 

Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on May 17, 2022

         

4.6

 

Form of Warrant

 

Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on October 19, 2023

         

4.7

 

Form of Pre-Funded Warrant

 

Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 27, 2024
         

4.8

 

Form of Warrant

 

Incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K as filed with the SEC on September 27, 2024
         
4.9   Form of Amended and Restated Warrant   Included in Exhibit 10.19
         

10.1

 

Lease Agreement for Industriparken 22C, 2750 Ballerup, Denmark

 

Incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K/A as filed with the SEC on November 15, 2011 (translated in English)

         

10.2

 

Form of Registration Rights Agreement, by and among the Company and the investors named therein

 

Incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K as filed with the SEC on June 2, 2020

         

10.3

 

Lease Contract for Benshoej Industrivej 24, 9500 Hobro

 

Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K as filed with the SEC on December 5, 2019

 

69

 

10.4*

 

LiqTech International, Inc. 2013 Share Incentive Plan

 

Incorporated by reference to Exhibit 99.1 to the Company’s Form S-8 as filed with the SEC on January 27, 2014

         

10.5

 

Note and Warrant Purchase Agreement, by and among the Company and the Purchasers

 

Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on June 27, 2022

         

10.6

 

Form of Note

 

Incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K as filed with the SEC on June 27, 2022

         

10.7

 

Registration Rights Agreement, by and among the Company and the Purchasers

 

Incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K as filed with the SEC on June 27, 2022

         

10.8

 

First Amendment to Note and Warrant Purchase Agreement

 

Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2023
         

10.9

 

Form of Allonge No. 1

 

Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2023
         

10.10*

 

Executive Service Agreement, dated July 26, 2022, by and between LiqTech Holdings A/S and Fei Chen

 

Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on August 1, 2022

         

10.11*

 

LiqTech International, Inc. 2022 Equity Incentive Plan

 

Incorporated by reference to Annex A to the Company’s Proxy Statement pursuant to Section 14(a) of the Exchange Act filed with the SEC on October 3, 2022

         

10.12

 

Exclusivity Agreement for Collaboration, Marketing and Deployment of Products and Associated Services, dated November 11, 2022, by and between the Company and NESR

 

Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on November 17, 2022

         

10.13*

 

Employment Contract, dated January 28, 2022, by and between LiqTech Holdings A/S and Phillip Massie Price

 

Incorporated by reference to Exhibit 10.16 to the Company’s Annual Report on Form 10-K as filed with the SEC on March 22, 2024

         

10.14*

 

Addendum to Employment Contract, dated March 20, 2024, by and between LiqTech Holdings A/S and Phillip Massie Price

 

Incorporated by reference to Exhibit 10.17 to the Company’s Annual Report on Form 10-K as filed with the SEC on March 22, 2024

         

10.15 †

 

Securities Purchase Agreement, by and among the Company and the investors named therein

 

Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 27, 2024
         

10.16

 

Registration Rights Agreement, by and among the Company and the investors named therein

 

Incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K as filed with the SEC on September 27, 2024
         

10.17*

 

Service Agreement between Liqtech Holding A/S and David Kowalczyk, dated January 27, 2025.

 

Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on January 31, 2025
         
10.18*   Separation Agreement between Liqtech Holding A/S and Phillip Massie Price, dated March 20, 2025   Filed herewith
         
10.19   Second Amendment to Note and Warrant Purchase Agreement   Filed herewith
         
10.20   Form of Allonge No. 2   Included in Exhibit 10.19
         

19.1

  Code of Conduct and Ethics

 

Filed herewith
         

21.1

 

List of Subsidiaries

 

Filed herewith

         

23.1

 

Consent of Sadler, Gibb

 

Filed herewith

         

31.1

 

Certifications of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

Filed herewith

         

31.2

 

Certifications of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

Filed herewith

         

32.1

 

Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of the Sarbanes-Oxley Act Of 2002

 

Furnished herewith

         

32.2

 

Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of the Sarbanes-Oxley Act Of 2002

 

Furnished herewith

         

97.1

 

Clawback Policy

 

Incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K as filed with the SEC on March 22, 2024

 

70

 

101. INS

 

Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

 

Provided herewith

         

101. CAL

 

Inline XBRL Taxonomy Extension Calculation Link base Document

 

Provided herewith

         

101. DEF

 

Inline XBRL Taxonomy Extension Definition Link base Document

 

Provided herewith

         

101. LAB

 

Inline XBRL Taxonomy Label Link base Document

 

Provided herewith

         

101. PRE

 

Inline XBRL Extension Presentation Link base Document

 

Provided herewith

         

101. SCH

 

Inline XBRL Taxonomy Extension Scheme Document

 

Provided herewith

         

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

Provided herewith

 

*

Denotes a management contract or compensatory plan or arrangement.

Schedules and similar attachments to this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such omitted materials to the SEC upon request.

 

71

 

Item 16.

Form 10-K Summary

 

Not Applicable.

 

72

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

LIQTECH INTERNATIONAL, INC.

Date: March 28, 2025

   
 

By:

/s/ Fei Chen

   

Fei Chen 

Chief Executive Officer and Principal Executive Officer

 

In accordance with the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on the dates indicated.

 

 

Signatures

 

Title

 

Date

         
         
         

/s/ Alexander Buehler

 

Chairman of the Board of Directors

 

March 28, 2025

Alexander Buehler

       
         
         

/s/ Fei Chen

 

President, Chief Executive Officer, Principal Executive Officer and Director

  March 28, 2025

Fei Chen

       
         
         

/s/ Phillip Massie Price

 

Interim Chief Financial Officer, Principal Financial and Accounting Officer

  March 28, 2025

Phillip Massie Price

       
         
         

/s/ Peyton Boswell

 

Director

  March 28, 2025

Peyton Boswell

       
         
         

/s/ Richard Meeusen

 

Director

  March 28, 2025

Richard Meeusen

       
         
         

/s/ Martin Kunz

 

Director

  March 28, 2025

Martin Kunz

       

 

73
EX-10.18 2 ex_795426.htm EXHIBIT 10.18 ex_795426.htm
 
 

Exhibit 10.18

Execution Copy

 

CONFIDENTIAL TRANSITION, SEPARATION,

AND RELEASE OF CLAIMS AGREEMENT

 

This CONFIDENTIAL TRANSITION, SEPARATION, AND RELEASE OF CLAIMS (“Agreement”) is entered into by and between LiqTech Holding A/S. (“Holding”), a Danish corporation that is a subsidiary of LiqTech International, Inc. (“International”), collectively referred as “Company”, and Phillip Massie Price (“Employee”) as of March 20, 2025, and is effective as of the Agreement Effective Date (as defined in Section 24). The Company (as defined below) and Employee may each be referred to herein as a “Party” and collectively referred to as “Parties.”

 

RECITALS

 

WHEREAS, Employee commenced employment as Head of Finance of Holding, on March 1, 2022; and

 

WHEREAS, in connection with commencing his employment, Employee executed an employment contract, dated January 28, 2022 (“Employment Agreement”); and

 

WHEREAS, Employee assumed the role of Interim Chief Financial Officer on April 1, 2024, pursuant to an Addendum for Interim CFO, dated March 20, 2024 (“Addendum”); and

 

WHEREAS, on January 30, 2025, Holding and Employee mutually agreed that Employee would step down as Interim Chief Financial Officer of Holding, effective March 1, 2025; and

 

WHEREAS, Employee agreed to assume the position of Principal Financial Officer of Holding from March 1, 2025 to April 30, 2025 (“Transition Period”), during which his functions and obligations will remain the same as those of Interim CFO; and

 

WHEREAS, Holding and Employee have mutually agreed that Employee’s employment with Holding will end on April 30, 2025 (“Separation Date”); and

 

WHEREAS, for purposes of avoiding any disputes, the Parties desire to compromise, fully and finally settle, and fully release any and all actual or potential claims, known and unknown, that Employee may have against the Company; and

 

NOW, THEREFORE, in consideration of the promises and the performance of the covenants and agreements hereinafter contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties to this Agreement hereby represent, warrant, consent, and agree as follows:

 

1.            Adoption of Recitals. The Parties hereto adopt the above recitals as being true and correct, and they are incorporated herein as material parts of this Agreement.

 

1

Execution Copy

 

2.            Transition Period.

 

a.    Interim Period. Employee shall remain employed by Holding and shall continue to serve as the Interim Chief Financial Officer of Holding through March 1, 2025 (“Interim Period”). During the Interim Period, Employee shall continue to receive the base salary and other applicable employment benefits under the same employment terms, conditions, and Company policies, including, but not limited to, those set forth in the Employment Agreement and Addendum thereto. During the Interim Period, Employee shall continue perform his regular duties as Interim Chief Financial Officer of Holding consistent with past practice and such other duties as may be requested from the Board of Directors (“Board”) from time to time.

 

b.    Transition Period. Provided Employee signs this Agreement without revoking it and complies with the terms of this Agreement, Employee shall remain employed by Holding and assume the position of Principal Financial Officer of Holding during the Transition Period. Employee shall continue to receive the base salary and other applicable employment benefits during the Transition Period under the same employment terms, conditions, and Company policies, including, but not limited to, those set forth in the Employment Agreement and Addendum thereto. During the Transition Period, Employee shall perform the regular duties associated with, and expected of, the position of Principal Financial Officer of Holding and such other duties as may be requested from the Board from time to time. During the Transition Period, Employee shall also (i) continue to provide his best efforts to the Company and to render his services to the Company in a professional manner; (ii) fully cooperate with the Company in winding up his work for the Company in his current position; (iii) serve as a resource to the Company personnel to effectuate the transition of his management responsibilities and institutional knowledge to persons whom the Company in its sole discretion, designates; (iv) provide such other services as the Parties may reasonably agree from time to time; and (v) respond promptly to reasonable requests for assistance by the Company to facilitate the transition and any additional matters that may arise.

 

c.    Irrevocability Following Effective Date; Breach of this Agreement. This Agreement becomes irrevocable on the Effective Date (as described in Section 24) and cannot be terminated by either party thereafter. Notwithstanding the foregoing, nothing in this Agreement shall prevent Holding from summarily dismissing Employee during the Interim Period or Transition Period based upon any breach of this Agreement, including any breach of Employee’s confidentiality and non-disparagement obligations or any failure by Employee to abide by Company policies that occurs or is discovered during the Interim Period or Transition Period. If Employee is summarily dismissed pursuant to this Section, Employee will not be entitled to any additional compensation or severance as described in Section 4 of this Agreement other than that which has been earned and accrued as of the effective date of the termination.

 

3.          Separation of Employment. Employee’s last day of employment with Holding is the Separation Date. On the Separation Date and provided Employee has worked through the Separation Date, Holding will provide Employee with the Second General Release Agreement concerning claims under U.S. law (“Second General Release”), attached as Exhibit 1. Following the Separation Date, Employee agrees that Employee will not represent himself as being an employee, officer, director, agent, or representative of the Company for any purpose. The Separation Date will be the employment termination date for Employee for all purposes, meaning Employee is released from all obligations relative to the role of Principal Financial Officer (except as expressly set forth herein) and is no longer entitled to any further compensation, monies or other benefits from the Company, including coverage under any benefit plans or programs sponsored by the Company after the Separation Date, except as expressly provided herein. Employee may be eligible to continue Employee’s group health insurance benefits at Employee’s own expense, subject to the terms and conditions of the applicable benefits plan.

 

2

Execution Copy

 

4.          Separation Benefits. If Employee remains employed by Holding through the Separation Date, signs this Agreement, executes the Second General Release attached as Exhibit 1 without revoking it, and complies with the material terms herein, Employee will receive the following separation benefits (“Separation Benefits”):

 

a.    Severance Pay. In consideration for the covenants and promises set forth herein, and provided that Employee (1) signs and returns this Agreement to Holding no later than twenty-one (21) calendar days after receiving this Agreement and does not revoke it as described in Section 10, (2) timely signs and returns the Second General Release to Holding without revoking it within sixty (60) calendar days following the Separation Date, and (3) complies with the material terms of this Agreement, Holding will pay Employee severance pay equal to seven (7) months of Employee’s ordinary salary (including pension contributions) as of the Separation Date, less any legally required or elected deductions or withholdings (such as applicable taxes) (the “Severance Pay”). The Severance Pay will be payable monthly in equal installments, less required deductions and withholdings, in accordance with Holding’s regular payroll policies and procedures, commencing on Holding’s first regularly scheduled payday following the Effective Date, as defined in Section 24 herein. The payments will be reported to the Danish Income Register (“e-indkomst”).

 

b.    Retention Bonus. Provided that Employee timely completes and submits a Form 10-K on behalf of the Company for the 2024 fiscal year, consistent with his past practice at the Company, to the U.S. Securities and Exchange Commission (“SEC”) by March 31, 2025, Employee will receive a one-time retention bonus in the amount of twenty-five thousand dollars and zero cents ($25,000.00), less any legally required or elected deductions or withholdings (the “Retention Bonus”). The Retention Bonus shall be paid to Employee in a lump sum payment no later than Holding’s first regularly scheduled payday following the later of the two events to occur: (1) Employee timely signs this Agreement and does not revoke it within the seven-day revocation period; and (2) seven (7) calendar days from Employee’s timely completion and submission of the Company’s Annual Report on Form 10-K to the SEC.

 

5.           Restricted Stock Units. Provided that Employee timely executes and does not revoke this Agreement and the Second General Release (as described herein) and complies with their terms and conditions, International will accelerate 8,019 of the unvested restricted stock units (“RSUs”) granted to Employee under the LiqTech International, Inc. 2022 Equity Incentive Plan (“Company Plan”) pursuant to that certain Notice of Grant of Restricted Stock Unit Award and related Terms and Conditions of Restricted Stock Unit Award dated June 5, 2024 (collectively, the “RSU Award Agreement”), such that 8,019 RSUs will now vest on April 30, 2025. Employee acknowledges and agrees that Employee will not, and is not otherwise entitled to, receive any awards under the Company Plan for 2025 or thereafter, in International’s Short-Term Incentive Program (“STIP”) for 2025 or thereafter, or any other long-term incentive plan or short-term incentive plan offered by International thereafter for 2025 or thereafter.

 

3

Execution Copy

 

6.          Compliance with Section 409A. The Parties to this Agreement intend that the Agreement complies with, or is exemption from Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and this Agreement shall be interpreted in a manner consistent with that intention. A separation of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a separation of employment unless such separation qualifies as a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such provision of this Agreement, references to a “termination,” “separation,” “separation of employment” or like terms shall mean “separation from service.” For purposes of Section 409A of the Code, each installment payment provided under this Agreement shall be treated as a separate payment. Notwithstanding any other provisions of this Agreement to the contrary, and solely to the extent necessary for compliance with Section 409A of the Code and not otherwise eligible for exclusion from the requirements of Section 409A, if as of the date of Employee’s separation from service from the Company, (i) Employee is deemed to be a “specified employee” (within the meaning of Section 409A of the Code and the applicable regulations), and (ii) the Company or any member of a controlled group including the Company is publicly traded on an established securities market or otherwise, no payment or other distribution required to be made to Employee hereunder (including any payment of cash, any transfer of property and any provision of taxable benefits) solely as a result of Employee’s separation from service shall be made earlier than the first day of the seventh month following the date on which Employee separates from service with the Company.

 

7.            Continuing Obligations.

 

a.    Acknowledgment and Reaffirmation of Nondisclosure of Confidential or Proprietary Information. Employee acknowledges and reaffirms Employee’s obligations to keep confidential and not to disclose any and all non-public information concerning the Company that Employee acquired during the course of Employee’s employment with the Company, including, but not limited to, any non-public information concerning the Company’s business affairs, business prospects, and financial condition. Employee further acknowledges and reaffirms Employee’s ongoing, post-employment obligations set forth in the Employment Agreement and Amendment thereto, including, but not limited to, those set forth in Section 5 (Confidentiality & Return of Materials), which is expressly incorporated herein

 

Employee acknowledges that all confidential information regarding the business of the Company compiled by, created by, obtained by, or furnished to, Employee during Employee’s employment with the Company is the exclusive property of the Company and Employee agrees that Employee will not, directly or indirectly, divulge or use such information, except as may be required by subpoena or court order. If Employee is required to make a disclosure restricted by this paragraph as a result of a court order, subpoena or under any applicable law, Employee will notify the Company’s Chief Executive Officer at least three (3) business days prior to any such disclosure. If disclosure or compliance is required sooner than three (3) business days of Employee’s receipt of such order, demand for disclosure, court order, or subpoena, Employee shall provide the required notice to the Company as soon as it is served and before disclosure or compliance is required. Employee also is obligated to return any confidential information including, but not limited to, information about business accounts, finance plans, operational methods, technical processes, inventions, research, records, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, documents, property, or reproductions of any aforementioned items belonging to the Company.

 

4

Execution Copy

 

Furthermore, it is stressed that Employee is not entitled to use or disclose the Company's trade secrets, cf. Section 4 of the Danish Act on Trade Secrets (in Danish: lov om forretningshemmeligheder), and may not take any action that is contrary to good marketing practice, cf. Section 3 of the Danish Marketing Practices Act (in Danish: markedsføringsloven).

Nothing in this Agreement releases Employee from these obligations to the Company. The Company will avail itself of its full legal remedies if Employee violates Employee’s on-going obligations to the Company. Furthermore, this Agreement is expressly conditioned upon Employee’s full and continued compliance with all terms of this Agreement not to disclose the Company’s confidential and trade secret information. To the extent that the Company learns that Employee is violating Employee’s obligations not to disclose confidential and trade secret information, Employee agrees that the Company may withhold any remaining Severance Pay, and that Employee is required to return or repay to the Company all Severance Pay that the Company paid to Employee under this Agreement.

 

b.    Return of Company Property. On Separation Date, Employee agrees to immediately return to the Company all Company property (including any property of the parent, affiliates, or subsidiaries of the Company) that has been provided to Employee or that is in Employee’s possession, including, but not limited to, Employee’s Company telephone, desktop computer, and/or laptop computer, electronically stored documents or files, and physical files.

Employee shall not delete, modify, or copy any business-related data belonging to the Company or relating to the business of the Company, unless doing so is in furtherance of Employee's performance of duties for the Company.

 

c.    Duty of Loyalty. Employee’s duty of loyalty to the Company shall continue until the Separation Date, which includes, but is not limited to, Employee’s duty to refrain from starting any kind of business or in any way engaging in any business which, directly or indirectly, competes with the Company’s activities, and Employee’s duty to refrain from professionally engaging in the activities and interests of the Company’s customers except as necessary for the performance of Employee’s duties.

 

d.    Notice of Immunity Under the U.S. Defend Trade Secrets Act of 2016 (“DTSA”). Notwithstanding any other provision of this Agreement, Employee will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose Company’s trade secrets to Employee’s attorney and use the trade secret information in the court proceeding if Employee: (i) files any document containing the trade secret under seal; and (ii) does not disclose the trade secret, except pursuant to court order.

 

5

Execution Copy

 

8.            General Release by Employee and Waiver of All Claims.

 

a.    Definitions. For purposes of this Section 8, “Released Parties” means one, all or any combination of the following: LiqTech International, Inc., LiqTech Holding A/S, LiqTech Water A/S, LiqTech Ceramics A/S, LiqTech Plastics A/S, and each of their respective related affiliates, subsidiaries, parents, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, executives, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities).

 

b.    Release of the Company. Other than as provided for herein, Employee unconditionally and irrevocably releases the Released Parties from all known or unknown claims, debts, liabilities, breaches of contract, compensation, stock options, claims for profits, claims for expenses, demands, damages, actions, causes of action, or suits of any kind or nature whatsoever, if any, that Employee presently has or could have, for any event, occurrence, or omission that has occurred prior to the Separation Date. Notwithstanding the foregoing, with respect to any claims under U.S. law, Employee releases the Released Parties from all known or unknown claims, debts, liabilities, breaches of contract, compensation, stock options, claims for profits, claims for expenses, demands, damages, actions, causes of action, or suits of any kind or nature whatsoever, if any, that Employee presently has or could have, for any event, occurrence, or omission that has occurred prior to signing this Agreement. The release includes, but is not limited to, all losses, debts, liabilities, breaches, claims and causes of action based on breach of contract, wrongful termination, public policy, accounting, misrepresentation, fraud, property damage, personal injury, infliction of emotional distress, defamation, privacy, disclosure of trade secrets and proprietary information, conflicts of interest, tortious interference, breach of fiduciary duties, demands, costs, loss of services, expenses, compensation, contribution, attorneys’ fees, and all compensatory, consequential, liquidated, special and punitive damages (collectively, the “Released Claims”). Employee understands that Released Claims specifically include, but are not limited to, to the maximum extent permitted by law, (1) any claims in connection with, relating to, or arising out of Employee’s employment with Holding, the terms and conditions of such employment, and/or the termination, resignation, separation or end of such employment; (2) any claims for compensation, salary, bonuses or similar benefits, severance pay, or vacation pay; (3) any claims in connection with, arising under or relating to any alleged written, oral or implied Employment Contract; and any claims under the Danish Contracts Act (in Danish: aftaleloven), the Danish Salaried Employees Act, the Danish Holiday Act, the Danish Share Options Act (in Danish: aktieoptionsloven), the Danish Act on Employment Certificates (in Danish: ansættelsesbevisloven), as well as equal treatment and non-discrimination legislation; (4) any and all claims under Nevada administrative statutory or codified law or regulation dealing with fair employment practices and/or wage and hour laws; (5) the Nevada Fair Employment Practices Act; (6) claims under Nevada's overtime, meal and rest period, and related wage and hour penalty statutes; (7) NRS 608.250 relating to the payment of minimum wage for each hour worked; (8) NRS 613.010, related to inducing a person to change their work location under false pretenses; (9) NRS 613.210, relating to the "blacklisting" of employees; and (10) any other law prohibiting discrimination, harassment and/or retaliation based on the exercise of Employee’s rights under any law providing whistleblower protection, providing workers’ compensation benefits, providing or protecting employee benefits and pension plans, regarding payment of wages or other compensation, protecting union activity, mandating leaves of absence, restricting an employer’s right to terminate employees or otherwise regulating employment, enforcing express or implied employment contracts, concerning government contracts and compliance with same, requiring an employer to deal with employees fairly or in good faith, providing recourse for alleged wrongful discharge, tort, physical or personal injury, emotional distress, fraud, negligent misrepresentation, defamation, and similar or related claims, or relating to salary, commission, compensation, benefits, and other matters.

 

6

Execution Copy

 

c.    The Agreement is conditional upon Employee not raising any Released Claims against the Company as described above. If Employee nevertheless raises any Released Claims, the Company may withhold any remaining Severance Pay, and that Employee is required to return or repay to the Company all Severance Pay that the Company paid to Employee under this Agreement.

 

d.    Notwithstanding the foregoing, Employee does not release any claims (1) for any breach of this Agreement, (2) any claims which cannot be waived by law (such as claims for unemployment benefit rights and workers’ compensation filed in the United States of America), (3) any right to file an unfair labor practice charge under the U.S. National Labor Relations Act, (4) indemnification rights Employee may have against the Company; and (5) any rights with respect to stock options or other similar equity‑based incentives granted to Employee as determined under the applicable plans and award agreement, including, but not limited to, the RSU Award Agreement and the Company Plan as modified herein (to the extent such rights survive a termination of employment).

 

e.    Employee further acknowledges and agrees that Employee has been paid for all salary, wages, bonuses, benefits, compensation, and consideration of any kind earned through the Separation Date, and that Employee is not entitled to receive, and shall not claim from the Company, any compensation, payments, or benefits except for those payments and benefits that are expressly set forth in this Agreement. To the extent that any such additional amount owed is otherwise determined to exist, the payments described herein are in lieu of and encompass such amounts.

f.    Employee acknowledges that the Company relied on the representations and promises in this Agreement and this release (described herein in Section 8) in agreeing to the Separation Benefits (described above in Section 4). Employee understands that by signing this Agreement, Employee is releasing any and all existing and potential claims under Danish law for events that have occurred prior to the Separation Date. Furthermore, Employee is releasing any and all claims under U.S. law for events that have occurred prior Employee signing this Agreement that Employee may not know about as of the date Employee executes this Agreement.

 

g.    WITH RESPECT TO ANY CLAIMS ARISING UNDER OR RELATED TO THE COMPANY PLAN AND/OR SERVICES RENDERED OR PERFORMED BY EMPLOYEE FOR THE COMPANY IN THE UNITED STATES OF AMERICA, NOTHING IN THIS RELEASE WILL BE CONSTRUED TO PROHIBIT EMPLOYEE FROM CONTACTING, FILING A CHARGE OR PARTICIPATING IN ANY PROCEEDING OR INVESTIGATION BY THE U.S. EQUAL EMPLOYMENT OPPORTUNITY COMMISSION (“EEOC”), DEPARTMENT OF LABOR (“DOL”), NATIONAL LABOR RELATIONS BOARD (“NLRB”), THE SEC OR A COMPARABLE STATE OR LOCAL ENTITY IN THE UNITED STATES OF AMERICA. NOTWITHSTANDING THE FOREGOING, EMPLOYEE WAIVES ANY RIGHT TO RECOVER MONETARY DAMAGES RELATED TO ANY CHARGE, COMPLAINT, OR LAWSUIT FILED BY EMPLOYEE OR ON EMPLOYEE’S BEHALF IN THE UNITED STATES OF AMERICA. THIS RELEASE DOES NOT LIMIT EMPLOYEE’S RIGHT TO RECEIVE AN AWARD FOR INFORMATION PROVIDED TO THE SEC. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THE EXCLUSIONS IN THIS SECTION 8.g DO NOT APPLY TO ANY CLAIMS OR CHARGES FILED IN DENMARK.

 

7

Execution Copy

 

9.          Covenant Not to Sue. Employee will not commence any lawsuit, arbitrations, or other proceedings or actions against the Company regarding any claims released in Section 8. Employee also represents and warrants that Employee has not commenced any complaints, charges of discrimination, causes of action, arbitrations, lawsuits, or legal proceedings against the Company. Employee also will never, individually or with any person or in any way, commence, participate in, aid in any way, prosecute, or cause or permit to be commenced or prosecuted against the Company any action or other proceeding based upon any claim, demand, cause of action, obligation, damage, or liability that is released in the Agreement. Nothing in the Agreement shall be construed to prohibit Employee from contacting, filing a charge, or participating in any proceeding or investigation by a competent public authority or comparable entity, such as the EEOC, SEC, DOL, NLRB, or Occupational Safety and Health Administration. Notwithstanding the foregoing, Employee waives any right to recover monetary damages in any charge.

 

10.        ADEA Waiver. As a part of this Agreement, Employee expressly agrees to the release of any rights or claims arising out of the U.S. Age Discrimination in Employment Act (29 U.S.C. § 621, et seq.) as amended, including the U.S. Older Workers Benefit Protection Act, and their implementing regulations, and in connection with such waiver, Employee acknowledges and confirms that:

 

a.    Employee has read this Agreement in its entirety and understands all of its terms;

 

b.    Employee has been advised to consult with an attorney prior to signing this Agreement;

 

c.    The Separation Benefits to Employee pursuant to this Agreement constitute special benefits that the Company is providing in its discretion due to Employee’s unique circumstances and that Employee is not otherwise entitled to receive;

 

d.    No rights or claims are released or waived that might arise after Employee signs this Agreement;

 

e.    Employee has twenty-one (21) calendar days from Employee’s receipt of this Agreement and the Second General Release within which to consider whether or not to sign it. However, under no circumstances shall Employee sign the Second General Release prior to the Separation Date. In the event Employee signs this Agreement and returns it to Holding prior to the end of the 21-day consideration period, Employee hereby acknowledges that Employee has freely and voluntarily chosen to waive the time period allotted for considering this Agreement;

 

8

Execution Copy

 

f.    Employee has seven (7) calendar days following Employee’s signature of this Agreement to revoke this Agreement;

 

g.    This Agreement shall not become effective or enforceable until immediately after the revocation period of seven (7) days has expired without Employee exercising Employee’s right to revoke this Agreement (“Expiration of Revocation Period”);

 

h.    If, after signing, Employee chooses to revoke this Agreement, Employee must do so by notifying the authorized representative signing this Agreement on behalf of Holding, in writing; and

 

i.    Changes to this Agreement, whether material or immaterial, do not restart the running of the 21-day consideration period referenced above.

 

11.         Confidentiality. Employee understands and agrees that this Agreement and all of its terms are entirely confidential, and that Employee shall not disclose, reveal, discuss, publish, or in any way communicate any of the terms, amount or fact of this Agreement to any other person or entity, including the amount of Severance Pay or Retention Bonus. As an exception to this provision, Employee may disclose information relating to this Agreement only as necessary (i) to Employee’s immediate family members and professional representatives (including attorneys, accountants and/or tax advisors), who shall be informed of and bound by this confidentiality clause and whom Employee will be identified with, with respect to any breach of this confidentiality clause; (ii) to the extent necessary to enforce or challenge the terms of this Agreement; or (iii) in connection with any charge or complaint filed by Employee as required under applicable law.

 

Further, if Employee breaches Section 11 or Section 12 of this Agreement, the Company shall be entitled to seek disgorgement of the Severance Pay as of the date of a breach by Employee of this Section 11 or 12.

 

If Employee is required to disclose the Agreement, its terms, or underlying facts, pursuant to legal compulsion by a government agency, a court, or similar authority by a court order and/or by a properly issued and served subpoena, then Employee shall so notify the Company in writing via e-mail and overnight mail within three (3) business days of Employee’s receipt of such order, demand for disclosure, court order, or subpoena and shall simultaneously provide the Company with a copy of such order, demand for disclosure, court order, or subpoena. If disclosure or compliance is required sooner than three (3) business days of Employee’s receipt of such order, demand for disclosure, court order, or subpoena, Employee shall provide the required notice to the Company as soon as it is served and before disclosure or compliance is required. Employee agrees to waive any objection to Company’s request that the document production or testimony be done in camera and under seal.

 

12.          Mutual Non-Disparagement.

 

a.    Employee understands and agrees that as a condition for the consideration herein described, Employee shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its affiliates, subsidiaries, directors, officers, employees, agents or representatives or about the Company's or its subsidiaries’ business affairs and/or financial condition. For purposes of this Agreement, “disparage” means any communication (written or oral, including through social media) that is reckless or maliciously untrue. Employee also will refrain from any defamation, libel, or slander of any of the Released Parties (as defined in Section 8 of this Agreement) and will refrain from tortious interference with the contracts and relationships of any of the Released Parties. However, these non-disparagement obligations, do not limit Employee’s ability to truthfully communicate with any government agency whether such communication is initiated by Employee or in response to the government. Further, nothing in this Agreement shall be construed to limit Employee’s right to engage in protected concerted activities under the U.S. National Labor Relations Act.

 

9

Execution Copy

 

b.    The Company agrees that the executive officers, managers, and directors of the Company shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding Employee and will refrain from any defamation, libel, or slander of Employee. For purposes of this Agreement, “disparage” means any communication (written or oral, including through social media) that is reckless or maliciously untrue. The Company understands and agrees that the Company’s commitment that its executive officers, managers, and directors will not defame, disparage, or impugn Employee’s reputation constitutes a willing and voluntary waiver of their rights under the First Amendment of the United States Constitution and other laws. However, these non-disparagement obligations do not limit the Company or its executive officers’, managers’, and directors’ abilities to truthfully communicate with any governmental agency or in response to a lawfully issued subpoena, whether such communication is initiated by the Company, its executive officers, managers, or directors, or in response to the government.

 

13.        Permitted Disclosures. Nothing in this Agreement prohibits or restricts Employee (or Employee’s attorney) from filing a charge or complaint with the SEC, the Financial Industry Regulatory Authority (“FINRA”), or any other securities regulatory agency or self-regulatory authority, reporting information about the Company’s breaches or potential breaches of the Danish Act on Measures to Prevent Money Laundering and Financing of Terrorism (in Danish: hvidvaskloven) and rules issued pursuant thereto to the public authorities, or reporting information about actual or potential breaches that are covered by the Company’s whistleblower scheme. Employee further understands that this Agreement does not limit Employee’s ability to communicate with any securities regulatory agency or authority or otherwise participate in any investigation or proceeding that may be conducted by any securities regulatory agency or authority without notice to the Company or Employee. This Agreement does not limit Employee’s right to receive an award for information provided to the SEC staff or any other securities regulatory agency or authority. Nothing in this Agreement prevents the Employee from disclosing or discussing any sexual assault or sexual harassment dispute arising after the execution of this Agreement. Nothing in this Agreement shall be construed to prevent disclosure of confidential information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation, or order. Further, nothing in this Agreement shall be construed to limit Employee’s right to engage in protected concerted activities under the U.S. National Labor Relations Act.

 

14.      Amendment, Modification, and Waiver. This Agreement shall be binding upon the Parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the Parties hereto. No delay or omission by the Company or Employee in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.

 

10

Execution Copy

 

15.         Validity. Should any provision of this Agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this Agreement.

 

16.         Non-Admission. Employee understands and agrees that this Agreement is a separation agreement and does not constitute an admission of liability or wrongdoing on the part of the Company. Nothing in this Agreement, including the above Separation Benefits, is to be construed as an admission of wrongdoing or of any liability by any Party. Each Party acknowledges that this Agreement represents a settlement and compromise reached between the Parties. The execution of this Agreement shall not be deemed, construed or interpreted, in any way, to be an admission by any Party regarding liability, damages, or the validity of any claim or defense which any Party has asserted or may assert. If this Agreement is not fully and finally consummated by its valid and binding execution date, then no statements contained herein shall be used for any purpose whatsoever against any Party.

 

17.          Tax Provision. In connection with the separation benefits to be provided to Employee, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and Employee shall be responsible for any and all applicable taxes with respect to such payments under applicable law. Employee acknowledges that Employee is not relying upon the advice or representation of the Company with respect to the tax treatment of any of the payments set forth herein.

 

18.         Voluntary Assent. Employee affirms that no other promises or agreements of any kind have been made to or with Employee by any person or entity whatsoever to cause Employee to sign this Agreement, and that Employee fully understands the meaning and intent of this Agreement. Employee states and represents that Employee had an opportunity to fully discuss and review the terms of this Agreement with an attorney. Employee further states and represents that Employee has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof and signs Employee’s name of Employee’s own free act.

 

19.         Opportunity to Consult with Counsel. The Parties hereby represent and acknowledge that they have been provided with the opportunity to discuss and review the terms of this Agreement with their respective attorneys before signing it and that they are freely and voluntarily signing this Agreement in exchange for the benefits provided herein. The Parties further represent and acknowledge that they have been provided a reasonable period of time within which to review the terms of this Agreement. If any fact with respect to which this Agreement is executed is found hereafter to be other than, or different from, the facts now believed by the Parties to be true, the Parties expressly accept and assume the risk of such possible differences in fact and this Agreement shall be and remain effective notwithstanding such difference in fact.

 

11

Execution Copy

 

20.         Entire Agreement. This Agreement (including Exhibit 1 attached hereto) and the Employment Agreement and Amendment thereto (expressly including their post-employment confidentiality provisions), as modified herein, together with the RSU Award Agreement and the Company Plan and as modified herein, set forth the entire agreement with respect to the subject matter hereof, and supersede all prior negotiations, understandings, and agreements. No provision of this Agreement may be modified, amended, or changed except by a writing signed by the parties hereto. Employee acknowledges that Employee has not relied on any prior or contemporaneous discussions or understandings in entering into this Agreement.

 

21.       Severability. If any provision or part of a provision of this Agreement (except any provision or part of a provision contained in Section 4 or 8 of this Agreement) shall be determined to be void or unenforceable by a court of law, administrative agency or tribunal of competent jurisdiction, the remainder of the Agreement shall remain valid and enforceable by any Party, and all other valid provisions of the Agreement shall survive and continue to bind the Parties. If, however, any provision or part of a provision contained in Section 4 or 8 of this Agreement shall be determined to be void or unenforceable by a court of law, administrative agency, or tribunal of competent jurisdiction, the entire Agreement shall be unenforceable, as each Party recognizes and acknowledges that the duties, rights, and obligations set forth in Section 4 and 8 of this Agreement are essential to the Agreement.

 

22.       Choice of Law. Except with respect to any matters relating to the RSUs, which shall be governed by the laws of the State of Nevada, USA, the provisions of this Agreement (including Exhibit 1 attached hereto) will be interpreted and governed under Danish law. Any dispute between the Parties concerning this Agreement, including its validity and interpretation, shall be governed by and construed and enforced in all respects in accordance with Danish law and before the Danish courts, without regard to choice of law provisions. With respect to any matters directly or indirectly relating to the RSUs, Employee submits and consents to the exclusive jurisdiction of the State of Nevada and agrees that any related litigation shall be conducted solely in the state courts of Nevada or the federal courts for the U.S. located in Reno, Nevada, where the Agreement is made and to be performed, and no other courts.

 

23.         Counterparts. This Agreement may be executed by DocuSign or PDF/email and in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. In any such case, the Party exchanging by email/PDF shall promptly thereafter upon request provide a signed original counterpart hereof to the other parties, provided that the non-delivery of such a signed counterpart shall not affect the validity or enforceability hereof.

 

24.          Agreement Effective Date. This Agreement is made effective on the later of the two events to occur (“Agreement Effective Date”): (1) the date that the Expiration of the Revocation Period set forth in Section 10 occurs; (2) the date that the Expiration of the Second Revocation Period set forth in the Second General Release occurs.

 

25.     Neutral Reference. To the extent the Company receives any inquiries about Employee from any prospective employers, the Company only will confirm Employee’s dates of employment and position(s) held.

 

12

Execution Copy
 

EMPLOYEE ACKNOWLEDGES AND AGREES THAT EMPLOYEE HAS FULLY READ, UNDERSTANDS, AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT EMPLOYEE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF EMPLOYEE’S CHOICE BEFORE SIGNING THIS AGREEMENT.

 

HAVING ELECTED TO EXECUTE THIS AGREEMENT, TO FULFIL THE PROMISES, AND TO RECEIVE THE SEPARATION BENEFITS SET FORTH ABOVE, EMPLOYEE FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS EMPLOYEE HAS OR MIGHT HAVE AGAINST THE RELEASED PARTIES.

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date set forth below in the signature block.

 

 

EMPLOYEE

 

/s/ Phillip Massie Price

Phillip Massie Price

Date: ___3/20/2025_______________         

LIQTECH HOLDING A/S.

By:/s/ Fei Chen         

Print Name: Fei Chen         

Title: CEO         

Date: ___3/20/2025________________         

 

1

Execution Copy

 

Exhibit 1

Second General Release

 

1.            General Release.

 

a.    In consideration for the benefits described in the attached Agreement, Phillip Massie Price (“Employee”) hereby releases and forever discharges LiqTech International, Inc., LiqTech Holding A/S, LiqTech Water A/S, LiqTech Ceramics A/S, LiqTech Plastics A/S, and each of their respective related affiliates, subsidiaries, parents, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, executives, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, “Released Parties”) from all known or unknown claims, debts, liabilities, breaches of contract, compensation, stock options, claims for profits, claims for expenses, demands, damages, actions, causes of action, or suits of any kind or nature whatsoever, if any, under U.S. law that Employee presently has or could have, for any event, occurrence, or omission that has occurred prior to the Separation Date (as defined in the Agreement to which this Exhibit 1 is attached), including, but not limited to, all losses, debts, liabilities, breaches, claims and causes of action based on breach of contract, wrongful termination, public policy, accounting, misrepresentation, fraud, property damage, personal injury, infliction of emotional distress, defamation, privacy, disclosure of trade secrets and proprietary information, conflicts of interest, tortious interference, breach of fiduciary duties, demands, costs, loss of services, expenses, compensation, contribution, attorneys’ fees, and all compensatory, consequential, liquidated, special and punitive damages (collectively, the “Released Claims”). Employee understands that Released Claims specifically include, but are not limited to, to the maximum extent permitted by law, (1) any claims in connection with, relating to, or arising out of Employee’s employment with Holding, the terms and conditions of such employment, and/or the termination, resignation, separation or end of such employment; (2) any claims for compensation, salary, bonuses or similar benefits, severance pay, or vacation pay; (3) any claims in connection with, arising under or relating to any alleged written, oral or implied Employment Contract; (4) any and all claims under Nevada administrative statutory or codified law or regulation dealing with fair employment practices and/or wage and hour laws; (5) the Nevada Fair Employment Practices Act; (6) claims under Nevada's overtime, meal and rest period, and related wage and hour penalty statutes; (7) NRS 608.250 relating to the payment of minimum wage for each hour worked; (8) NRS 613.010, related to inducing a person to change their work location under false pretenses; (9) NRS 613.210, relating to the "blacklisting" of employees; and (10) any other law prohibiting discrimination, harassment and/or retaliation based on the exercise of Employee’s rights under any law providing whistleblower protection, providing workers’ compensation benefits, providing or protecting employee benefits and pension plans, regarding payment of wages or other compensation, protecting union activity, mandating leaves of absence, restricting an employer’s right to terminate employees or otherwise regulating employment, enforcing express or implied employment contracts, concerning government contracts and compliance with same, requiring an employer to deal with employees fairly or in good faith, providing recourse for alleged wrongful discharge, tort, physical or personal injury, emotional distress, fraud, negligent misrepresentation, defamation, and similar or related claims, or relating to salary, commission, compensation, benefits, and other matters.

 

1

Execution Copy

 

b.    Notwithstanding the foregoing, Employee does not release any claims (1) for any breach of the Agreement to which this Second General Release is attached, (2) any claims which cannot be waived by law (such as claims for unemployment benefit rights and workers’ compensation filed in the United States of America), (3) any right to file an unfair labor practice charge under the National Labor Relations Act, (4) indemnification rights Employee may have against the Company; and (5) any rights with respect to stock options or other similar equity‑based incentives granted to Employee as determined under the applicable plans and award agreement, including, but not limited to, the RSU Award Agreement and the Company Plan as modified herein (to the extent such rights survive a termination of employment).

 

c.    Employee acknowledges and agrees that Employee has already released the Released Parties from all existing and potential claims under Danish law that occurred, or could have occurred, prior to the Separation Date.

 

By signing below, Employee further acknowledges and agrees that Employee has been paid for all salary, wages, bonuses, benefits, compensation, and consideration of any kind earned through the Separation Date, and that Employee is not entitled to receive, and shall not claim from the Company, any compensation, payments, or benefits except for those payments and benefits that are expressly set forth in this Agreement. To the extent that any such additional amount owed is otherwise determined to exist, the payments described herein are in lieu of and encompass such amounts.

 

2.            ADEA Release. As a part of this Second General Release, Employee expressly agrees to the release of any rights or claims arising out of the US Age Discrimination in Employment Act (“ADEA,” 29 U.S.C. § 621, et seq.), and in connection with such waiver:

 

a.    Employee is hereby advised to consult with an attorney prior to signing this Second General Release;

 

b.    Employee shall have a period of twenty-one (21) calendar days from the date of receipt of this Agreement and Second Release in which to consider the terms of the Agreement and Second General Release, however this Second General Release cannot be executed prior to the Separation Date;

 

c.    Employee may revoke this Second General Release at any time during the first seven (7) calendar days following execution of the Second General Release, and the waiver and release shall not be effective or enforceable until the 7-day revocation period has expired without Employee having revoked the Second General Release (“Expiration of Second Revocation Date”).

 

d.    As between Employee and the Released Parties, this Second General Release does not constitute a waiver of any claim under the ADEA that may arise after the date of the execution of this Second General Release.

 

e.    Employee further understands and agrees that Employee may be waiving significant legal rights by signing this Second General Release, and represents that Employee has entered into this Second General Release voluntarily, with a full understanding of and in agreement with all of its terms.f.Employee further acknowledges that Employee has read and fully understands this Second General Release.

 

2

Execution Copy

 

g.    Employee acknowledges and agrees that Employee has been advised, by virtue of the Agreement and this Second General Release, to consult with an attorney before signing it, and has had an opportunity to consult with an attorney of his choice.

 

h.    Employee understands that this document is a complete release of any and all existing claims, known or unknown, which she may have against the Released Parties. This Second General Release will become effective and enforceable seven (7) days after it has been executed by Employee without Employee revoking it. Employee has the right to revoke this Agreement by giving written notice of Employee’s intent to do so to an authorized representative of the Company at any time during that 7-day period.

 

AGREED TO AND ACCEPTED BY:

 

 

   

Phillip Massie Price

 

Date:    

 

Signature Page 3  
 
EX-10.19 3 ex_795425.htm EXHIBIT 10.19 ex_795425.htm

Exhibit 10.19

 

LIQTECH INTERNATIONAL, INC.

 

SECOND AMENDMENT TO

 

NOTE AND WARRANT PURCHASE AGREEMENT

 

This SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT (this “Amendment”) is effective as of March 26, 2025 (the “Effective Date”), by and among LiqTech International, Inc., a Nevada corporation (the “Company”), and 21 April Fund, Ltd. and 21 April Fund, L.P. (collectively, the “Investors” and, each, an “Investor”).

 

WHEREAS, the Company and the Investors are parties to that certain Note and Warrant Purchase Agreement, dated as of June 22, 2022, as amended by that certain First Amendment to Note and Warrant Purchase Agreement, effective as of September 30, 2023 (and as further amended, amended and restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”), pursuant to which the Company issued and sold to the Investors $6,000,000 aggregate principal amount of promissory notes in the respective amounts set forth on Schedule A to the Purchase Agreement (as amended by that certain Allonge No. 1 to Promissory Note, collectively, the “Notes” and, each, a “Note”);

 

WHEREAS, pursuant to the Purchase Agreement, the Company also issued warrants to purchase shares of common stock of the Company (“Common Stock”) in the respective amounts set forth on Schedule A to the Purchase Agreement (collectively, the “Original Warrants” and, each, an “Original Warrant”);

 

WHEREAS, Section 6.10 of the Purchase Agreement provides that any term of the Purchase Agreement may be amended only with the written consent of the Company and the Investors, Section 6 of each Note provides that any term of such Note may be amended only with the written consent of the Company and the Investor party thereto, and Section 5 of each Original Warrant provides that such Original Warrant may be modified or amended with the written consent of the Company and the holder thereof; and

 

WHEREAS, the Investors and the Company desire to further amend the Notes and to amend and restate the Original Warrants, in each case, on the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants set forth in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors agree as follows:

 

 

1.

Defined Terms. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Purchase Agreement.

 

 

2.

Amendment to Notes; Restatement of Warrants. Simultaneous with the execution and delivery of this Amendment, the Company shall execute and deliver to each Investor (a) Allonge No. 2 to such Investor’s Note substantially in the form attached hereto as Exhibit A  (“Allonge No. 2”) and (b) an Amended and Restated Warrant substantially in the form attached hereto as Exhibit B (the “Amended and Restated Warrants” and, each, an “Amended and Restated Warrant”) for the number of shares of Common Stock set forth on Schedule A of the Purchase Agreement.

 







 
 

3.

Amendment to Purchase Agreement. The Purchase Agreement is hereby amended as follows:

 

 

(a)

The Amended and Restated Warrants shall be considered “Warrants” as such term is defined and used in the Purchase Agreement and, the (i) shares of Common Stock issuable upon exercise of the Amended and Restated Warrants and (ii) the Note Shares, if any, shall be considered “Warrant Shares” for all purposes of the Registration Rights Agreement.

 

 

4.

Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor that as of the Effective Date:

 

 

(a)

The Company is duly incorporated, validly existing, and in good standing under the laws of the jurisdiction of its organization. The Company has all requisite power and authority to own and operate its respective properties and assets and to carry on its business as presently conducted and as proposed to be conducted. The Company is qualified to do business as a foreign entity in every jurisdiction in which the failure to be so qualified would have, or would reasonably be expected to have, a Material Adverse Effect.

 

 

(b)

The representations and warranties of the Company set forth in Sections 2.3 through 2.9 of the Purchase Agreement, subject to the following amendments, are true and correct as of the Effective Date: (i) the term “Transaction Documents” shall be defined as “this Amendment, Allonge No. 2 to each Note, the Amended and Restated Warrants and any ancillary agreements and instruments to be entered into by the Company under this Amendment”; (ii) any reference to “this Agreement” shall be replaced with “this Amendment”; (iii) any reference to the “Notes,” except for the reference contained in the definition of “Transaction Documents,” shall be to the Notes as amended by Allonge No. 2; (iv) any reference to the “Warrants” shall be replaced with the “Amended and Restated Warrants”; (v) the term “Warrant Shares” shall be defined as “shares of Common Stock underlying the Amended and Restated Warrants” and (vi) references to “date hereof”, “date of the Closing” or “date of this Agreement” shall be replaced with “Effective Date.”

 

 

(c)

The following representations and warranties of the Company are true and correct as of the Effective Date: (i) the shares of Common Stock to be issued pursuant to the Notes (the “Note Shares”) have been duly authorized by all necessary corporate action and such Note Shares, when and if issued pursuant to the terms of the applicable Note, will be validly issued, fully paid, and nonassessable, and will be free of any lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other material restriction with respect to the issuance thereof; provided, however, that such Note Shares shall be subject to restrictions on transfer under state or federal securities laws as set forth in this Amendment, or as otherwise may be required under state or federal securities laws as set forth in this Amendment at the time a transfer is proposed; and (ii) assuming the accuracy of each of the representations and warranties of the Investors herein, the issuance by the Company of the Notes, and any shares of Common Stock issuable upon the exercise thereof, are or will be, as applicable, exempt from registration under the Securities Act.

 

- 2 -

 

 

(d)

The representations and warranties of the Company set forth in Sections 2.1, 2.2 and 2.10 through 2.20 of the Purchase Agreement are true and correct in all material respects as of the Effective Date as if made on and as of the Effective Date (and, for the avoidance of doubt, references to “date hereof”, “date of the Closing” or “date of this Agreement” shall be replaced with “Effective Date”).

 

 

5.

Representations and Warranties of the Investors. Each Investor hereby represents and warrants severally, and not jointly, that the representations and warranties of such Investor set forth in Section 3 of the Purchase Agreement, subject to the following amendments, are true and correct as of the Effective Date: (i) the term “Transaction Documents” shall be defined as “this Amendment, Allonge No. 2 to each Note, the Amended and Restated Warrants and any ancillary agreements and instruments to be entered into by such Investor under this Amendment”; (ii) any reference to “this Agreement” shall be replaced with “this Amendment”; (iii) any reference to the “Notes,” except for the reference contained in the definition of “Transaction Documents,” shall be to the Notes as amended by Allonge No. 2; (iv) the term “Securities” shall be defined as “the Notes, the Amended and Restated Warrants and any capital stock issuable upon exercise of the Amended and Restated Warrants or payment under the Notes”; and (v) any reference to the “Warrants” shall be replaced with the “Amended and Restated Warrants”.

 

 

6.

Covenants of the Company.

 

 

(a)

Reservation of Stock. The Company covenants that during the term the Amended and Restated Warrants are exercisable, the Company will reserve from its authorized and unissued capital stock a sufficient number of shares to provide for the issuance of Common Stock upon the exercise of all outstanding Amended and Restated Warrants.

 

 

(b)

Use of Proceeds from Payments of Exercise Price. The Company covenants that, for so long as the Notes are outstanding, all payments of Exercise Price (as defined in the Amended and Restated Warrants) received by the Company shall be used by the Company to repay any amounts outstanding under the Notes, on a pro rata basis.

 

 

(c)

Securities Laws Disclosure. The Company will file a Current Report on Form 8-K with the SEC describing the terms of the Transaction Documents (the “8-K Filing”) within the time required by the Exchange Act. Neither the Company or its subsidiaries, on the one hand, nor the Investors, on the other hand, shall issue any press releases or any other public statements with respect to the transactions contemplated hereby without the prior consent of the other party; provided, however, the Company or the Investors each shall be entitled, without the prior approval of the other, to make any press release or other public disclosure with respect to such transactions (a) in substantial conformity with the 8-K Filing and contemporaneously therewith and (b) as is required by applicable law and regulations.

 

- 3 -

 

 

7.

Miscellaneous.

 

 

(a)

Effect on the Notes and the Purchase Agreement. Except as specifically provided herein and in the Allonge No. 2 to each Note, each of the Notes and the Purchase Agreement shall remain in full force and effect. To the extent that any term or provision of this Amendment is or may be inconsistent with any term or provision in the Purchase Agreement or any Note, the terms and provisions of this Amendment shall control.

 

 

(b)

Affixation to Each Note. Each Investor agrees to affix a fully executed copy of Allonge No. 2 to such Investor’s Note, as applicable, and such Allonge No. 2 shall become a part thereof.

 

 

(c)

Survival of Warranties. The warranties, representations and covenants of the Company and each Investor contained in or made pursuant to this Amendment with respect to the Effective Date shall survive the execution and delivery of this Amendment and such Effective Date.

 

 

(d)

Governing Law; Jurisdiction. This Amendment shall be governed by and construed under the laws of the State of New York as applied to agreements among New York residents entered into and to be performed entirely within New York. With respect to any disputes arising out of or related to this Amendment, the parties consent to the exclusive jurisdiction of the New York County Supreme Court or, in the event that such court does not have jurisdiction over the dispute, to the federal district court of the Southern District of New York or to the state courts of the State of New York.

 

 

(e)

Counterparts; Electronic Signatures. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and upon such delivery any such signature shall be deemed to have the same effect as if the original signature had been delivered to the other party.

 

 

(f)

Expenses. Each Investor shall individually bear such Investor’s full costs and expenses incurred with respect to the negotiation, execution, delivery and performance of this Amendment and the other Transaction Documents.

 

 

(g)

Further Assurances. The parties agree to execute and deliver all such further documents, agreements and instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Amendment.

 

- 4 -

 

 

(h)

California Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AMENDMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AMENDMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.

 

[Remainder of this page intentionally left blank.]

 

- 5 -

 

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

 

 

 

COMPANY: 

 

     
  LIQTECH INTERNATIONAL, INC.  

 

 

 

 

 

By:

/s/ Fei Chen

 

 

Name: 

Fei Chen 

 

 

Title: 

Chief Executive Officer 

 

 

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 


 

 

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

 

 

INVESTORS: 

 

     
  21 APRIL FUND, LTD.  

 

 

 

 

 

 

 

 

 

By:

/s/ Michael Kellen

 

 

Name: 

Michael Kellen 

 

 

Title: 

Portfolio Manager 

 

 

 

 

21 APRIL FUND, LP. 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Michael Kellen

 

 

Name: 

Michael Kellen 

 

 

Title: 

Portfolio Manager 

 

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE


 

 

EXHIBIT A

 

FORM OF ALLONGE NO. 2 TO PROMISSORY NOTE

 

 

LIQTECH INTERNATIONAL, INC.

 

ALLONGE NO. 2 TO
PROMISSORY NOTE

 

Effective as of March 26, 2025

 

This Allonge No. 2 to Promissory Note (this “Allonge”) is intended to be permanently affixed to that certain Promissory Note, dated June 22, 2022, issued by LiqTech International, Inc., a Nevada corporation (the “Company”), in favor of [21 April Fund, Ltd.] [21 April Fund, L.P.] (the “Holder”), in the original principal amount of [$4,250,000] [$1,750,000], as previously amended by that certain Allonge No. 1 to Promissory Note, dated September 30, 2023 (as so amended, the “Note”). When so affixed, this Allonge shall constitute part of the Note. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Note.

 

The Note is hereby amended, effective as of the date of its issuance, in the following manner:

 

1.    The second sentence of Section 1.1 of the Note is hereby amended and restated in its entirety as follows: “This Promissory Note (this “Note”) shall not bear interest until January 1, 2026. Beginning on January 1, 2026, this Note shall bear interest at a rate of 10% per annum (calculated on the basis of a three hundred sixty-five (365) day year and the actual days elapsed) until the Note is repaid in full. Notwithstanding the foregoing, if at any time following the date hereof (x) the Note is not repaid in full on or by the Maturity Date (as defined below), or (y) if any Event of Default occurs which is continuing, in each case and without limiting any other remedies available to the Holder, the Note shall thereafter bear interest on the unpaid principal balance thereof at the rate of 13% per annum for the first month after the Maturity Date or after the occurrence of such Event of Default which is continuing (as applicable), and such rate shall increase by 1% on (I) in the case of clause (x) above, the 20th day of each month after the Maturity Date until the Note is repaid in full, or (II) in the case of clause (y) above, the corresponding day of the month for each month after the occurrence of such Event of Default (provided that, for any month in which there is not a day corresponding to the date on which such Event of Default occurred, then the corresponding day shall be the last day of such month) until such Event of Default has been cured, in each case, up to a maximum of 16% per annum (such interest, collectively, “Default Interest”). If at any time the interest rate payable on this Note shall exceed the maximum rate of interest permitted under applicable law, such interest rate shall be reduced automatically to the maximum rate permitted. All payments of interest, aside from Default Interest, shall be paid semi-annually in arrears on each of June 1 and December 1 (each, an “Interest Payment Date”) beginning on June 1, 2026, in either cash or shares of the Company’s common stock (“Common Stock”) in accordance with Section 1.4 hereof.”

 

 

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

2.    The following new Section 1.4 is hereby added to the Note:

 

“1.4         The decision whether to pay interest hereunder in shares of Common Stock or cash shall be at the discretion of the Company. Should the Company elect to pay interest in kind, it shall be paid in shares of Common Stock valued for purposes thereof at the volume-weighted average of the closing price per share as reported by the Nasdaq Capital Market for the five (5) consecutive trading days ending on the last trading day immediately preceding the Interest Payment Date; provided that in no event shall the price per share used to calculate the interest payment be less than $0.50 per share; provided, further, that notwithstanding anything in this Note to the contrary, the Company shall not elect to pay interest in kind or otherwise issue any shares of Common Stock pursuant to this Note, if the issuance of such shares of Common Stock, together with any shares of Common Stock issued in connection with the transactions contemplated by the Purchase Agreement would exceed 19.99% of the shares of Common Stock outstanding as of the date of the Purchase Agreement or such lower number of shares as a result of the aggregation of the transactions contemplated by the Purchase Agreement with any other transaction or series of transactions under applicable rules of The Nasdaq Stock Market LLC. No less than 10 trading days prior to each Interest Payment Date, the Company shall provide the Holder with written notice of its election to pay interest hereunder either in cash or shares of Common Stock (the Company may indicate in such notice that the election contained in such notice shall continue for later periods until revised).”

 

3.    The Maturity Date is hereby extended by sixteen (16) months to May 1, 2027. Therefore, the definition of “Maturity Date” in Section 1.2 of the Note is hereby amended to mean “May 1, 2027.”

 

4.    Nothing contained in this Allonge shall be construed as a substitution or novation of the existing indebtedness evidenced by the Note, which indebtedness remains outstanding and in full force and effect, as modified hereby. The Company hereby acknowledges and agrees that the Note (as modified by this Allonge) remains and shall continue in full force and effect without impairment.

 

5.    This Allonge may be executed in any number of counterparts, each of which so executed and delivered shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same instrument.

 

[remainder of this page intentionally left blank]

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

 

IN WITNESS WHEREOF, the Company has caused this Allonge No. 2 to Promissory Note to be duly executed as of the date first above written.

 

 

COMPANY: 

 

     
  LIQTECH INTERNATIONAL, INC.  

 

 

 

 

 

 

 

 

 

By:

 

 

 

Name: 

Fei Chen 

 

 

Title: 

         Chief Executive Officer                   

 

 

 

 

ACCEPTED AND AGREED TO: 

 

     
  HOLDER:  
     
     
  [21 April Fund, Ltd.] [21 April Fund, L.P.]  

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

EXHIBIT B

 

FORM OF AMENDED AND RESTATED WARRANT

 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

AMENDED AND RESTATED

COMMON STOCK PURCHASE WARRANT

 

LIQTECH INTERNATIONAL, INC.

 

 

Warrant Shares: [ ]

Initial Exercise Date: June 22, 2022

 

Amendment Date: March 26, 2025

 

THIS AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [21 April Fund, Ltd.] [21 April Fund, L.P.], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Amendment Date”) and on or prior to the close of business on December 31, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from LIQTECH INTERNATIONAL, INC., a Nevada corporation (the “Company”), up to [376,302][154,948] ([Three Hundred Seventy-Six Thousand Three Hundred and Two][One Hundred Fifty-Four Thousand Nine

Hundred and Forty-Eight]) shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. Notwithstanding the foregoing, subject to the Company’s compliance with the notice provisions set forth in Section 3(g) hereof, this Warrant will terminate upon the consummation of a Change of Control. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). It is intended that this Warrant amend and restate in its entirety that warrant originally issued by the Company to the Holder on June 22, 2022 (the “Original Warrant”). From the Amendment Date, the terms of this Warrant supersede in full the terms of the Original Warrant.

 

Section 1. Definitions. In addition to the terms defined elsewhere in the Warrant, the following terms have the meanings indicated in this Section 1.

 

a) “Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person.

 

b) “Change of Control Transaction” means the occurrence after the applicable Original Issue Date in one or more related transactions of any of (a) an acquisition (whether by way of merger, share exchange, consolidation, business combination or similar transaction) by an individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, or by contract) of in excess of 50% of the voting securities of the Company, (b) the Company merges into or consolidates with any other Person, or any Person merges into or consolidates with the Company and, after giving effect to such transaction, the stockholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the Company or the successor entity of such transaction, or (c) the Company sells, leases, licenses, conveys, transfers or otherwise disposes of all or substantially all of its assets to another Person.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

c) “Commission” means the United States Securities and Exchange Commission.

 

d) “Common Stock” means the shares of common stock, par value $0.001 per share, of the Company.

 

e) “Common Stock Equivalents” means any securities or instruments of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

f) “Convertible Securities” means evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for shares or Common Stock, including but not limited to the preferred stock, warrants, notes, or other rights to acquire securities of the Company (but excluding Options).

 

g) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

h) “Note” means the senior promissory note issued to the initial Holder of this Warrant on the Amendment Date.

 

i) “Options” means rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities, but excludes options issued to employees, directors, officers, consultants, contractors, or advisors to the Company or any of its subsidiaries in connection with the provision of bona fide services pursuant to a plan, agreement or arrangement approved by the Board of Directors.

 

j) “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

k) “Purchase Agreement” means that certain Note and Warrant Purchase Agreement, dated June 22, 2022, among the Company and the purchasers signatory thereto, as amended by that certain First Amendment to Note and Warrant Purchase Agreement, dated effective September 30, 2023 and that certain Second Amendment to the Note and Warrant Purchase agreement, dated effective March [●], 2025..

 

l) “Trading Day” means a day on which the principal Trading Market is open for business.

 

m) “Trading Market” means any of the following markets or exchanges on which Common Stock is listed or quoted for trading on the date in question: the Nasdaq Stock Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

n) “Transfer Agent” means Securities Transfer Corporation, the current transfer agent of the Company with a mailing address of 2901 N. Dallas Parkway, Suite 380, Plano, TX 75093 and a telephone number of 469.633.0101, and any successor transfer agent of the Company.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

Section 2. Exercise.

 

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Amendment Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto. Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(c)(i) below) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) business day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $2.00 subject to adjustment hereunder (the “Exercise Price”).

 

c) Mechanics of Exercise.

 

i. Delivery of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate or evidence that the Warrant Shares have been electronically issued in “book-entry” form, in each case, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is one (1) Trading Day after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares; provided payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period of delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

v. Charges; Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vi. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

 

d) Holder’s Exercise Limitations. Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the extent that, after giving effect to such exercise, the Holder (or any of the Holder’s Affiliates or any Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, the “Attribution Parties”)) would beneficially own in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and the Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Holder or any the Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of the Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 2(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with the Attribution Parties) and of how many Warrant Shares are issuable shall be in the sole discretion of the Holder (provided that such determination by the Holder shall be reasonably acceptable to the Company), and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with the Attribution Parties) and of which portion of this Warrant is exercisable, in each case, subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(d), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Company’s most recent periodic or annual report filed with the Commission, as the case may be; (ii) a more recent public announcement by the Company; or (iii) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of the Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or the Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares issuable upon exercise of this Warrant by the Holder. The Holder, upon notice to the Company, may waive the Beneficial Ownership Limitation provisions of this Section 2(d), provided that such waiver (A) will not be effective until the 61st day after such notice is delivered to the Company, (B) shall only apply to the Holder, and (C) will not be effective to the extent such waiver would require the prior approval of the Company’s stockholders, unless such approval has been obtained. The limitations contained in this Section 2(d) shall apply to a successor holder of this Warrant.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

Section 3. Certain Adjustments.

 

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant); (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of Common Stock, any shares of capital stock of the Company, then, in each case, the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.

 

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

c) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution.

 

d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of Common Stock or any compulsory share exchange pursuant to which Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, in connection with the consummation of such Fundamental Transaction, the Holder shall receive, for each Warrant Share that would have been issuable to the Holder upon such exercise on a cashless basis immediately prior to the occurrence of such Fundamental Transaction (and without regard to the Beneficial Ownership Limitation), the amount of consideration or, if applicable, the number of shares of capital stock of the successor or acquiring corporation or shares of Common Stock of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to the Beneficial Ownership Limitations). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives with respect to this Warrant in connection with such Fundamental Transaction.

 

e) Sale of Shares Below Exercise Price.

 

i.         If at any time or from time to time after the Amendment Date but prior to the nine-month anniversary of the date on which each Note is repaid in full, the Company grants, issues or sells Additional Shares of Common Stock (a “Subsequent Financing”) for an Effective Price less than the then existing Exercise Price, then the Exercise Price shall be reduced, effective as of the closing of such Subsequent Financing, to a price determined by multiplying that Exercise Price by a fraction, the numerator of which shall be (A) the number of shares of Common Stock outstanding as of the close of business on the day preceding the closing of the Subsequent Financing (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of all rights, options or warrants or upon conversion of all securities convertible into or exchangeable for Common Stock (including this Warrant) outstanding as of the close of business on the day preceding the closing of the Subsequent Financing) plus (B) the number of shares of Common Stock which the aggregate consideration received (or by the express provisions hereof is deemed to have been received) by the Company for the total number of Additional Shares of Common Stock so issued would purchase at such Exercise Price (prior to such adjustment) and the denominator of which shall be (X) the number of shares of Common Stock outstanding immediately prior to the closing of the Subsequent Financing (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of all rights, options or warrants or upon conversion of all securities convertible into or exchangeable for Common Stock (including this Warrant) outstanding as of the close of business on the day preceding the closing of the Subsequent Financing) plus (Y) the number of such Additional Shares of Common Stock issued or sold in the Subsequent Financing. For the purpose of making any adjustment required under this Section 3(e), the consideration received by the Company for any issue or sale of securities in a Subsequent Financing shall (A) to the extent it consists of cash be computed at the amount of cash received by the Company, (B) to the extent it consists of property other than cash, be computed at the fair market value of that property as reasonably determined in good faith by the Board of Directors, and (C) if Additional Shares of Common Stock, Convertible Securities or Options are issued or sold together with other stock or securities or other assets of the Company for a consideration which covers both, be computed as the portion of the consideration so received that may be reasonably determined in good faith by the Board of Directors to be allocable to such Additional Shares of Common Stock, Convertible Securities or Options.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

ii.         For the purpose of the adjustment required under Section 3(e)(i), if the Company issues or sells any Convertible Securities or Options (or securities directly or indirectly convertible into or exchangeable for Additional Shares of Common Stock, Convertible Securities or Options), and if the Effective Price of such Common Stock underlying any such Convertible Securities or Options is less than the Exercise Price then in effect, then in each case the Company shall be deemed to have issued at the time of the issuance of such Convertible Securities or Options the maximum number of Additional Shares of Common Stock issuable upon exercise or conversion thereof and to have received as consideration for the issuance of such shares an amount equal to the total amount of the consideration, if any, received by the Company for the issuance of Convertible Securities or Options, plus, in the case of any Options, the minimum amounts of consideration, if any, payable to the Company upon the exercise of such Options, plus, in the case of Convertible Securities, the minimum amounts of consideration, if any, payable to the Company (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) upon the conversion thereof. No further adjustment of the Exercise Price, adjusted upon the issuance of such Convertible Securities or Options, shall be made as a result of the actual issuance of Additional Shares of Common Stock on the exercise of any such rights or options or the conversion of any such Convertible Securities.

 

iii.         If any such Options or the conversion privilege represented by any such Convertible Securities shall expire without having been exercised, the Exercise Price as adjusted upon the issuance of such Options or Convertible Securities shall be readjusted to the Exercise Price which would have been in effect had an adjustment been made on the basis that the only Additional Shares of Common Stock so issued were the Additional Shares of Common Stock, if any, actually issued or sold on the exercise of such Options or rights of conversion of such Convertible Securities, and such Additional Shares of Common Stock, if any, were issued or sold for the consideration actually received by the Company upon such exercise, plus the consideration, if any, actually received by the Company for the granting of all such rights or options, whether or not exercised, plus the consideration received for issuing or selling the Convertible Securities actually converted, plus the consideration, if any, actually received by the Company (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) on the conversion of such Convertible Securities.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

iv.         If the purchase price provided for in any Options, the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time, the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price, which would have been in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price, additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold. For purposes of this Section 3(e)(iv), if the terms of any Option or Convertible Security that was outstanding as of the date hereof are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible Security and the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section 3(e) shall be made if such adjustment would result in an increase of the Exercise Price then in effect.

 

v.         “Additional Shares of Common Stock” shall mean all shares of Common Stock issued (or deemed issued hereunder) by the Company after the Amendment Date, whether or not subsequently reacquired or retired by the Company, other than: (A) shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on preferred stock; (B) shares of Common Stock, Convertible Securities or options issued to employees, directors, officers, consultants, contractors, or advisors to the Company or any of its subsidiaries in connection with the provision of bona fide services pursuant to a plan, agreement or arrangement approved by the Board of Directors; (C) shares of Common Stock or Convertible Securities actually issued upon the exercise of Options outstanding on the Amendment Date or thereafter issued in accordance with the Articles of Incorporation of the Company or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities outstanding on the Amendment Date or thereafter issued in accordance with the Articles of Incorporation of the Company, in each case, provided such issuance is pursuant to the terms of such Option or Convertible Security; (D) shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors in connection with the provision of bona fide goods or services pursuant to a debt financing, equipment leasing, commercial credit arrangements, real property leasing transactions or similar transaction approved by the Board of Directors; (E) shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers in connection with the provision of bona fide goods or services pursuant to transactions approved by the Board of Directors; (F) shares of Common Stock, Options or Convertible Securities issued pursuant to the acquisition of another entity by the Company through a merger, the purchase of all or substantially all of the assets of the other entity, other reorganization, or in connection with a joint venture agreement, technology license agreement or other acquisition agreement pursuant to which the Company acquires technology or other assets in a transaction or series of related transactions, in each case, approved by the Board of Directors; and (G) shares of Common Stock, Options or Convertible Securities issued upon conversion of preferred stock or the exercise of this Warrant. The “Effective Price” of Additional Shares of Common Stock shall mean the quotient determined by dividing the aggregate consideration received, or deemed to have been received by the Company for such issue under this Section 3(e), for such Additional Shares of Common Stock by the total number of Additional Shares of Common Stock issued or sold, or deemed to have been issued or sold by the Company under this Section 3(e).

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

f) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g) Notice to Holder.

 

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 5 Trading Days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

Section 4. Transfer of Warrant.

 

a) Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 3.8 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part (i) to an affiliate of the Holder or (ii) to any other person only with the written consent of the Company, in each case, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

b) New Warrant. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original issue date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 3.8 of the Purchase Agreement.

 

e) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section 5. Miscellaneous.

 

a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(c)(i), except as expressly set forth in Section 3.

 

b) Registration Rights. All Warrant Shares issued upon exercise of this Warrant shall be covered by the Registration Rights Agreement of even date herewith, entered into between the Holder and the Company.

 

c) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

d) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.

 

e) Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

 

f) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

 

g) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.

 

h) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

i) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

j) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

 

k) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

l) Successors and Assigns. Subject to applicable securities laws and the conditions set forth in Section 4(d) hereof and the provisions of Section 3.8 of the Purchase Agreement, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

m) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

n) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

o) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

********************

(Signature Page Follows)

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

LIQTECH INTERNATIONAL, INC. 

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

Name: 

Fei Chen 

 

 

Title: 

Chief Executive Officer 

 

 

 

 

 

 

[Signature Page to Warrant]

 

Exhibit B-1


 

 

NOTICE OF EXERCISE

 

TO: LIQTECH INTERNATIONAL, INC.

 

(1) The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

     

 

The Warrant Shares shall be delivered to the following DWAC Account Number:

     

 

(3) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

Signature of Authorized Signatory of Investing Entity:

 

Name of Authorized Signatory:

 

Title of Authorized Signatory:

 

Date:

 

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE

 

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to:

 

Name:

       

Address:

       

Phone Number:

   

Email Address:

   

Dated:

 

,

 

Holder’s Signature:

 

Holder’s Address:

       

 

LIQTECH INTERNATIONAL, INC.
SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT
SIGNATURE PAGE
EX-19.1 4 ex_787987.htm EXHIBIT 19.1 ex_787987.htm

Exhibit 19.1

 

LIQTECH INTERNATIONAL, INC.

CODE OF CONDUCT AND ETHICS

 

Adopted January 01, 2012

Amended and Restated September 20, 2021

 

1.     INTRODUCTION

 

1.1    The following Code of Conduct and Ethics (this “Code”) has been adopted by management and approved by the Board of Directors of LiqTech International, Inc., a Nevada corporation (together with its subsidiaries, the “Company”), in order to:

 

1.1.1.    promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest;

 

1.1.2.    promote full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission (the “SEC”) and in other public communications made by the Company;

 

1.1.3.    promote compliance with applicable governmental laws, rules and regulations;

 

1.1.4.    promote the protection of Company assets, including corporate opportunities and confidential information;

 

1.1.5.    promote fair dealing practices;

 

1.1.6.    deter wrongdoing; and

 

1.1.7.    ensure accountability for adherence to this Code.

 

1.2    All directors, officers and employees are required to be familiar with this Code, comply with its provisions and report any suspected violations as described below in Section [10], Reporting and Enforcement.

 

1.3    The Company has many detailed policies that address certain of the topics in this document. The specific issues discussed in this Code do not cover all situations where a law or policy may apply. However, this Code should help clarify the general principles stated above. It is the responsibility of each director, officer, manager, and employee to understand and follow all Company policies.

 

2.     HONEST AND ETHICAL CONDUCT

 

2.1    The Company’s policy is to promote high standards of integrity by conducting its affairs honestly and ethically.

 

2.2    Each director, officer and employee must act with integrity and observe the highest ethical standards of business conduct in his or her dealings with the Company’s customers, suppliers, partners, service providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job.

 







 

3.     CONFLICTS OF INTEREST

 

3.1    A conflict of interest occurs when an individual’s private interest (or the interest of a family member) interferes, or even appears to interfere, with the interests of the Company as a whole. A conflict of interest can arise when an employee, officer or director (or a member of his or her family) takes actions or has interests that may make it difficult to perform his or her work for the Company objectively and effectively. Conflicts of interest also arise when an employee, officer or director (or a member of his or her family) receives improper personal benefits as a result of his or her position in the Company.

 

3.2    It would be impossible to detail every situation in which a conflict of interest may arise. However, below is a non-exhaustive list of types of conflicts all employees must avoid.

 

3.2.1.    Acquiring a material interest in any supplier, competitor or customer of the Company;

 

3.2.2.    Accepting any personal consulting or employment relationship that is or may be competitive with the Company;

 

3.2.3.    Engaging in any outside business activity that is or may be competitive with any of the Company’s businesses or interests;

 

3.2.4.    Accepting any outside employment which might affect the employee’s ability to devote the appropriate amount of time and attention to his or her duties and responsibilities with the Company;

 

3.2.5.    Receiving entertainment or anything of more than nominal value, whether as a gift or otherwise, from any individual or company with which the Company has a business relationship (normal and customary business meals, gifts of nominal value and customary business entertainment being excepted);

 

3.2.6.    Serving as an officer, director or in any other capacity for any customer, supplier or competitor of the Company unless approved by the Chief Executive Officer;

 

3.2.7.    Accepting loans from another business or individual if your position is one that interacts with, or influences, the Company’s transactions with that business or individual;

 

3.2.8.    Supervising, influencing, reviewing or having influence with respect to job evaluations, compensation or benefits for any “family member” who is an employee of the Company; and

 

3.2.9.    Taking personal advantage or obtaining personal gain from an opportunity learned of or discovered during the course and scope of employment with the Company when that opportunity or discovery could be of benefit or interest to the Company (this includes the invention or discovery of methods, formulas, flavors or techniques that are related to the employee’s duties or the business of the Company or outside opportunities in which the Company might be interested).

 







 

3.3    Such conflicts of interest may not only present themselves to an employee but could also present themselves to members of the employee’s family. For example, a conflict would arise if the employee’s spouse were to receive a valuable gift from a supplier of the Company. For the purpose of this Code, “family member” shall mean the employee’s spouse, children, parents, grandparents, parents-in-law, brothers, sisters, brothers-in-law, sisters-in-law and the children of his or her brothers, sisters, brothers-in-law or sisters-in-law.

 

3.4    Determining whether a conflict exists can be unclear. Conflicts of interest should be avoided unless specifically authorized as described in Section 3.5.

 

3.5    The Company’s policy in this area is not intended to restrict employees from participating in normal and customary business-related functions or events, or from engaging in the exchange of corporate gifts of nominal value. Persons other than directors and executive officers who have questions about a potential conflict of interest or who become aware of an actual or potential conflict should discuss the matter with, and seek a determination and prior authorization or approval from the Chief Financial Officer or the Chief Executive Officer. A [manager] may not authorize or approve conflict of interest matters or make determinations as to whether a problematic conflict of interest exists without first providing the Chief Executive Officer with a written description of the activity and seeking the Chief Executive Officer’s written approval. If the manager is himself involved in the potential or actual conflict, the matter should instead be discussed directly with the Chief Executive Officer.1

 

3.6    Directors and executive officers must seek determinations and prior authorizations or approvals of potential conflicts of interest exclusively from the [Audit Committee Chair].

 

4.     COMPLIANCE.

 

4.1    Employees, officers and directors should comply, both in letter and spirit, with all applicable laws, rules and regulations in the cities, states and countries in which the Company operates.

 

4.2    Although not all employees, officers and directors are expected to know the details of all applicable laws, rules and regulations, it is important to know enough to determine when to seek advice from appropriate personnel. Questions about compliance should be addressed to the Company’s Chief Executive officer. The Chief Executive Officer shall consult legal counsel for issues related to compliance.

 


1 Note to Draft: Nasdaq/SEC do not prescribe any specific procedure here. The Company may use its discretion.







 

4.3    Insider Trading.

 

4.3.1.     During the course of employment with the Company, employees may acquire information that is not generally known to the public. This may include financial information, forecasts, business plans and strategies, information on sales programs, product development, and other material information that is not known to individuals outside of the Company.

 

4.3.2.    No director, officer or employee may purchase or sell any Company securities while in possession of material nonpublic information regarding the Company, nor may any director, officer or employee purchase or sell another company’s securities while in possession of material nonpublic information regarding that company. It is against Company policies and illegal for any director, officer or employee to use material nonpublic information regarding the Company or any other company to:

 

4.3.2.1.    obtain profit for himself or herself; or

 

4.3.2.2.    directly or indirectly “tip” others who might make an investment decision on the basis of that information.

 

4.4    A violation of this policy, or the laws upon which this policy is based, could result not only in the termination of employment with the Company, but also civil and criminal proceedings. All employees, officers, and directors must comply with the Company’s Insider Trading Policy.

 

4.5    Foreign Corrupt Practices Act.

 

4.5.1.    The Foreign Corrupt Practices Act (the “FCPA”) became U.S. federal law in 1977. It applies to U.S. individuals, companies and businesses, including their controlled international subsidiaries.

 

4.5.2.    The FCPA makes it unlawful for U.S. companies operating in the United States or abroad and their employees to make direct or indirect payments to foreign government officials or political parties or candidates for the purpose of obtaining or retaining business.

 

4.5.3.    Employees of the Company or others acting on its behalf may not offer, pay, promise or authorize the payment of money or anything of value to: (a) foreign government officials, (b) foreign political parties, party officials or political candidates, or (c) any person if it is known, or firmly believed that the money or thing of value will be given or promised to a person described in (a) or (b) above, in order to obtain or retain business.

 

4.5.4.    In addition, no payments may be made to these individuals for the purpose of influencing the action or decision of the recipient, inducing the recipient to do or refrain from doing any act in violation of his or her lawful duty or inducing the recipient to exert influence on any foreign government, or any department, agency or instrumentality of a foreign government.

 







 

4.5.5.    Under the FCPA, the Company is required to keep books, records and accounts that accurately and fairly reflect the transactions and dispositions of its assets, and to maintain a system of internal accounting controls sufficient to provide reasonable assurances that assets are safeguarded from unauthorized use, that corporate transactions conform to managerial authorizations and that records are accurate.

 

4.6    Antitrust Laws. It is the policy of the Company to comply with the applicable antitrust laws of each nation in which the Company manufactures or sells products and services. These laws generally limit business practices that restrict competition. Agreements with competitors or other market participants that fix prices, divide markets or limit outputs or business activity are generally prohibited by the antitrust laws and criminal sanctions in the form of fines and imprisonment are frequently imposed.

 

4.7    Improper Payments and Political Activity.

 

4.7.1.    No payment will be made by or on behalf of the Company either directly or indirectly to government officials, political candidates, political parties or officers or employees of customers, suppliers or competitors if (a) the payment is designed to secure favored treatment for the Company or (b) the payment would violate applicable laws.

 

4.7.2.    Improper payments include unearned commissions or refunds, the donation or loan of the Company’s property or services of the Company’s personnel, the incurring or paying of expenses on behalf of another and the reimbursing of officers, employees or agents of the Company for payments made by them on the Company’s behalf.

 

4.7.3.    This policy does not include lawful political contributions authorized by the Chief Executive Officer or the Board of Directors, reasonable entertainment of customers or suppliers, potential customers or suppliers or others involved with the Company’s business in a manner appropriate to the business relationship and the discussion of business matters, gifts of sales promotion items, or, where the local custom requires, payment of small gratuities to minor governmental functionaries to secure the routine processing of paper work (for example, gratuities to minor customs officials for processing import documents) provided that such payments (a) are not either individually or in the aggregate significant in amount, (b) are fully disclosed in the Company’s records and (c) are approved by the manager of the local operation. While these transactions are not prohibited by this policy, they must be accurately disclosed in the Company’s books of account.

 

4.7.4.    This policy does not affect the right of employees, acting in an individual capacity and not as representatives of the Company, to support political parties or candidates of the employee’s choice. Since violation of this policy can create public reporting and tax problems for the Company as well as expose the Company and its officers, directors and the employee involved to civil and criminal sanctions, strict adherence is required. It is the responsibility of management at all levels to enforce this policy and of all employees to report violations to, or, in doubtful cases, to seek advice from their managers or from the Company’s Chief Executive Officer.

 







 

4.8    Discrimination and Harassment. The Company observes a policy of equal employment opportunity for all matters. The Company will not discriminate against any employee or prospective employee on the basis of race, color, religion, sex, age, national origin, handicap or veteran status. The Company will provide a workplace free from harassment on the basis of any of the above. The Company will also expect all of its employees, suppliers and representatives to observe and further the goals of this policy.

 

4.9    Environmental Matters. It is the policy of the Company to comply with all applicable laws and regulations for the protection of the environment and the conservation of natural resources. The Company believes that observing all such requirements is critical to the goal of acting as a responsible business citizen while also reducing the exposure to liability associated with even unintentional violation of environmental laws. It is the responsibility of every employee to conduct the business of the Company in a manner consistent with the goal of compliance with all applicable environmental laws and requirements.

 

4.10    Health and Occupational Safety. It is the policy of the Company to provide its employees with a place to work which is free from hazards and to comply with all applicable health and safety laws and regulations. Each employee is responsible for conducting the business of the Company in a way that does not endanger the health and safety of other employees and customers. Employees should, at all times, act in a manner that ensures the Company’s compliance with all applicable governmental health and safety laws and requirements.

 

4.11    Substance Abuse. The possession, distribution or use of an illegal controlled substance or alcohol, while on Company property, or while conducting the Company’s business is strictly prohibited. This does not prohibit moderate consumption of alcohol after work hours or during dinner meetings or events of a similar nature. The employee should do everything possible to make the workplace free from drugs and alcohol. Violation of this policy puts the employee and the employee’s co-workers at risk.

 

5.     IMPLEMENTATION OF THIS CODE.

 

5.1    Each manager shall distribute a copy of this Code to the employees for whom the manager is responsible. Each manager should also work to ensure that all of the employees under his or her supervision read, understand and comply with this Code and the policies addressed under this Code.

 

5.2    The Company’s Chief Executive Officer shall be responsible for the interpretation of this Code and the policies addressed within. Any questions regarding interpretation of this Code should be addressed to the Company’s Chief Executive Officer. If the Chief Executive Officer is less than certain on the proper interpretation of this Code, he should contact the Company’s legal counsel.

 

6.     REPORTING VIOLATIONS

 

6.1    Any employee who becomes aware of a violation of this Code or any of the policies addressed herein, or believes a violation has taken place, should report that violation to the employee’s manager. The manager shall then report the violation to the Company’s Chief Executive Officer. If the manager to whom the violation was reported takes no further action, or the employee feels that it would be appropriate to report the matter to a person of higher authority, the employee should bring the matter to the attention of the Chief Executive Officer of the Company or the Chair of the Audit Committee of the Board of Directors (the “Audit Committee”).

 







 

6.2    If any employee or officer of the Company becomes aware of the violation or potential violation of this Code, such employee or officer should report such activity via e-mail to the Company’s whistleblower e-mail address at whistleblower@liqtech.com. Any such e-mail shall be held in confidence and reported directly to the Chairman Audit Committee.

 

6.3    After receiving a report of an alleged prohibited action, the Chief Executive Officer, or the Chair of the Audit Committee must promptly take all appropriate actions necessary to investigate.

 

6.4    All directors, officers and employees are expected to cooperate in any internal investigation of misconduct.

 

6.5    The Company prohibits retaliation against anyone for the good faith reporting of a perceived Code violation or cooperation with an internal or external investigation of such a violation. Such retaliation by any associate or third party acting on behalf of an associate is itself a violation of this Code. This provision of this Code does not limit the Company’s recourse if the associate reporting the violation is ultimately found to have been a participant in the violation, or if the report is found to be a deliberate attempt to cause harm or harass another associate.

 

6.6    To assure that a reporting employee is protected from reprisal, requests for anonymity will be respected to the extent they do not result in the violation of the rights of another employee. Any attempt at reprisals against the reporting employee will not be tolerated.

 

7.     ENFORCEMENT

 

7.1    The Company must ensure prompt and consistent action against violations of this Code.

 

7.2    If, after investigating a report of an alleged prohibited action by a director or executive officer, the Audit Committee determines that a violation of this Code has occurred, the Audit Committee will report such determination to the Board of Directors.

 

7.3    If, after investigating a report of an alleged prohibited action by any other person, the relevant manager or Chair of the Audit Committee determines that a violation of this Code has occurred, the manager or Chair of the Audit Committee will report such determination to the Company’s legal counsel.

 

7.4    Upon receipt of a determination that there has been a violation of this Code, the Board of Directors or the General Counsel will take such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal and, in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.

 







 

8.     ACCOUNTING AND INTERNAL CONTROLS

 

8.1    Internal accounting controls have been established to manage the Company’s financial transactions. The Company adopted these controls to satisfy internal needs and to assure compliance with generally accepted accounting principles and the requirements of applicable laws and regulations. The Company is required to keep books, records and accounts that accurately and fairly reflect transactions and maintain an effective system of internal controls.

 

8.2    Proper accounting for all transactions is essential to the Company’s control of its affairs and the accuracy of its financial reporting. To maintain the integrity of the accounting records, all cash funds, bank accounts and other accounts must be disclosed in the Company’s books of account and all entries in the Company’s books must be prepared carefully, timely and honestly and must be supported by adequate documentation to provide a complete, accurate and auditable record of the transactions they describe.

 

8.3    No false or misleading entries may be made for any reason and no employee may assist any other person in making such entries.

 

8.4    Full and certain disclosure reinforces responsibility and acts as a powerful deterrent to wrongdoing. Therefore, it is vital that no fund, asset, liability, revenue or expense of the Company be concealed or incompletely recorded in any situation for any purpose. Any employee having information or knowledge of any unrecorded fund, asset, liability, revenue or expense or any prohibited act should promptly report it to the Company’s Chief Executive Officer.

 

8.5    The Company’s audit functions play a significant role in providing management with evaluations of the effectiveness of internal controls over accounting, operations and administrative functions. The Company’s internal and external auditors are charged with the responsibility of conducting objective and independent examinations, taking into account the high standards of business ethics, integrity and honesty required of all employees. All employees must cooperate fully with the Company’s auditors. Making intentionally false or misleading statements to auditors, whether internal or external, is considered a falsification of records.

 

9.     DISCLOSURE

 

9.1    The Company’s periodic reports and other documents filed with the SEC, including all financial statements and other financial information, must comply with applicable federal securities laws and SEC rules.

 

9.2    The accounting department and the Audit Committee bear special responsibility for promoting integrity throughout the organization, with responsibilities to shareholders both inside and outside of the Company. The Audit Committee, the Chief Executive Officer, the Chief Financial Officer and other accounting department personnel have a special role both to adhere to these principles themselves and also to ensure that a culture exists throughout the Company as a whole that ensures the fair and timely reporting of the Company’s financial results and condition.

 







 

9.3    Each director, officer and employee who is involved in the Company’s disclosure process must:

 

9.3.1.    be familiar with and comply with the Company’s disclosure controls and procedures and its internal control over financial reporting; and

 

9.3.2.    take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business condition of the Company provide full, fair, accurate, timely and understandable disclosure.

 

9.4    Each director, officer and employee who contributes in any way to the preparation or verification of the Company’s financial statements and other financial information must ensure that the Company’s books, records and accounts are accurately maintained. Each director, officer and employee must cooperate fully with the Company’s accounting and internal audit departments, as well as the Company’s independent public accountants and counsel. Employees, officers and directors should promptly report to the Chair of the Audit Committee any conduct that the individual believes may impair the Company’s full, fair, accurate, timely and understandable disclosure in reports and documents that it files with the Securities and Exchange Commission and in other public communications.

 

9.5    The Company expects all of its personnel to take this disclosure responsibility very seriously and to provide prompt and accurate answers to inquiries related to the Company’s public disclosure requirements.

 

10.     [TRADE SECRETS AND CONFIDENTIALITY.

 

10.1    During the course of employment with the Company, employees may access or acquire information that would be deemed confidential or a “trade secret.” Trade secrets and confidential information could be any non-public information that is of value to the Company, or information that, if made public, would be a detriment to the Company. While not an exhaustive list, typical trade secrets include information such as the development of new products, new flavors, the formula or recipe for products, new business initiatives, customer lists, price lists, pricing strategies, sales and promotions and any other non-public information that might be of value to the Company or the Company’s competitors. It is critical that the secrecy of all such confidential information and trade secrets be maintained and that employees take no action to either directly or indirectly allow such information to be released to individuals or businesses outside of the Company, or to be made public, except to the Company’s authorized advisers.]

 

11.     ELECTRONIC MEDIA AND SOFTWARE.

 

11.1    All electronic media and communications systems such as voice mail, e-mail, commercial software and access to the Internet through any Internet service provider are the property of the Company. Communications on these systems are not private communications, but are business records that may be monitored by the Company or subpoenaed by a court of law, and you should have no privacy expectations with respect to communications sent over these systems.

 

11.2    These systems should not be used to knowingly, recklessly or maliciously post, store, transmit, download or distribute any threatening, abusive, libelous, defamatory or obscene materials of any kind constituting a criminal offense, giving rise to civil liability or otherwise violating any laws. The Company’s policy against sexual harassment and discrimination applies fully to the use of e-mail and other electronic media.

 







 

12.     DUTY OF LOYALTY; CORPORATE OPPORTUNITIES.

 

12.1    The Company expects its employees to adhere to high standards of business ethics and undivided loyalty to the Company. Activities and personal interests that conflict with the best interests of the Company are inconsistent with employees’ duty of loyalty to the Company.

 

12.2    All directors, officers and employees owe a duty to the Company to advance its interests when the opportunity arises. Directors, officers and employees are prohibited from taking for themselves personally (or for the benefit of friends or family members) opportunities that are discovered through the use of Company assets, property, information or position. Directors, officers and employees may not use Company assets, property, information or position for personal gain (including gain of friends or family members). In addition, no director, officer or employee may compete with the Company.

 

13.     SHAREHOLDER & MEDIA RELATIONS.

 

13.1    The Company will provide accurate, appropriate and timely material information to the public, including its shareholders and the media to keep them informed of matters that affect our organization. To assure consistency and accuracy in these communications and to prevent the inadvertent disclosure of confidential information, you should not give statements to shareholders, the media or any other non-employee of the Company. If you are contacted by a shareholder, the request should be immediately forwarded to the Company’s Chief Financial Officer. If you are contacted by the media, or anyone requesting information regarding the Company, the Company’s plans or performance or any other potentially sensitive competitive information, the request should be forwarded to the Chief Financial Officer of the Company or, if regarding a legal matter, to the Company’s Chief Executive Officer.

 

14.     WAIVER

 

14.1    A majority of the Board of Directors (in the case of a violation by a director or executive officer) or the Chief Executive Officer or the Chair of the Audit Committee (in the case of a violation by any other person) may, in their discretion, waive any violation of this Code.

 

14.2    Any waiver for a director or an executive officer shall be disclosed as required by SEC regulations and the Nasdaq Listing Rules.

 



 

 

 

LIQTECH INTERNATIONAL, INC.

CODE OF CONDUCT AND ETHICS2

 

ACKNOWLEDGMENT OF RECEIPT AND REVIEW

 

I, _______________________, acknowledge that I have received and read a copy of the LiqTech International, Inc. Code of Conduct and Ethics (the “Code”). I understand the contents of the Code and I agree to comply with the policies and procedures set out in the Code.

 

I understand that I should contact the Chief Executive Officer if I have any questions about the Code generally or any questions about reporting a suspected conflict of interest or other violation of the Code.

 

 


2 To be signed and returned to the Company’s Chief Financial Officer.

 

 
EX-21.1 5 ex_762129.htm EXHIBIT 21.1 ex_762129.htm

Exhibit 21.1

 

Subsidiaries

 

1) LiqTech USA, Inc., a Delaware corporation;

 

2) LiqTech International A/S, a Danish limited company;

 

3) Liqtech NA, Inc., a Delaware corporation; and

 

4) LiqTech Water Projects A/S, a Danish company

 

5) Liqtech Ceramics A/S, a Danish limited company;

 

6) Liqtech Water A/S, a Danish limited company;

 

7) Liqtech Plastic A/S, a Danish limited company;

 

8) Liqtech Emission Control A/S, a Danish limited company; and

 

9) Nantong JiTRI LiqTech Green Energy Technology Co., Ltd., a Chinese limited company.

 

 

 
EX-23.1 6 ex_762130.htm EXHIBIT 23.1 ex_762130.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors

LiqTech International, Inc.

 

As independent registered public accountants, we hereby consent to the use of our report dated March 28, 2025, with respect to the consolidated financial statements for LiqTech International, Inc., it its registration statements on Form S-1 (File no. 333-239364), Form S-3 (File no. 333-262604) and Form S-8 (File No. 333-193580 and 333-269233) relating to the December 31, 2024 and 2023 consolidated financial statements, which is incorporated by reference. 

 

/s/ Sadler, Gibb & Associates, LLC

 

Draper, UT

March 28, 2025 

 

 
EX-31.1 7 ex_762131.htm EXHIBIT 31.1 ex_762131.htm

Exhibit 31.1

 

OFFICER’S CERTIFICATE

PURSUANT TO SECTION 302

 

I, Fei Chen, certify that:

 

1.          I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024 of Liqtech International, Inc.;

 

2.          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.          Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.          The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.          The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 28, 2025

By:

/s/ Fei Chen

 

Name:

Fei Chen

 

Title:

Chief Executive Officer and Principal

Executive Officer

 

 
EX-31.2 8 ex_762132.htm EXHIBIT 31.2 ex_762132.htm

Exhibit 31.2

 

OFFICER’S CERTIFICATE

PURSUANT TO SECTION 302

 

I, Phillip Massie Price, certify that:

 

1.          I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024 of Liqtech International, Inc.;

 

2.          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.          Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.          The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.          The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)         Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 28, 2025

By:

/s/ Phillip Massie Price

 

Name:

Phillip Massie Price

 

Title:

Interim Chief Financial Officer and Principal

Financial and Accounting Officer

 

 
EX-32.1 9 ex_762133.htm EXHIBIT 32.1 ex_762133.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Liqtech International, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2024 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:

 

1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date: March 28, 2025

By:

/s/ Fei Chen

 

Name:

Fei Chen

 

Title:

Chief Executive Officer and Principal

Executive Officer

 

 

A signed original of this written statement required by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

 

 

 

 
EX-32.2 10 ex_762134.htm EXHIBIT 32.2 ex_762134.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Liqtech International, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2024 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date: March 28, 2025

By:

/s/ Phillip Massie Price

 

Name:

Phillip Massie Price
 

Title:

Interim Chief Financial Officer and Principal Financial and Accounting Officer

 

 

A signed original of this written statement required by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.